documents incorporated reference document part proxy statement annual meeting part iii shareholders held may filed securities exchange commission within days close fiscal year covered reporttable contents part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item properties item legal proceedings executive officers registrant item reserved part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data financial statements notes consolidated financial statements report independent registered public accounting firm b supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures consent independent registered public accounting firm independent auditors consent ex ex ex ex ex ex ex ex ex ex ex ex ex ex ex ex instance document ex schema document ex calculation linkbase document ex labels linkbase document ex presentation linkbase document ex definition linkbase documenttable contents part item business november merck co inc old merck scheringplough corporation scheringplough completed previouslyannounced merger merger merger scheringplough acquired shares old merck became whollyowned subsidiary scheringplough renamed merck sharp dohme corp scheringplough continued surviving public company renamed merck co inc new merck company however accounting purposes merger treated acquisition old merck considered accounting acquirer accordingly accompanying financial statements reflect old mercks standalone operations existed prior completion merger results scheringploughs business included new mercks financial statements periods subsequent completion merger therefore new mercks financial results reflect full year legacy scheringplough operations references report accompanying financial statements merck periods prior merger refer old merck periods completion merger new merck company global health care company delivers innovative health solutions medicines vaccines biologic therapies consumer animal products markets directly joint ventures companys operations principally managed products basis comprised one reportable segment pharmaceutical segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventative pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value pharmaceutical vaccine products health care professionals private practice group practices managed care organizations company also animal health operations discover develop manufacture market animal health products including vaccines companys professional representatives communicate safety value companys animal health products veterinarians distributors animal producers additionally company consumer health care operations develop manufacture market overthecounter otc foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets united states canada financial information information pharmaceutical segment see item managements discussion analysis financial condition results operations item financial statements supplementary data product service marks appearing type form different surrounding text trademarks service marks owned licensed promoted distributed merck subsidiaries affiliates except noted cozaar hyzaar registered trademarks ei du pont de nemours company wilmington de trademarks services marks respective owners overview discussed merger completed november merger old merck shareholders received one share common stock new merck share old merck stock owned scheringplough shareholders received share common stock new merck cash share scheringplough stock owned consideration merger valued billion aggregate scheringplough old mercks longterm partner merckscheringplough cholesterol partnership msp partnership cash portion consideration funded table contents combination existing cash including proceeds sale old mercks interest merial limited sale redemption investments issuance debt combined company research development pipeline greater depth breadth many promising drug candidates significantly broader portfolio medicines expanded presence key international markets particularly highgrowth emerging markets company anticipates efficiencies gained merger allow invest promising pipeline candidates well strategic external research development opportunities combination increased companys pipeline early mid late stage product candidates including significant increase number potential medicines company phase iii development candidates additionally number candidates currently review united states internationally merger also expected accelerate expansion therapeutic areas old merck focused recent years addition scheringploughs established presence expertise oncology neuroscience novel biologics merger expected broaden companys commercial portfolio leading franchises key therapeutic areas including cardiovascular respiratory oncology neuroscience infectious diseases immunology womens health additionally combined company expected realize potential benefits animal health business portfolio consumer health brands including claritin coppertone dr scholls many legacy scheringploughs products expected long periods marketing exclusivity leveraging combined companys expanded product offerings company expects benefit additional revenue growth opportunities example combined company expected expanded opportunities lifecycle management introduction potential new combinations formulations existing products two legacy companies also company expanded global presence geographically diverse revenue base scheringploughs significant international presence accelerate old mercks international growth efforts revenue increased driven largely incremental sales resulting inclusion postmerger results legacy scheringplough products remicade infliximab treatment inflammatory diseases temodar temozolomide treatment certain types brain tumors nasonex mometasone furoate monohydrate nasal spray inhaled nasal corticosteroid treatment nasal allergy symptoms pegintron peginterferon alphab treating chronic hepatitis c well recognition revenue sales zetia ezetimibe vytorin ezetimibesimvastatin cholesterol modifying medicines prior merger sales zetia vytorin recognized msp partnership results old mercks interest msp partnership recorded equity income affiliates result merger msp partnership whollyowned company therefore revenues products postmerger period reflected sales additionally company recognized sales postmerger period legacy scheringplough animal health consumer health care products also contributing sales increase growth januvia sitagliptin phosphate janumet sitagliptin phosphate metformin hydrochloride treatment type diabetes isentress raltegravir antiretroviral therapy treatment hiv infection singulair montelukast sodium medicine indicated chronic treatment asthma relief symptoms allergic rhinitis varivax varicella virus vaccine live vaccine help prevent chickenpox varicella pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease increases partially offset lower sales fosamax alendronate sodium treatment prevention osteoporosis fosamax fosamax plus alendronate sodiumcholecalciferol lost market exclusivity substantially formulations united states february april respectively revenue also negatively affected lower sales gardasil human papillomavirus quadrivalent types vaccine recombinant vaccine help prevent cervical vulvar vaginal cancers precancerous dysplastic lesions genital warts caused human papillomavirus hpv types cosopt dorzolamide hydrochloride timolol maleate ophthalmic solutiontrusopt dorzolamide hydrochloride ophthalmic solution ophthalmic products lost us market exclusivity october lower revenue companys relationship astrazeneca lp azlp products experiencing declines include rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infants table contents children zocor simvastatin companys statin modifying cholesterol primaxin imipenem cilastatin sodium treatment bacterial infections result merger company expects achieve substantial cost savings across areas including consolidation sales marketing research development application companys lean manufacturing sourcing strategies expanded operations full integration msp partnership february company announced first phase new global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough businesses merger restructuring program intended optimize cost structure combined company part first phase merger restructuring program end company expects reduce total workforce approximately across areas company worldwide company also plans eliminate vacant positions part first phase program workforce reductions primarily come elimination duplicative positions sales administrative headquarters organizations well consolidation certain manufacturing facilities research development operations company continue hire new employees strategic growth areas business period certain actions ongoing reevaluation manufacturing research development facilities worldwide yet completed included later phases merger restructuring program connection first phase merger restructuring program separation costs companys existing severance programs worldwide recorded fourth quarter extent costs probable reasonably estimable company recorded pretax restructuring costs billion primarily employee separation costs related merger restructuring program fourth quarter first phase merger restructuring program expected completed end total pretax costs estimated billion billion company estimates approximately cumulative pretax costs relate cash outlays primarily related employee separation expense approximately cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested company expects first phase merger restructuring program yield annual savings approximately billion billion anticipated savings relate first phase merger restructuring program therefore portion estimated billion incremental annual savings originally disclosed merger announced company expects additional savings generated subsequent phases merger restructuring program announced later year well non restructuring related activities procurement savings initiatives cost savings expected come areas companys pharmaceutical business addition previously announced ongoing cost reduction initiatives legacy companies result merger company obtained controlling interest msp partnership owned company accordingly company required remeasure mercks previously held equity interest msp partnership mergerdate fair value recognize resulting gain earnings result company recorded gain billion recognized income expense net also old merck sold interest merial limited merial sanofiaventis billion cash sale resulted recognition billion gain reflected income expense net see note consolidated financial statements item financial statements supplementary data information earnings per common share eps assuming dilution reflect net impact resulting gains related msp partnership sale merial partially offset increased expenses amortization purchase accounting adjustments restructuring mergerrelated costs eps also affected dilutive impact shares issued merger table contents product sales sales companys products follows millions pharmaceutical bone respiratory immunology dermatology singulair fosamax propecia remicade arcoxia nasonex clarinex asmanex cardiovascular vytorin zetia integrilin diabetes obesity januvia janumet infectious disease isentress primaxin cancidas invanz crixivanstocrin pegintron avelox rebetol mature brands cozaarhyzaar zocor vasotecvaseretic proscar claritin rx proventil neurosciences ophthalmology maxalt cosopttrusopt remeron subutexsuboxone oncology emend temodar caelyx intron vaccines proquadmmr iivarivax gardasil rotateq pneumovax zostavax womens health endocrine follistimpuregon nuvaring pharmaceutical segment revenues total segment revenues sales legacy scheringplough products reflect results postmerger period december sales msp partnership products zetia vytorin represent sales postmerger period december prior merger sales zetia vytorin primarily recognized msp partnership results old mercks interest msp partnership recorded equity income affiliates sales zetia vytorin reflect old mercks sales products latin america part msp partnership amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd pharmaceutical primarily includes sales human pharmaceutical products including products within franchises listed separately reflects nonreportable segments including animal health consumer health care revenue companys relationship azlp primarily relating sales nexium well prilosec revenue azlp billion billion billion respectively revenues primarily comprised miscellaneous corporate revenues third party manufacturing sales sales related divested products businesses supply sales included segment results table contents pharmaceutical companys pharmaceutical products include therapeutic preventive agents generally sold prescription treatment human disorders among bone respiratory immunology dermatology singulair remicade fosamax nasonex propecia finasteride product treatment male pattern hair loss clarinex desloratadine nonsedating antihistamine treatment allergic rhinitis arcoxia etoricoxib treatment arthritis pain asmanex twisthaler mometasone furoate inhalation powder oral drypowder corticosteroid inhaler firstline maintenance treatment asthma cardiovascular disease zetia marketed ezetrol outside united states vytorin marketed inegy outside united states integrilin eptifibatide injection platelet receptor gp iibiiia inhibitor treatment patients acute coronary syndrome undergoing percutaneous coronary intervention united states well prevention early myocardial infarction patients acute coronary syndrome countries diabetes obesity januvia janumet infectious disease isentress primaxin cancidas caspofungin acetate antifungal product pegintron invanz ertapenem sodium treatment certain infections avelox moxifloxacin company markets united states broadspectrum fluoroquinolone antibiotic certain respiratory skin infections crixivan indinavir sulfate stocrin efavirenz antiretroviral therapies treatment hiv infection rebetol ribavirin usp capsules oral solution use combination pegintron intron interferon alphab recombinant treating chronic hepatitis c mature brands cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate vaseretic enalapril maleatehydrochlorothiazide companys significant hypertension andor heart failure products zocor proscar finasteride urology product treatment symptomatic benign prostate enlargement claritin rx proventil hfa albuterol inhalation aerosol relief bronchospasm patients years older neurosciences ophthalmology maxalt rizatriptan benzoate acute migraine product cosopt trusopt mercks largestselling ophthalmological products remeron mirtazapine antidepressant subutex sublingual tablet formulation buprenorphine suboxone sublingual tablet combination buprenorphine naloxone marketed company certain countries outside united states treatment opiate addiction oncology temodartemodal emend aprepitant prevention chemotherapyinduced postoperative nausea vomiting caelyx pegylated liposomal doxorubicin hydrochloride longcirculating formulation cancer drug doxorubicin marketed company outside united states treatment certain ovarian cancers kaposis sarcoma metastatic breast cancer intron injection marketed chronic hepatitis b c numerous anticancer indications worldwide including adjuvant therapy malignant melanoma vaccines mmr ii measles mumps rubella virus vaccine live vaccine measles mumps rubella proquad measles mumps rubella varicella virus vaccine live pediatric combination vaccine measles mumps rubella varicella varivax gardasil rotateq pneumovax zostavax zoster vaccine live womens health follistimpuregon follitropin beta injection fertility treatment nuvaring etonogestrelethinyl estradiol vaginal contraceptive ring animal health animal health segment discovers develops manufactures markets animal health products including vaccines principal marketed products segment include livestock products nuflor antibiotic range use cattle swine bovilisvista vaccine lines infectious diseases cattle banamine bovine swine antiinflammatory estrumate treatment fertility table contents disorders cattle regumatematrix fertility management swine horses resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zilmax revalor improve production efficiencies beef cattle mpac swine pneumonia vaccine porcilis vaccine line infectious diseases swine poultry products nobilisinnovax vaccine lines poultry paracox coccivac coccidiosis vaccines companion animal products nobivaccontinuum vaccine lines flexible dog cat vaccination otomaxmometamaxposatex ear ointments acute chronic otitis caninsulinvetsulin diabetes mellitus treatment dogs cats panacursafeguard broadspectrum anthelmintic dewormer use many animals scaliborexspot protecting bites fleas ticks mosquitoes sandflies aquaculture products slice parasiticide sea lice salmon aquavacnorvax vaccines bacterial viral disease fish compact pd vaccine salmon aquaflor antibiotic farmraised fish consumer health care consumer health care segment develops manufactures markets otc foot care sun care products principal products segment include otc products claritin nondrowsy antihistamines miralax treatment occasional constipation coricidin hbp decongestantfree coldflu medicine people high blood pressure afrin nasal decongestant spray correctol laxative tablets foot care dr scholls foot care products lotrimin topical antifungal products tinactin topical antifungal products foot sneaker odorwetness products sun care coppertone sun care lotions sprays dry oils lipprotection products sunless tanning products solarcaine sunburn relief products discussion sales companys products see item managements discussion analysis financial condition results operations product approvals july us food drug administration fda approved expanded indication isentress broadened indication includes use treatment adult patients starting hiv therapy first time treatmentnave well treatmentexperienced adult patients august fda approved saphris asenapine sublingual tablets acute treatment schizophrenia adults acute treatment manic mixed episodes associated bipolar disorder without psychotic features adults saphris used firstline treatment first psychotropic drug receive initial approval indications simultaneously october fda approved gardasil use boys men years age prevention genital warts caused hpv types making gardasil hpv vaccine approved use males gardasil also hpv vaccine protects hpv types cause approximately percent genital warts cases addition october old merck announced us centers disease control preventions advisory committee immunization practices acip supports permissive use gardasil boys young men ages means gardasil may given males ages reduce likelihood acquiring genital warts discretion patients health care provider acip also voted recommend funding provided use gardasil males vaccines children program october european commission ec approved simponi golimumab oncemonthly subcutaneous treatment certain inflammatory diseases december fda approved zegerid otc omeprazole mgsodium bicarbonate mg capsules otc treatment frequent heartburn table contents january merck received ec approval elonva corifollitropin alpha injection new fertility treatment elonva indicated controlled ovarian stimulation combination gnrh antagonist development multiple follicles women participating assisted reproductive technology program joint ventures merckscheringplough partnership old merck scheringplough collectively legacy companies entered agreement create equallyowned partnership develop market united states new prescription medicines cholesterol management december cholesterolmanagement partnership expanded include countries world excluding japan october zetia first new class cholesterollowering agents launched united states july vytorin combination product containing active ingredients zetia zocor approved united states previously disclosed january legacy companies announced results effect combination ezetimibe highdose simvastatin vs simvastatin alone atherosclerotic process patients heterozygous familial hypercholesterolemia enhance clinical trial imaging trial patients heterozygous familial hypercholesterolemia rare genetic condition causes high levels ldl bad cholesterol greatly increases risk premature coronary artery disease previously reported despite fact ezetimibesimvastatin mg vytorin significantly lowered ldl bad cholesterol simvastatin mg alone significant difference treatment ezetimibesimvastatin simvastatin alone prespecified primary endpoint change thickness carotid artery walls two years measured ultrasound improved reduction highrisk subjects presenting acute coronary syndrome improveit trial underway designed provide cardiovascular outcomes data ezetimibesimvastatin patients acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrated simvastatin established january fda announced completed review final clinical study report enhance fda stated results enhance change position elevated ldl cholesterol risk factor cardiovascular disease lowering ldl cholesterol reduces risk cardiovascular disease discussion concerning litigation arising enhance study see item risk factors item legal proceedings july efficacy safety results simvastatin ezetimibe aortic stenosis seas study announced seas designed evaluate whether intensive lipid lowering vytorin mg would reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patients asymptomatic mild moderate aortic stenosis indication statin therapy vytorin failed meet primary endpoint reduction major cardiovascular events study patients group took vytorin mg higher incidence cancer group took placebo also nonsignificant increase deaths cancer patients group took vytorin versus took placebo cancer cancer deaths distributed across major organ systems company believes cancer finding seas likely anomaly taken light available data support association vytorin august fda announced investigating results seas trial december fda announced completed review data seas trial well review interim data study heart renal protection sharp improveit trials based currently available information fda indicated believed unlikely vytorin zetia increase risk cancerrelated death sharp trial expected completed improveit trial scheduled completion improveit trial blinded interim efficacy analysis conducted data safety monitoring board trial approximately endpoints accrued interim analysis expected conducted company committed working regulatory agencies evaluate available data interpretations data however company believe changes clinical use vytorin warranted table contents astrazeneca lp old merck entered agreement astra ab astra develop market astra products united states old merck astra formed equally owned joint venture developed marketed astras new prescription medicines united states including prilosec omeprazole first class medications known proton pump inhibitors slows production acid cells stomach lining old merck astra restructured joint venture whereby old merck acquired astras interest joint venture renamed kbi inc kbi contributed kbis operating assets new us limited partnership named astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights company earns certain partnership returns well ongoing revenue based sales current future kbi products partnership returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing companys share undistributed partnership azlp generally accepted accounting principles gaap earnings astrazeneca merger triggered partial redemption march old mercks interest certain azlp product rights upon redemption old merck received billion azlp amount based primarily multiple old mercks average annual variable returns derived sales former astra usa inc products three years prior redemption limited partner share agreed value old merck recorded billion pretax gain partial redemption partial redemption old mercks interest product rights result change old mercks limited partnership interest described item managements discussion analysis financial condition results operations certain adjustments old merck recorded aggregate pretax gain billion conjunction restructuring astra purchased option asset option payment million recorded deferred income buy old mercks interest kbi products excluding gastrointestinal medicines nexium esomeprazole prilosec nonppi products astrazeneca exercise asset option first half exercise price million represents net present value march projected future pretax revenue received company nonppi products appraised value february astrazeneca notified company exercising asset option old merck also right require astra purchase interest appraised value february old merck advised astrazeneca would exercise asset option thus million remains deferred recognized asset option consummated addition old merck granted astra option shares option buy old mercks common stock interest kbi therefore old mercks interest nexium prilosec exercisable two years astras exercise asset option astra also exercise shares option combined annual sales two products fall minimum amount provided case long astrazenecas asset option exercised exercise price shares option based net present value estimated future net sales nexium prilosec determined time exercise subject certain trueup mechanisms sanofi pasteur msd old merck pasteur mrieux connaught sanofi pasteur sa formed joint venture market human vaccines europe collaborate development combination vaccines distribution existing eu european free trade association old merck sanofi pasteur contributed among things european vaccine businesses equal shares joint venture known pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintains presence directly affiliates branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributors rest territory table contents johnson johnsonomerck consumer pharmaceuticals company old merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned joint venture also includes canada significant joint venture products pepcid ac famotidine otc form old mercks ulcer medication pepcid famotidine well pepcid complete otc product combines companys ulcer medication antacids calcium carbonate magnesium hydroxide merial limited old merck rhnepoulenc sa sanofiaventis combined respective animal health businesses form merial limited merial fully integrated animal health company standalone joint venture owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species september old merck sold interest merial sanofiaventis billion cash sale resulted recognition billion gain reflected income expense net also connection sale merial old merck sanofiaventis scheringplough signed call option agreement terms call option agreement following closing merger sanofiaventis option require company combine intervetscheringplough animal health business merial form animal health joint venture would owned equally company sanofiaventis part call option agreement value merial fixed billion minimum total value received company affiliates contributing intervetscheringplough combined entity would billion subject customary transaction adjustments consisting floor valuation intervetscheringplough fixed minimum billion subject potential upward revision based valuation exercise two parties additional payment sanofiaventis million based valuation exercise intervetscheringplough customary transaction adjustments merial intervetscheringplough combined payment may required paid either party make joint venture equally owned company sanofiaventis payment would trueup value contributions equal formation new animal health joint venture sanofiaventis subject customary closing conditions including antitrust review united states europe prior closing merger agreements provided old merck certain rights terminate call option fee million recognition termination fee deferred fourth quarter conditions could triggered payment lapsed licenses subsidiary scheringplough entered licensing agreement centocor inc johnson johnson company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi fully human monoclonal antibody company exclusive marketing rights products outside united states japan certain asian markets december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade simponi extending companys rights exclusively market remicade match duration companys exclusive marketing rights simponi addition scheringplough centocor agreed share certain development costs relating simponis autoinjector delivery system october ec approved simponi treatment rheumatoid arthritis immune system disorders two presentations novel autoinjector prefilled syringe result companys marketing rights products extend years first commercial sale simponi within eu following receipt pricing reimbursement approval within eu operating expenses subject certain adjustments company entitled receive approximate share profits companys distribution companys marketing territory beginning share profits change time share profits products share profits remain fixed thereafter remainder term company may independently develop market simponi crohns disease indication territories option centocor participate centocor instituted arbitration proceeding terminate agreement companys rights distribute products see item risk factors item legal proceedings table contents competition markets company conducts business pharmaceutical industry highly competitive highly regulated companys operations may affected technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors new information clinical trials marketed products postmarketing surveillance generic competition companys products mature addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result recognition impairment charge respect certain products competitive pressures intensified pressures industry grown effect operations competitive factors patent disputes predicted pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively longstanding emphasis research development company well positioned compete search technological innovations additional resources meet market challenges include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products external alliances joint ventures licenses refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth companys products therapeutic category global efforts toward healthcare cost containment continue exert pressure product pricing access addressing cost containment pressure company makes continuing effort demonstrate medicines provide value patients pay health care addition pricing flexibility across companys product portfolio encouraged growing use medicines mitigated effects increasing cost pressures individual medicines outside united states difficult government budgetary environments company worked payers encourage allocation scarce resources optimize healthcare outcomes limiting potentially detrimental effects government policies sales growth access innovative medicines vaccines support discovery development innovative products benefit patients company also working governments many emerging markets eastern europe latin america asia encourage increase investments health thereby improve citizens access medicines addition certain countries within eu recognizing economic importance researchbased pharmaceutical industry value innovative medicines society working industry representatives improve competitive climate variety means including market deregulation company anticipates worldwide trend toward cost containment continue resulting ongoing pressures healthcare budgets united states major healthcare reform introduced passed houses congress final revised bill unifies versions may considered adopted law impact actions well budget pressures governments united states nations predicted time company continues successfully launch new products contribute health care debates monitor reforms new products policies strategies enable maintain strong position changing economic environment although one predict outcome legislative regulatory advocacy initiatives company believes well positioned respond evolving health care environment market forces access medicines company also committed improving access medicines enhancing quality life people around world cite one example african comprehensive hivaids partnerships table contents botswana partnership government botswana bill melinda gates foundation merck company foundationmerck co inc supporting botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support catalyze access hiv medicines developing countries company makes profit sale current hivaids medicines worlds poorest countries hardest hit pandemic offers hivaids medicines significantly reduced prices mediumincome countries february old merck announced reduced price stocrin least developed countries world hardest hit pandemic actions company working independently partners public private sectors address critical barriers access medicines developing world addressing barriers requires investments education training health infrastructure improve capacity achieved increased international assistance sustainable financing addition old merck committed providing rotateq global alliance vaccines immunizationeligible countries prices profit also old merck wellcome trust established msd wellcome trust hilleman laboratories joint venture india develop vaccines millions people poorest areas world government regulation pharmaceutical industry subject regulation regional country state local agencies around world particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time resources necessary develop new products bring market united states food drug administration modernization act fda modernization act passed culmination comprehensive legislative reform effort designed streamline regulatory procedures within fda improve regulation drugs medical devices food legislation principally designed ensure timely availability safe effective drugs biologics expediting premarket review process new products key provision legislation reauthorization prescription drug user fee act permits continued collection user fees prescription drug manufacturers augment fda resources earmarked review human drug applications helps provide resources necessary ensure prompt approval safe effective new drugs united states government expanded access senior citizens prescription drug coverage enacting medicare prescription drug improvement modernization act signed law december prescription drug coverage began january legislation supports companys goal improving access medicines expanding insurance coverage preserving marketbased incentives pharmaceutical innovation time legislation helped control cost prescription drug costs competitive pressures encouraging appropriate use medicines mentioned united states major healthcare reform introduced passed houses congress final revised bill unifies versions may considered adopted law us congress also considered may consider proposals increase governments role pharmaceutical pricing medicare program proposals may include removing current legal prohibition secretary health human services intervening price negotiations medicare drug benefit program plans pharmaceutical companies may also include mandating payment rebates pharmaceutical utilization medicare drug benefit plans addition congress may consider proposals allow certain conditions importation medicines countries many years pharmaceutical industry federal state oversight approval process new drugs drug safety advertising promotion drug purchasing reimbursement programs formularies company believes continue able conduct operations including introduction new drugs market regulatory environment company continues work private public payors slow increases healthcare spending also us federal state governments pursued methods directly reduce cost drugs vaccines table contents pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities disproportionate share hospitals hospitals meeting certain criteria provide minimum discounts defined nonfederal average manufacturer price purchases certain components federal government department veterans affairs department defense initiatives states seek rebates beyond minimum required medicaid legislation cases patients beyond eligible medicaid federal vaccines children entitlement program us centers disease control prevention cdc funds purchases recommended pediatric vaccines public sector price immunization medicaideligible uninsured native american certain underinsured children old merck awarded cdc contract supply pediatric vaccines vaccines children program outside united states company encounters similar regulatory legislative issues countries business primary thrust governmental inquiry action toward determining drug safety effectiveness often mechanisms controlling prices reimbursement prescription drugs profits prescription drug companies eu adopted directives concerning classification labeling advertising wholesale distribution approval marketing medicinal products human use companys policies procedures already consistent substance directives consequently believed material effect companys business january ec launched sector inquiry pharmaceutical industry rules eu competition law part inquiry old mercks offices germany inspected authorities beginning january preliminary report ec issued november following public consultation period final report issued july final report confirmed decline number novel medicines reaching market instances delayed market entry generic medicines discussed industry practices may contributed phenomena ec issued inquiries respect subject investigation ec alleged company subsidiaries engaged unlawful practices company subject jurisdiction various regulatory agencies therefore subject potential administrative actions actions may include seizures products civil criminal sanctions certain circumstances company may deem advisable initiate product recalls company believes able compete effectively within environment privacy data protection company subject number privacy data protection laws regulations globally legislative regulatory landscape privacy data protection continues evolve increasing attention privacy data protection issues potential affect directly companys business including recently enacted laws regulations united states internationally requiring notification individuals government authorities security breaches involving certain categories personal information distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccines sold primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices managed care organizations companys professional representatives communicate safety value companys animal health products veterinarians distributors animal producers companys otc foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets table contents raw materials raw materials supplies generally available multiple sources purchased worldwide normally available quantities adequate meet needs companys business patents trademarks licenses patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage fda modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant exclusivity provisions reauthorized prescription drug user fee act passed september current us patent law provides additional patent term patent term restoration periods patented product regulatory review fda table contents patent portfolios developed products introduced company normally provide market exclusivity company following key us patent protection including patent term restoration pediatric exclusivity major marketed products product year expiration us cozaar hyzaar crixivan compound formulation maxalt compound singulair cancidas compound composition propecia formulationuse asmanex use formulation avelox integrilin compound useformulation nasonex useformulationformulation temodar emend follistimpuregon pegintron conjugates mature ifnalpha zolinza invanz compound composition zostavax zetiavytorin nuvaring delivery system noxafil rotateq clarinex formulation comvax method makingvectors intron recombivax method makingvectors saphrissycrest useformulation subject pending patent term restoration application januviajanumet compound salt isentress gardasil method makinguseproduct process compound patent unless otherwise noted agreement dr reddys laboratories may launch generic january january court held patent temodar unenforceable decision appealed see item legal proceedings patent litigation virtue litigation settlement generics given right enter market expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states certain countries market exclusivity may available relevant law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries table contents patents provide us market exclusivity cozaar hyzaar expire april addition patent cozaar expire number major european markets march hyzaar lost patent protection major european markets february company expects sales products decline rapidly expiration patents particularly united states since expected multiple sources generic products time patent expiry addition patent provides us market exclusivity singulair expires august company expects within two years following patent expiration lose substantially us sales singulair declines coming first full year following patent expiration also patent singulair expire number major european markets august company expects sales singulair markets decline significantly thereafter additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset general increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties information respect companys patents see item risk factors item legal proceedings patent litigation worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalties received patent knowhow licenses rights amounted million merck also paid royalties amounting billion patent knowhow licenses holds research development companys business characterized introduction new products new uses existing products strong research development program approximately people employed companys research activities research development expenses included restructuring costs billion billion billion company maintains ongoing commitment research broad range therapeutic areas clinical development support new products company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources disease areas unmet medical needs scientific opportunity commercial opportunity merck managing research development portfolio across diverse approaches discovery development balancing investments appropriately novel innovative targets potential major impact human health developing bestinclass approaches delivering maximum value new medicines vaccines new indications new formulations another important component companys sciencebased diversification based expanding companys portfolio modalities include small molecules vaccines also biologics peptides rnai merck moved diversify portfolio creating new division merck bioventures potential harness market opportunity presented biological medicine patent expiries delivering high quality followon biologic products enhance access patients worldwide company continue pursue appropriate external licensing opportunities integration plans research development focused integrating research operations legacy companies including providing effective transition employees realizing projected merger synergies form cost savings revenue growth opportunities maintaining momentum companys latestage pipeline merck continued implementing new model basic research global operating strategy legacy merck research laboratories sites new model align franchise function well align resources disease area priorities balance capacity across discovery phases allow company act upon programs highest probability success additionally across table contents disease area priorities companys strategy designed expand access worldwide external science incorporate external research key component companys early discovery pipeline order translate basic research productivity latestage clinical success companys clinical pipeline includes candidates multiple disease areas including anemia atherosclerosis cancer diabetes heart disease hypertension infectious diseases inflammatoryautoimmune diseases migraine neurodegenerative diseases ophthalmics osteoporosis psychiatric diseases respiratory disease womens health company supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug vaccine may marketed united states recorded data preclinical clinical experience included new drug application nda drug biologics license application bla vaccine biologic submitted fda required approval companys scientists discover new small molecule compound believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase ii studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness data phase ii trials satisfactory company commences largescale phase iii trials confirm compounds efficacy safety upon completion trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed vaccine development follows general pathway drugs preclinical testing focuses vaccines safety ability elicit protective immune response immunogenicity premarketing vaccine clinical trials typically done three phases initial phase clinical studies conducted normal subjects evaluate safety tolerability immunogenicity vaccine candidate phase ii studies doseranging studies finally phase iii trials provide necessary data effectiveness safety successful company submits regulatory filings appropriate regulatory agencies also stage proposed manufacturing facility undergoes preapproval inspection production vaccine progress examined detail united states fda review process begins complete nda submitted received fda pursuant prescription drug user fee act fda review period targets ndas supplemental ndas either six months priority review ten months standard review within days receipt nda fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review review timelines defined fda generally act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information days extensions review period communicated company fda act application issuing approval letter complete response letter research development update connection merger company assessing pipeline identify promising highpotential compounds development company completed prioritization clinical development table contents programs company continuing work prioritization value adding programs related currently marketed products preclinicaldiscovery programs company anticipates full prioritization process completed first half connection process company may recognize noncash impairment charges cancellation certain legacy scheringplough pipeline programs measured fair value capitalized connection merger noncash impairment charges anticipated excluded companys nongaap earnings could material companys future gaap earnings company currently number candidates regulatory review united states internationally additionally company drug candidates phase iii development mk vernakalant iv investigational candidate treatment atrial fibrillation currently undergoing regulatory review eu april old merck cardiome pharma corp cardiome announced collaboration license agreement development commercialization vernakalant provides merck exclusive rights outside united states canada mexico intravenous formulation vernakalant vernakalent oral currently phase ii development merck exclusive global rights oral formulation vernakalent maintenance normal heart rhythm patients atrial fibrillation sch mff combination two previously approved drugs treatment asthma mometasone asmanex formoterol foradil company aiming create new option patients bringing two key treatments together july scheringplough announced filed nda fda mff mff also currently regulatory review eu sch nomace oral contraceptive combines selective progestin estradiol estrogen women produce naturally drug currently regulatory review eu phase iii development us market sch saphris asenapine central nervous system compound bipolar disorder schizophrenia currently undergoing regulatory review eu fda approved saphris august sch bridion sugammadex medication designed rapidly reverse effects certain muscle relaxants used part general anesthesia ensure patients remain immobile surgical procedures differs reversal agents administered muscle relaxant begins wear bridion received regulatory approval eu australia new zealand japan regulatory review markets including united states prior merger scheringplough received complete response letter fda bridion following communication fda company assessing agencys feedback order determine new timetable response sch boceprevir hepatitis c protease inhibitor currently development boceprevir fully enrolled phase iii program company expects conclude mid company expects submit nda fda boceprevir end treatmentexperienced treatmentnave patients hepatitis c mk ridaforolimus novel mtor mammalian target rapamycin inhibitor evaluated treatment cancer drug candidate jointly developed commercialized ariad pharmaceuticals inc agreement entered phase iii study succeed patients metastatic softtissue bone sarcomas underway company continues anticipate filing nda ridaforolimus fda subject review results planned interim analysis succeed sch allergy immunotherapy sublingual tablet ait grass pollen allergy developed company november sch met primary endpoint phase iii study adult subjects united states history grass pollen induced rhinoconjunctivitis without asthma investigational grass ait treatment designed work inducing protective immune response grass pollen allergy providing sustained prevention allergy symptoms treating symptoms underlying cause disease sch ait ragweed allergy also phase iii development us market table contents sch vorapaxar thrombin receptor antagonist antiplatelet protease activated receptor inhibitor studied prevention treatment thrombosis november merck announced completion patient enrollment patients tra ptimi clinical trial phase iii randomized doubleblind placebocontrolled multinational study trial assess ability sch prevent major cardiovascular events added current antiplatelet regimens aspirin aspirin plus adp inhibitor patients previously experienced heart attack stroke peripheral arterial disease sch also studied treatment patients acute coronary syndrome ongoing phase iii thrombin receptor antagonist clinical event reduction acute coronary syndrome trial led duke clinical research institute company anticipates filing nda vorapaxar fda mk tafluprost preservative free synthetic analogue prostaglandin f reduction elevated intraocular pressure appropriate patients primary openangle glaucoma ocular hypertension april old merck santen announced worldwide licensing agreement tafluprost previously disclosed old merck submitted filing nda fda mkc ezetimibe combined atorvastatin investigational medication treatment dyslipidemia fda refused file application fda identified additional manufacturing stability data needed company assessing fdas response anticipates filing mkc candidate currently phase iii clinical development combines januvia pioglitazone another type diabetes therapy company continues anticipate filing nda mkc fda mk odanacatib oral onceweekly investigational treatment osteoporosis osteoporosis disease reduces bone density strength results increased risk bone fractures odanacatib cathepsin k inhibitor selectively inhibits cathepsin k enzyme cathepsin k known play central role function osteoclasts cells break existing bone tissue particularly protein components bone inhibition cathepsin k novel approach treatment osteoporosis september data phase iib clinical study odanacatib presented st annual meeting american society bone mineral research showed stopping treatment two years increases lower back lumbar spine bone mineral density bmd reversed next year bmd hip femoral neck remained levels observed start study additionally three years treatment odanacatib mg demonstrated increases bmd key fracture sites minimal impact formation new bone measured biochemical markers bone turnover odanacatib currently phase iii clinical trials evaluated largescale global outcomes study determine effects vertebral hip nonvertebral fractures company continues anticipate filing nda fda v ninevalent hpv vaccine development expand protection cancercausing hpv types phase iii clinical program underway merck anticipates filing bla fda mka drug candidate combines extendedrelease er niacin novel flushing inhibitor laropiprant mka demonstrated ability lower ldlcholesterol ldlc bad cholesterol raise hdlcholesterol hdlc good cholesterol lower triglycerides significantly less flushing traditional extended release niacin alone high ldl c low hdlc elevated triglycerides risk factors associated heart attacks strokes april old merck received nonapprovable action letter fda response nda mka meeting discuss letter fda stated additional efficacy safety data required suggested old merck wait results treatment hdl reduce incidence vascular events hpsthrive cardiovascular outcomes study expected completed company anticipates filing nda fda mk mka approved countries outside united states treatment dyslipidemia particularly patients combined mixed dyslipidemia characterized elevated levels ldlc triglycerides low hdlc patients primary hypercholesterolemia heterozygous familial nonfamilial marketed tredaptive cordaptive certain countries tredaptive used patients combination statins cholesterol lowering effects statin monotherapy inadequate tredaptive used monotherapy patients statins considered inappropriate tolerated table contents mkb drug candidate combines novel approach raising hdlc lowering triglycerides er niacin combined laropiprant proven benefits simvastatin one combination product merck seek approval mkb united states files complete response relating mka mk anacetrapib inhibitor cholesteryl ester transfer protein shown promise lipid management raising hdlc reducing ldlc without raising blood pressure november merck announced phase iib study patients primary hypercholesterolemia mixed hyperlipidemia treated anacetrapib monotherapy co administered atorvastatin persistent lipid effects higher dose arms monotherapy coadministration treatment groups eight weeks stopping active therapy anacetrapib effect cetp inhibition cardiovascular risk yet established phase iii trial titled define ongoing evaluate safety efficacy anacetrapib patients coronary heart disease company anticipates filing nda fda beyond previously disclosed old merck announced delaying filing us application telcagepant mk companys investigational calcitonin gene related peptide cgrpreceptor antagonist intermittent treatment acute migraine decision based findings phase iia exploratory study small number patients taking telcagepant twice daily three months prevention migraine found marked elevations liver transaminases daily dosing regimen prevention study different dosing regimen used phase iii studies telcagepant intermittently administered one two doses treat individual migraine attacks occurred studies telcagepant acute intermittent treatment migraine continue following meetings regulatory agencies end merck planning conduct additional safety study part overall phase iii program telcagepant results study inform planned filings approval sch acadesine potential firstin class adenosine regulating agent ischemia reperfusioninjury patients undergoing heart bypass surgery patient enrollment red cabg phase iii clinical trial initiated sch vicriviroc treatment hiv infection treatment experienced evaluated two phase iii studies patient population announced january primary efficacy endpoint met merck submit nda fda vicriviroc treatmentexperienced hivinfected patients time continue evaluate vicriviroc firstline therapy treatmentnaive patients previously disclosed cubist pharmaceuticals inc cubist entered license agreement old merck development commercialization cubicin daptomycin injection mk japan merck develop commercialize cubicin whollyowned subsidiary banyu pharmaceutical co ltd cubist commercializes cubicin united states mk currently phase iii development mk orexin receptor antagonist potential new approach treatment chronic insomnia currently phase iii development sch elonva corifollitropin alpha injection approved ec controlled ovarian stimulation combination gnrh antagonist development multiple follicles women participating assisted reproductive technology program currently phase iii development united states merck terminated internal clinical development program esmirtazapine sch hot flashes insomnia strategic reasons previously disclosed old merck announced preliminary results pivotal phase iii study rolofylline mk investigational medicine treatment acute heart failure showed rolofylline meet primary secondary efficacy endpoints old merck terminated clinical development program rolofylline chart reflects companys current research pipeline february candidates shown phase iii include specific products candidates shown phase ii include advanced compound specific mechanism listed compounds mechanism currently intended table contents commercialization given therapeutic area small molecules biologics given mknumber schnumber designations vaccine candidates given vnumber designations candidates phase additional indications therapeutic area additional claims line extensions formulations inline products shown phase ii allergy sch anemia mk asthma mkc atrial fibrillation mk vernakalant oral cancer mk dalotuzumab sch dinaciclib sch clostridium difficile infection mka copd sch diabetes mk mk hepatitis c mk vaniprevir hiv sch vicriviroc hot flashes mk hypertension mk insomnia mk osteoporosis mk parkinsons disease sch preladenant pediatric vaccine v progeria sch sarasar lonafarnib schizophrenia mk sch staph infection v thrombosis mk betrixaban phase iii allergy sch grass pollen sch ragweed anesthesia reversal sch sugammadex us atherosclerosis mka extendedrelease niacin laropiprant us mkb extendedrelease niacin laropiprantsimvastin mk anacetrapib cervical cancer v contraception sch nomace us diabetes mkc januviapioglitazone fertility sch corifollitropin alfa injection us glaucoma mk tafluprost us hepatitis c sch boceprevir insomnia mk ischemiareperfusion injury sch acadesine migraine mk telcagepant osteoporosis mk odanacatib sarcoma mk ridaforolimus staph infection mk daptomycin injection thrombosis sch vorapaxar tra review asthma sch momestasone formoterol combination useu atrial fibrillation mk vernakalant iv eu contraception sch nomace eu schizophreniabipolar disorder sch asenapine eu footnotes exclusive rights outside united states canada mexico vernakalant iv north american rights approved certain countries europe approved certain countries europe japan japanese rights mkc fixed dose combination ezetimibe atorvastatin anticipated submitted us fda commercialized regulatory legal requirements satisfied employees december company approximately employees worldwide approximately employed united states including puerto rico approximately worldwide employees company represented various collective bargaining groups october old merck announced global restructuring program restructuring program reduce cost structure increase efficiency enhance competitiveness part restructuring program company expects eliminate approximately positions active employees vacancies across areas company worldwide end total table contents reductions occur united states part restructuring program old merck streamlining management layers reducing total number senior midlevel executives globally prior merger scheringplough commenced productivity transformation program designed reduce avoid costs increase productivity february company announced first phase new global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough businesses merger restructuring program intended optimize cost structure combined company part first phase merger restructuring program end company expects reduce total workforce approximately across areas company worldwide company also plans eliminate vacant positions part first phase program workforce reductions primarily come elimination duplicative positions sales administrative headquarters organizations well consolidation certain manufacturing facilities research development operations environmental matters company believes compliance issues associated applicable environmental laws regulations would material adverse effect company merck incurred capital expenditures approximately million environmental protection facilities company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million million million estimated million years amounts consider potential recoveries parties company taken active role identifying providing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million december although possible predict certainty outcome environmental matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures material adverse effect companys financial position results operations liquidity capital resources year geographic area information companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states sales sales sales increase proportion sales outside united states primarily due inclusion results scheringplough following close merger companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions result merger merck expanded operations countries located latin america middle east africa eastern europe asia pacific business developing areas sometimes less stable offers important opportunities growth time financial information geographic areas companys business discussed item financial statements supplementary data available information companys internet website address wwwmerckcom company make available free charge investor information portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant table contents section securities exchange act amended soon reasonably practicable reports electronically filed furnished securities exchange commission sec companys corporate governance guidelines charters board directors six standing committees available companys website wwwmerckcomaboutleadership information available print stockholder requests company item risk factors investors carefully consider information set forth including following risk factors deciding invest companys securities risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations prospects could materially adversely affected risks also contains forwardlooking statements involve risks uncertainties companys results could materially differ anticipated forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results certain companys major products going lose patent protection near future occurs company expects significant decline sales products company depends upon patents provide exclusive marketing rights products period time product patents several companys products recently expired expire united states countries company faces strong competition lower priced generic drugs loss patent protection one companys products typically leads rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss patent protection material adverse effect companys business cash flow results operations financial position prospects patents provide us market exclusivity cozaar hyzaar expire april addition patent cozaar expire number major european markets march hyzaar lost patent protection major european markets february company expects significant declines sales products times addition patent provides us market exclusivity singulair expires august company expects within two years following patent expiration lose substantially us sales singulair declines coming first full year following patent expiration also patent singulair expire number major european markets august company expects sales singulair markets decline significantly thereafter chart listing us patent protection companys major marketed products set forth item business patents trademarks licenses key company products generate significant amount companys profits cash flows events adversely affect markets leading products could material negative impact results operations cash flows companys ability generate profits operating cash flow depends largely upon continued profitability companys key products singulair remicade vytorin zetia januvia nasonex gardasil result companys dependence key products event adversely affects products markets products could significant impact results operations cash flows events could include loss patent protection recent case temodar increased costs associated manufacturing generic otc availability companys product competitive product discovery previously unknown side effects increased competition introduction new effective treatments discontinuation removal market product reason companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lost patent protection table contents like major pharmaceutical companies order remain competitive company must continue launch new products year declines sales products fosamax cozaar hyzaar loss market exclusivity mean companys future success dependent pipeline new products including new products may develop joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties high rate failure inherent research develop new drugs treat diseases result high risk funds invested company research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested description research development process see research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals accordingly company may abandon product invested substantial amounts time resources risks encountered research development process include following preclinical testing new compound may yield disappointing results clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved fda intended use may possible obtain patent new drug sales new product may disappointing company state certainty whether products development approved launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications brand extensions existing products sufficient cover substantial research development costs replace sales lost profitable products fosamax cozaar hyzaar lose patent protection displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial position prospects companys success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications increasing uncertainties time required obtain regulatory approvals benefitrisk standards applied regulatory agencies determining whether grant approvals lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others connection merger company assessing pipeline identify promising highpotential compounds development company completed prioritization clinical development programs company continuing work prioritization value adding programs related currently marketed products preclinicaldiscovery programs company anticipates full prioritization process completed first half connection process company may recognize non cash impairment charges cancellation certain legacy scheringplough pipeline programs measured fair value capitalized connection merger noncash impairment charges anticipated excluded companys nongaap earnings could material companys future gaap earnings table contents companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities united states including fda foreign regulatory authorities including ec united states fda particular importance company administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states regulation outside united states also primarily focused drug safety effectiveness many cases cost reduction fda foreign regulatory authorities substantial discretion require additional testing delay withhold registration marketing approval mandate product withdrawals even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling new products jurisdiction approval obtained ever company would able realize revenues new products jurisdiction approval company dependent patent rights patent rights invalidated circumvented business would adversely affected patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business defend successfully patent rights provide market exclusivity products company often involved patent disputes relating challenges patents infringement similar claims company company aggressively defends important patents within outside united states including filing claims infringement parties see item legal proceedings patent litigation particular manufacturers generic pharmaceutical products time time file abbreviated new drug applications anda fda seeking market generic forms companys products prior expiration relevant patents owned company company normally responds vigorously defending patent including filing lawsuits alleging patent infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases third party patents may prevent company marketing selling product particular geographic area additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies could diminish eliminate sales profits regions negatively affect companys results operations recent court decisions relating companies us patents potential us legislation relating patent reform well regulatory initiatives may result erosion intellectual property protection one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available case certain products loss could result impairment charge companys results operations may adversely affected lost sales unless company successfully launched commercially successful replacement products table contents companys hypertension products cozaar hyzaar lose patent protection united states april addition patent cozaar expire number major european markets march hyzaar lost patent protection major european markets february company expects significant declines sales products times addition patent provides us market exclusivity singulair expires august company expects within two years following patent expiration lose substantially us sales singulair declines coming first full year following patent expiration also patent singulair expire number major european markets august company expects sales singulair markets decline significantly thereafter company faces intense competition lowercost generic products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection significantly weaker united states eu united states political pressure reduce spending prescription drugs led legislation encourages use generic products although companys policy actively protect patent rights generic challenges companys products arise time may able prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time united states countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially business cash flow results operations financial position prospects company faces intense competition new products companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective effectively marketed sold companys products alternatively case generic competition may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business cash flow results operations financial position prospects company faces pricing pressure respect products company faces increasing pricing pressure globally managed care organizations institutions government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act act act included prescription drug benefit individuals first went effect january increased purchasing power entities negotiate behalf medicare beneficiaries could result pricing pressures outside united states numerous major markets pervasive government involvement funding healthcare regard fix pricing reimbursement pharmaceutical vaccine products consequently markets company subject government decision making budgetary actions respect products company expects pricing pressures increase future healthcare industry continue subject increasing regulation political action company believes healthcare industry continue subject increasing regulation well political legal action future proposals reform healthcare system considered congress state legislatures recently major health care reform introduced passed houses congress final revised bill unifies versions may considered adopted law congress may table contents also choose take action comprehensive reform instead move consider incremental health care proposals may may involve pharmaceuticalrelated issues proposals included house senate versions health reform could adversely affect companys sales profit margins enacted proposals could call government intervention pharmaceutical pricing changes government reimbursement increased rebates discounts sales related state federal government programs among changes proposals might enacted would adversely affect business include legalization commercial drug importation united states involuntary approval medicines otc use addition individual states enacted proposed regulations restrict certain sales marketing activities andor require tracking disclosure payments financial support healthcare professionals similar regulations may proposed federal level regulations could adversely affect companys sales profit margins new legislative initiatives enacted may increase government regulation government involvement healthcare lower reimbursement rates otherwise change operating environment healthcare companies government regulations applicable companys current future products interpretation existing regulations might change thereby prevent company marketing products services period time indefinitely company predict likelihood future changes healthcare industry general pharmaceutical industry particular impact may companys results operations financial condition business company experiencing difficulties delays manufacturing certain products previously disclosed old merck past experienced difficulties manufacturing certain vaccines products issues continuing particular respect manufacture bulk varicella required production companys varicella zoster viruscontaining vaccines varivax proquad zostavax similarly scheringplough past experienced difficulties manufacturing certain animal health products company working issues assurance issues finally resolved addition difficulties company experiencing currently company may experience difficulties delays inherent manufacturing products failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing ii construction delays related construction new facilities expansion existing facilities including intended support future demand companys products iii manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could impact continuous supply manufacturing difficulties result product shortages leading lost sales company faces significant litigation related vioxx september old merck voluntarily withdrew vioxx arthritis acute pain medication market worldwide although old merck settled major portion us product liability litigation company still faces material litigation arising voluntary withdrawal vioxx addition vioxx product liability lawsuits various purported class actions individual lawsuits brought old merck several current former officers directors company alleging old merck made false misleading statements regarding vioxx violation federal state securities laws suits referred vioxx securities lawsuits april judge chesler granted defendants motion dismiss complaint prejudice plaintiffs appealed judge cheslers decision united states court appeals third circuit september third circuit issued opinion reversing judge cheslers order remanding case district court old merck filed petition writ certiorari united states supreme court granted oral argument held supreme court november decision expected first half old mercks table contents petition certiorari pending plaintiffs filed consolidated fifth amended class action complaint district court may defendants moved dismiss fiffth amended class action complaint motion withdrawn without prejudice refile pending outcome supreme court addition various putative class actions brought old merck several current former employees officers directors company alleging violations erisa suits referred vioxx erisa lawsuits together vioxx securities lawsuits vioxx shareholder lawsuits vioxx shareholder lawsuits discussed fully item legal proceedings old merck also named defendant actions various countries outside united states suits referred vioxx foreign lawsuits old merck also sued ten states five counties new york city respect marketing vioxx us department justice doj issued subpoenas requesting information relating old mercks research marketing selling activities respect vioxx federal health care investigation criminal statutes investigation includes subpoenas witnesses appear grand jury also ongoing investigations local authorities europe company cooperating authorities investigations investigations referred vioxx investigations company predict outcome investigations however could result potential civil andor criminal remedies vioxx product liability litigation discussed fully item legal proceedings trial representative action australia concluded june federal court australia named plaintiff alleges suffered mi seeks represent others australia ingested vioxx suffered mi thrombotic stroke unstable angina transient ischemic attack peripheral vascular disease trial judge reserved decision matter company currently anticipates two us vioxx product liability lawsuits tried company predict timing trials related vioxx litigation company believes meritorious defenses vioxx product liability lawsuits vioxx shareholder lawsuits vioxx foreign lawsuits collectively vioxx lawsuits vigorously defend companys insurance coverage respect vioxx lawsuits adequate cover defense costs losses merck spent approximately million aggregate legal defense costs worldwide related vioxx lawsuits ii vioxx investigations collectively vioxx litigation merck recorded charges million including million fourth quarter add reserve solely future legal defense costs related vioxx litigation million december million vioxx reserve december amount vioxx reserve based certain assumptions described item legal proceedings best estimate minimum amount company believes incurred connection remaining aspects vioxx litigation however events additional trials vioxx litigation events could arise course vioxx litigation could affect ultimate amount defense costs incurred company company currently able estimate additional amounts may required pay connection vioxx lawsuits vioxx investigations proceedings still expected continue years company predict course proceedings take view inherent difficulty predicting outcome litigation particularly many claimants claimants seek unspecified damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits included settlement program reserve established connection settlement shareholder derivative actions discussed item legal proceedings company established reserves potential liability relating vioxx lawsuits included settlement program vioxx investigations series unfavorable outcomes vioxx lawsuits vioxx investigations resulting payment substantial damages fines resulting criminal penalties could material adverse effect companys business cash flow results operations financial position prospects table contents issues concerning vytorin enhance seas clinical trials adverse effect sales vytorin zetia united states results ongoing trials could adverse effect sales company sells vytorin zetia previously disclosed january legacy companies announced results enhance clinical trial imaging trial patients heterozygous familial hypercholesterolemia rare genetic condition causes high levels ldl bad cholesterol greatly increases risk premature coronary artery disease previously reported despite fact ezetimibesimvastatin mg vytorin significantly lowered ldl bad cholesterol simvastatin mg alone significant difference treatment ezetimibesimvastatin simvastatin alone prespecified primary endpoint change thickness carotid artery walls two years measured ultrasound improveit trial underway designed provide cardiovascular outcomes data ezetimibesimvastatin patients acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrated simvastatin established january fda announced completed review final clinical study report enhance fda stated results enhance change position elevated ldl cholesterol risk factor cardiovascular disease lowering ldl cholesterol reduces risk cardiovascular disease discussion concerning litigation arising enhance study see item legal proceedings previously disclosed legacy companies received several letters addressed companies house committee energy commerce subcommittee oversight investigations oi ranking minority member senate finance committee collectively seeking combination witness interviews documents information variety issues related enhance clinical trial sale promotion vytorin well sales stock corporate officers addition legacy companies received three additional letters oi seeking certain information documents related seas clinical trial described detail legacy companies also received subpoenas new york new jersey state attorneys general offices letter connecticut attorney general seeking similar information documents finally september legacy companies received letter civil division doj informing doj investigating whether companies conduct relating promotion vytorin caused false claims submitted federal health care programs company cooperating investigations previously disclosed number shareholder lawsuits arising enhance study brought old merck scheringplough july efficacy safety results seas study announced seas designed evaluate whether intensive lipid lowering vytorin mg would reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patients asymptomatic mild moderate aortic stenosis indication statin therapy vytorin failed meet primary endpoint reduction major cardiovascular events study patients group took vytorin mg higher incidence cancer group took placebo also nonsignificant increase deaths cancer patients group took vytorin versus took placebo cancer cancer deaths distributed across major organ systems company believes cancer finding seas likely anomaly taken light available data support association vytorin august fda announced investigating results seas trial december fda announced completed review data seas trial well review interim data sharp improveit trials based currently available information fda indicated believed unlikely vytorin zetia increase risk cancerrelated death sharp trial expected completed improveit trial scheduled completion improveit trial blinded interim efficacy analysis conducted data safety monitoring board trial approximately endpoints accrued interim analysis expected conducted based results interim analysis trial halted concerns related vytorin could material adverse effect sales vytorin zetia similarly noted sharp trial expected completed negative results sharp trial could also adverse affect sales vytorin zetia table contents following announcements enhance seas clinical trial results sales vytorin zetia declined united states issues concerning enhance seas clinical trials adverse effect sales vytorin zetia could continue adverse effect sales sales products materially adversely affected companys business cash flow results operations financial position prospects could also materially adversely affected addition unfavorable outcomes resulting litigation concerning sale promotion products could material adverse effect companys business cash flow results operations financial position prospects arbitration proceeding commenced centocor scheringplough may result companys loss rights market remicade simponi subsidiary company party distribution agreement centocor wholly owned subsidiary johnson johnson scheringplough subsidiary rights distribute commercialize rheumatoid arthritis treatment remicade simponi nextgeneration treatment certain territories section c distribution agreement either party acquired third party otherwise comes control defined section distribution agreement third party promptly notify party subject change control party subject change control right however later thirty days notification notify writing party subject change control termination agreement taking effect immediately used herein change control shall mean merger reorganization consolidation combination party agreement surviving corporation ii person within meaning section section securities exchange act excluding partys affiliates becomes beneficial owner directly indirectly securities party representing fifty percent either thenoutstanding shares common stock party b combined voting power partys thenoutstanding voting securities iii individuals effective date april constitute board directors party incumbent board cease reason constitute least majority board directors party provided however individual becoming director subsequent effective date whose election nomination election partys shareholders approved vote least majority directors comprising incumbent board shall considered though individual member incumbent board excluding purpose individual whose initial assumption office occurs result actual threatened election contest respect election removal directors actual threatened solicitation proxies consents behalf person board iv approval shareholders party complete liquidation complete dissolution party section distribution agreement defines control mean ability entity controlling entity directly indirectly ownership securities agreement method direct manner fifty percent outstanding voting rights entity controlled entity whether represented securities shall cast right receive fifty percent profits earnings otherwise control management decisions entity also controlled entity may centocor delivered scheringplough notice initiating arbitration proceeding resolve whether result proposed merger centocor permitted terminate distribution agreement related agreements part arbitration process centocor take position right terminate distribution agreement grounds merger scheringplough scheringplough subsidiary party distribution agreement acquired third party otherwise comeing control defined section third party andor ii undergoing change control defined section c hearing arbitration scheduled commence late september sales remicade simponi included companys results postmerger period million million respectively sales remicade recognized scheringplough prior merger billion company vigorously contesting centocors attempt terminate distribution agreement result merger however arbitrator conclude centocor permitted terminate distribution agreement result merger centocor fact terminates distribution agreement table contents companys subsidiary would able distribute remicade simponi addition arbitration centocor claiming damages amount determined result mercks alleged nontermination distribution agreement centocor prevail arbitration merck could liable net damages including offsets mitigation arbitration panel finds centocor incurred result nontermination company would suffer impairment charge unfavorable outcome arbitration would material adverse effect companys financial position liquidity results operations finally due uncertainty surrounding outcome arbitration parties may choose settle dispute mutually agreeable terms agreement reached centocor resolve dispute distribution agreement may result terms distribution agreement modified manner may reduce benefits distribution agreement company pharmaceutical products develop unexpected safety efficacy concerns unexpected safety efficacy concerns arise respect marketed products whether scientifically justified leading product recalls withdrawals declining sales well product liability consumer fraud andor claims changes laws regulations could adversely affect companys business aspects companys business including research development manufacturing marketing pricing sales litigation intellectual property rights subject extensive legislation regulation changes applicable federal state laws agency regulations could material adverse effect companys business reliance third party relationships outsourcing arrangements could adversely affect companys business company depends third parties including suppliers alliances pharmaceutical biotechnology companies third party service providers key aspects business including development manufacture commercialization products support information technology systems failure third parties meet contractual regulatory obligations company development factors materially disrupt relationships company third parties could material adverse effect companys business company increasingly dependent sophisticated information technology infrastructure company increasingly dependent sophisticated information technology infrastructure significant breakdown intrusion interruption corruption systems data breaches could material adverse effect business addition company currently proceeding multiyear implementation enterprise wide resource planning system includes modification design operation documentation internal controls financial reporting intends implement resource planning system united states material problems implementation could material adverse effect companys business developments following regulatory approval may adversely affect sales companys products even product reaches market certain developments following regulatory approval including results postmarketing phase iv trials may decrease demand companys products including following rereview products already marketed new scientific information evolution scientific theories recall loss marketing approval products already marketed changing government standards public expectations regarding safety efficacy labeling changes greater scrutiny advertising promotion table contents past several years clinical trials postmarketing surveillance certain marketed drugs company competitors within industry raised safety concerns led recalls withdrawals adverse labeling marketed products clinical trials postmarketing surveillance certain marketed drugs also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials led increased volatility market reaction matters often attract litigation even basis litigation groundless considerable resources may needed respond addition following wake product withdrawals significant safety issues health authorities fda european medicines agency emea pharmaceutical medical device agency increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications rereviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown side effects discovered increase negative publicity regarding known side effects companys products could significantly reduce demand product require company take actions could negatively affect sales including removing product market restricting distribution applying labeling changes current environment pharmaceutical companies operate company risk product liability claims products negative events animal health industry could negative impact future results operations future sales key animal health products could adversely impacted number risk factors including certain risks specific animal health business example outbreak disease carried animals bovine spongiform encephalopathy bse mad cow disease could lead widespread death precautionary destruction well reduced consumption demand animals could adversely impact companys results operations also outbreak highly contagious diseases near companys main production sites could require company immediately halt production vaccines sites force company incur substantial expenses procuring raw materials vaccines elsewhere risks specific animal health include epidemics pandemics government procurement pricing practices weather global agribusiness economic events animal health segment companys business becomes significant impact events future results operations would also become significant biologics carry unique risks uncertainties could negative impact future results operations successful development testing manufacturing commercialization biologics particularly human animal health vaccines long expensive uncertain process unique risks uncertainties biologics including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple jurisdictions united states european states within eu could result restricted access transport use materials company loses access sufficient sources materials tighter restrictions imposed use materials company may able conduct research activities planned may incur additional development costs development manufacturing marketing biologics subject regulation fda emea regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example united states bla including preclinical clinical trial data extensive data regarding manufacturing table contents procedures required human vaccine candidates fda approval required release manufactured lot manufacturing biologics especially large quantities often complex may require use innovative technologies handle living microorganisms lot approved biologic must undergo thorough testing identity strength quality purity potency manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage changes made manufacturing process company may required provide preclinical clinical data showing comparable identity strength quality purity potency products changes biologics frequently costly manufacture production ingredients derived living animal plant material biologics made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines use biologically derived ingredients lead allegations harm including infections allergic reactions closure product facilities due possible contamination events could result substantial costs currently process united states submission approval generic biologics based upon abbreviated data packages showing sameness another approved biologic public dialogue fda congress regarding scientific statutory basis upon products known biosimilars follow biologics could approved marketed united states company certain congress create statutory pathway approval biosimilars company predict impact approval biosimilars would sales company products united states europe however emea issued guidelines approving biological products abbreviated pathway biosimilars approved europe biosimilar version one companys products approved europe could negative effect sales product company exposed market risk fluctuations currency exchange rates interest rates company operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally company entered enter acquisition licensing borrowings financial transactions may give rise currency interest rate exposure since company certainty foresee mitigate adverse fluctuations fluctuations currency exchange rates interest rates could negatively affect companys results operations financial position cash flows order mitigate adverse impact market fluctuations company time time enter hedging agreements hedging agreements currency options interest rate swaps may limit exposure exchange rate interest rate fluctuations attempts mitigate risks may costly always successful company subject evolving complex tax laws may result additional liabilities may affect results operations company subject evolving complex tax laws jurisdictions operates significant judgment required determining companys tax liabilities companys tax returns periodically examined various tax authorities company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities however due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued february president obamas administration proposed significant changes us international tax laws including changes would limit us tax deductions expenses related unrepatriated table contents foreignsource income modify us foreign tax credit rules determine whether proposals enacted law changes may made proposals prior enacted law changes us international tax laws enacted could significant impact financial results company addition company may impacted changes tax laws including tax rate changes changes laws related remittance foreign earnings deferral limitations impacting us tax treatment foreign earnings new tax laws revised tax law interpretations domestic foreign jurisdictions company may fail realize anticipated cost savings revenue enhancements benefits expected merger could adversely affect value companys common stock success merger depend part companys ability successfully combine businesses old merck scheringplough realize anticipated benefits cost savings combination two companies combined company able achieve objectives within anticipated time frame value companys common stock may adversely affected possible integration process could result loss key employees result disruption legacy companys ongoing businesses identify inconsistencies standards controls procedures policies adversely affect ability maintain relationships customers suppliers distributors creditors lessors clinical trial investigators managers achieve anticipated benefits merger specifically issues must addressed integrating operations two legacy companies order realize anticipated benefits merger include among things integrating research development manufacturing distribution marketing promotion activities information technology systems old merck schering plough conforming standards controls procedures accounting policies business cultures compensation structures companies identifying eliminating redundant underperforming operations assets managing tax costs inefficiencies associated integrating operations combined company integration efforts two companies also divert management attention resources inability realize full extent anticipated benefits merger well delays encountered integration process could adverse effect companys business results operations may affect value shares company common stock addition actual integration may result additional unforeseen expenses anticipated benefits integration plan may realized actual cost sales synergies achieved may lower company expects may take longer achieve anticipated company able adequately address challenges may unable successfully integrate operations two legacy companies realize anticipated benefits integration two legacy companies delays encountered integration process could material adverse effect revenues expenses operating results financial condition company although company expects significant benefits increased cost savings result merger assurance company realize anticipated benefits company incur significant transaction mergerrelated transition costs connection merger company incur significant costs connection consummating merger integrating operations two companies significant portion costs incurred first year completion merger company continues assess magnitude costs additional unanticipated costs may incurred integration businesses two legacy companies although company believes elimination duplicative costs well realization efficiencies related integration businesses offset incremental transaction mergerrelated costs time assurance given net benefit achieved near term table contents companys debt obligations incurred finance merger could adversely affect business companys financing strategy merger focused preserving financial strength flexibility continue invest companys business key growth drivers postmerger debt obligations incurred finance merger could affect companys flexibility planning reacting changes business industry operates thereby placing competitive disadvantage compared competitors less indebtedness company decides retire pay indebtedness early may required dedicate substantial portion cash flow operations thereby reducing availability cash flow purposes including business development efforts mergers acquisitions product liability insurance products may limited cost prohibitive unavailable result number factors product liability insurance become less available cost increased significantly respect product liability company self insures substantially risk availability commercial insurance become restrictive company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august including liability legacy merck products first sold date company continually assess efficient means address risk however guarantee insurance coverage obtained obtained sufficient fully cover product liabilities may arise company significant global operations expose additional risks adverse event could material negative impact companys results operations extent companys operations outside united states significant due fact majority scheringploughs legacy operations outside united states risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets multiple regulatory requirements could restrict companys ability manufacture sell products key markets trade protection measures import export licensing requirements foreign exchange fluctuations diminished protection intellectual property countries possible nationalization expropriation discussed venezuelan economy recently determined hyperinflationary requires company remeasure local currency operations us dollars remeasurement recorded first quarter addition venezuelan government recently devalued currency actions adverse effect companys results operations financial position cash flows addition may changes companys business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease cautionary factors may affect future results cautionary statements private securities litigation reform act report including annual report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product table contents potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following competition generic products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales significant litigation related vioxx vytorin zetia arbitration proceeding involving companys right distribute remicade simponi legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority states united states requiring security breach notification changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties see risk factors item b unresolved staff comments none table contents item properties companys corporate headquarters located whitehouse station new jersey companys us commercial operations headquartered upper gwynedd pennsylvania companys us pharmaceutical business conducted divisional headquarters located upper gwynedd whitehouse station new jersey companys vaccines business conducted divisional headquarters located west point pennsylvania mercks animal health global headquarters located boxmeer netherlands principal us research facilities located rahway kenilworth summit union new jersey west point palo alto california nebraska animal health principal research facilities outside us located netherlands scotland company also production facilities human health products locations united states puerto rico outside united states subsidiaries company owns interest manufacturing plants properties australia canada japan singapore south africa countries western europe central south america asia capital expenditures billion compared billion united states amounted million million abroad expenditures amounted million million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company considers properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions vioxx litigation product liability lawsuits previously disclosed individual putative class actions filed old merck state federal courts alleging personal injury andor economic loss respect purchase use vioxx actions filed federal court coordinated multidistrict litigation us district court eastern district louisiana mdl district judge eldon e fallon number actions filed state court coordinated separate coordinated proceedings state courts new jersey california texas counties philadelphia pennsylvania washoe clark counties nevada december company served aware named defendant approximately pending lawsuits include approximately plaintiff groups alleging personal injuries resulting use vioxx approximately putative class actions alleging personal injuries andor economic loss actions discussed paragraph lawsuits collectively referred vioxx product liability lawsuits lawsuits approximately lawsuits representing approximately plaintiff groups slated federal mdl approximately lawsuits representing approximately plaintiff groups included coordinated proceeding new jersey superior court judge carol e higbee plaintiff groups described currently vioxx settlement program described december plaintiff groups otherwise eligible settlement program participated claims remain pending old merck addition claims approximately plaintiff groups eligible settlement program remain pending old merck number plaintiff groups subject various motions dismiss failure comply courtordered deadlines since december certain plaintiff groups since dismissed addition table contents claims plaintiffs dismissed december vast majority dismissed result settlement process discussed november old merck announced entered agreement settlement agreement law firms comprise executive committee plaintiffs steering committee psc federal vioxx mdl well representatives plaintiffs counsel texas new jersey california state coordinated proceedings resolve state federal myocardial infarction mi ischemic stroke claims filed date united states settlement agreement applies us legal residents allege mi occurred united states settlement agreement provided old merck pay fixed aggregate amount billion two funds billion mi claims million claims interim final payments made certain qualifying claimants expected remainder full billion distributed first half company completed making payments settlement funds two us vioxx product liability lawsuits currently scheduled trial old merck previously disclosed outcomes several vioxx product liability lawsuits tried prior cases went trial mcdarby matter resolved fourth quarter leaving two unresolved posttrial appeals ernst v merck garza v merck previously reported september old merck filed notice appeal august jury verdict favor plaintiff texas state court case ernst v merck may texas court appeals reversed trial courts judgment issued judgment favor old merck court appeals found evidence legally insufficient issue causation plaintiff filed motion rehearing en banc court appeals june response plaintiffs motion rehearing court appeals issued new opinion reversing jurys verdict rendered judgment old merck september plaintiff filed second motion rehearing en banc court appeals denied november december plaintiff filed another motion rehearing court appeals denied plaintiff filed petition review supreme court texas february previously reported april garza v merck jury state court rio grande city texas returned verdict favor family decedent leonel garza jury awarded total million compensatory damages mr garzas widow three sons jury also purported award million punitive damages even though texas law case potential punitive damages capped may san antonio court appeals reversed judgment rendered judgment favor old merck december court appeals rehearing vacated prior ruling issued replacement new ruling court ordered takenothing judgment old merck design defect claim reversed remanded new trial strict liability claim juror misconduct january old merck filed petition review texas supreme court texas supreme court granted old mercks petition review oral argument held january lawsuits approximately claims individual private thirdparty payors filed new jersey court federal court mdl september old merck announced finalized settlement agreement previously disclosed resolve pending lawsuits usbased private thirdparty payors tpps sought reimbursement covering vioxx purchased plan members certain claimants participated resolution well agreement provided old merck admit wrongdoing fault settlement agreement old merck paid fixed total million amount includes settlement fund divided among tpps insurers employee benefit plans union welfare funds participating resolution accordance formula based product volume provision potential payment attorneys fees return settling tpps dismiss lawsuits release claims old merck stipulated dismissals settled ttp actions filed new jersey mdl december old merck recorded charge million second quarter related settlement paid table contents million fourth quarter since settlement one additional tpp case filed pending mdl proceeding separately also still pending various us courts putative class actions purportedly brought behalf individual purchasers users vioxx seeking reimbursement alleged economic loss mdl proceeding class actions remain old merck moved dismiss master complaint includes cases mdl court yet ruled motion march new jersey superior court denied plaintiffs motion class certification martinkleinman v merck putative consumer class action plaintiffs moved leave appeal decision new jersey supreme court november january new jersey supreme court denied plaintiffs request appellate review denial class certification june missouri state court certified class missouri plaintiffs seeking reimbursement outofpocket costs relating vioxx plaintiffs allege personal injuries taking vioxx missouri court appeals affirmed trial courts certification class may missouri supreme court denied old mercks application review decision september trial set april addition indiana plaintiffs filed motion certify class indiana vioxx purchasers case pending circuit court marion county indiana discovery case ongoing briefing complete plaintiffs motion certify class kentucky vioxx purchasers circuit court pike county kentucky hearing matter held february judge cook county illinois consolidated three putative class actions brought vioxx purchasers plaintiffs actions recently voluntarily dismissed lawsuits plaintiffs also filed class action california state court seeking certification class california thirdparty payors endusers trial court denied motion class certification april court appeal affirmed ruling december january plaintiffs filed petition review california supreme court old merck also named defendant twentyone separate lawsuits brought government entities including attorneys general thirteen states five counties city new york private citizens brought qui tam taxpayer derivative suits actions allege old merck misrepresented safety vioxx seek recovery cost vioxx purchased reimbursed government entity agencies ii reimbursement sums paid government entity agencies medical services treatment persons injured vioxx iii damages various common law theories andor iv remedies various state statutory theories including state consumer fraud andor fair business practices medicaid fraud statutes including civil penalties nine thirteen cases pending mdl proceeding two subject conditional orders transferring mdl proceeding two remanded state court one lawsuits brought counties class action filed santa clara county california behalf similarly situated california counties old mercks motion summary judgment granted november case brought attorney general texas scheduled go trial early texas attorney general appeal michigan attorney general case old merck currently seeking appellate review trial courts order denying old mercks motion dismiss trial court entered stay proceedings including discovery pending result appeal finally attorney general actions mdl described previous paragraph discovery phase louisiana attorney general case currently scheduled trial mdl court april shareholder lawsuits previously disclosed addition vioxx product liability lawsuits old merck various current former officers directors defendants various putative class actions individual lawsuits federal securities laws state securities laws vioxx securities lawsuits vioxx securities lawsuits pending federal court transferred judicial panel multidistrict litigation jpml us district court district new jersey district judge stanley r chesler inclusion nationwide mdl shareholder mdl judge chesler consolidated vioxx securities table contents lawsuits purposes putative class action requested damages behalf purchasers old merck stock may october alleged defendants made false misleading statements regarding vioxx violation sections b securities exchange act sought unspecified compensatory damages costs suit including attorneys fees complaint also asserted claims section securities exchange act certain defendants relating sales old merck stock sections securities act certain defendants based statements registration statement certain prospectuses filed connection old merck stock investment plan dividend reinvestment plan april judge chesler granted defendants motion dismiss complaint prejudice plaintiffs appealed judge cheslers decision us court appeals third circuit september third circuit issued opinion reversing judge cheslers order remanding case district court old merck filed petition writ certiorari united states supreme court january supreme court granted may oral argument held november decision expected first half petition certiorari pending plaintiffs filed consolidated fifth amended class action complaint district court old merck filed motion dismiss complaint may following district court proceedings stayed pending outcome supreme court appeal motion dismiss district court withdrawn without prejudice old mercks right refile motion pending outcome supreme court appeal october dutch pension fund filed complaint district new jersey alleging violations federal securities laws well violations state law old merck certain officers pursuant case management order governing shareholder mdl case based allegations vioxx securities lawsuits consolidated vioxx securities lawsuits defendants motion dismiss pension funds complaint filed august september dutch pension fund filed amended complaint rather responding defendants motion dismiss addition six new complaints filed district new jersey behalf various foreign institutional investors also alleging violations federal securities laws well violations state law old merck certain officers stipulation defendants required respond complaints resolution motion dismiss consolidated securities action addition previously disclosed various putative class actions filed federal court employee retirement income security act erisa old merck certain current former officers directors vioxx erisa lawsuits together vioxx securities lawsuits vioxx derivative lawsuits described vioxx shareholder lawsuits transferred shareholder mdl consolidated purposes consolidated complaint asserts claims breach fiduciary duty behalf certain old mercks current former employees participants certain old mercks retirement plans complaint makes similar allegations respect vioxx allegations contained vioxx securities lawsuits july judge chesler granted part denied part defendants motion dismiss erisa complaint october plaintiffs moved certification class individuals participants beneficiaries old mercks retirement savings plans time october september whose plan accounts included investments old merck common stock fund andor old merck common stock february court denied motion certification class one count granted motion remaining counts court also excluded class definition individuals injured connection investments old merck stock ii executed post separation settlement agreements released claims erisa march judge chesler denied defendants motion judgment pleadings may judge chesler entered order denying plaintiffs motion partial summary judgment certain individual defendants filed december previously disclosed october two individual shareholders made demand old mercks board take legal action mr raymond gilmartin former chairman president chief executive officer individuals allegedly causing damage old merck respect allegedly improper marketing vioxx december special committee board directors retained honorable john martin jr debevoise plimpton llp conduct independent investigation among things allegations set forth demand judge martins report made public september table contents based special committees recommendation made careful consideration martin report impact derivative litigation would old merck board rejected demand october two shareholders filed shareholder derivative lawsuit purportedly old mercks behalf state court atlantic county new jersey current former officers directors old merck plaintiffs alleged boards rejection demand unreasonable improper defendants breached various duties old merck allowing vioxx marketed parties reached proposed settlement february court issued order preliminarily approving settlement requiring notice proposed settlement made mercks shareholders setting hearing consider final approval settlement march february merck notified shareholders proposed settlement terms proposed settlement merck agreed make certain corporate governance changes supplement policies procedures previously established company agreed pay award fees expenses plaintiffs attorneys amount determined court exceed million addition merck plaintiffs individual defendants exchange full mutual releases claims could asserted derivative actions proposed settlement constitute admission liability wrongful conduct merck defendants named actions approved court proposed settlement also resolve federal consolidated shareholder derivative action described previously disclosed various shareholder derivative actions filed federal court transferred shareholder mdl consolidated purposes judge chesler vioxx derivative lawsuits may judge chesler granted defendants motion dismiss grounds plaintiffs failed demonstrate demand excused denied plaintiffs request leave amend complaint plaintiffs appealed arguing judge chesler erred denying plaintiffs leave amend complaint documents acquired stipulation parties july united states court appeals third circuit reversed district courts decision grounds judge chesler allowed plaintiffs seek leave amend complaint using documents acquired stipulation remanded case district courts consideration whether even additional materials plaintiffs proposed amendment would futile plaintiffs filed brief support request leave amend complaint along proposed amended complaint november court denied motion june dismissed case one plaintiffs appealed judge cheslers decision united states court appeals third circuit oral argument appeal held july november decision issued appeal stayed pending approval settlement reached derivative action pending new jersey superior court would resolve state federal shareholder derivative claims relating vioxx international lawsuits previously disclosed addition lawsuits discussed old merck named defendant litigation relating vioxx various countries collectively vioxx foreign lawsuits europe well canada brazil argentina australia turkey israel philippines singapore november superior court quebec authorized institution class action behalf individuals quebec consumed vioxx suffered damages arising ingestion may plaintiffs served introductory motion class action based upon authorization case remains preliminary stages litigation may provincial court queens bench saskatchewan canada entered order certifying class vioxx users canada except quebec old merck appealed certification order march court appeal granted old mercks appeal quashed certification order october supreme court canada dismissed plaintiffs appeal application decided review judgment saskatchewan court appeal july superior court ontario denied old mercks motion stay class proceedings ontario decided certify overlapping class vioxx users canada except quebec saskatchewan allege negligence entitlement elect waive tort february ontario divisional court dismissed appeal order denying stay may ontario court appeal denied leave appeal october supreme court canada dismissed old mercks application decided review judgment ontario court appeal court appeal saskatchewan quashed multijurisdictional certification order entered province old merck applied ontario court appeal leave appeal table contents ontario certification order leave appeal granted appeal filed may accordance courts decision old merck sought leave appeal divisional court denied december procedural decisions canadian litigation address merits plaintiffs claims litigation canada remains early stage trial representative action australia commenced march federal court australia named plaintiff alleges suffered mi seeks represent others australia ingested vioxx suffered mi thrombotic stroke unstable angina transient ischemic attack peripheral vascular disease march trial judge entered order directing advance issues proceeding issues determined trial issues fact law named plaintiffs individual case issues fact law trial judge finds hearing evidence common claims group members named plaintiff alleged represents trial representative action concluded june trial judge reserved decision insurance previously disclosed company directors officers insurance coverage applicable vioxx securities lawsuits vioxx derivative lawsuits stated upper limits approximately million company fiduciary insurance vioxx erisa lawsuits stated upper limits approximately million result previously disclosed arbitration additional insurance coverage claims also available needed upperlevel excess policies provide coverage variety risks disputes insurers availability companys insurance coverage claims likely additional disputes amounts actually recovered policies discussed paragraph may less stated upper limits investigations previously disclosed old merck received subpoenas doj requesting information related old mercks research marketing selling activities respect vioxx federal health care investigation criminal statutes investigation includes subpoenas witnesses appear grand jury previously disclosed march old merck received letter us attorneys office district massachusetts identifying target grand jury investigation regarding vioxx previously disclosed investigations conducted local authorities certain cities europe order determine whether criminal charges brought concerning vioxx company cooperating governmental entities respective investigations vioxx investigations company predict outcome inquiries however could result potential civil andor criminal remedies addition old merck received subpoena september state california attorney general seeking documents information related placement vioxx californias medical formulary company cooperating attorney general responding subpoena reserves discussed november old merck entered settlement agreement law firms comprise executive committee psc federal vioxx mdl well representatives plaintiffs counsel texas new jersey california state coordinated proceedings resolve state federal mi claims filed date united states result entering settlement agreement old merck recorded pretax charge billion represents fixed aggregate amount paid plaintiffs qualifying payment settlement program two us vioxx product liability lawsuit trials scheduled trial company predict timing trials related vioxx litigation company believes meritorious defenses vioxx product liability lawsuits vioxx shareholder lawsuits vioxx foreign lawsuits collectively vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits included table contents settlement program company established reserves potential liability relating vioxx lawsuits included settlement program reserve established connection resolution shareholder derivative lawsuits discussed vioxx investigations unfavorable outcomes vioxx litigation could material adverse effect companys financial position liquidity results operations legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable december old merck aggregate reserve approximately billion vioxx reserve settlement program future legal defense costs related vioxx litigation merck spent approximately million aggregate legal defense costs worldwide including approximately million fourth quarter related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation addition old merck paid additional billion settlement funds connection settlement program also merck recorded million charges including million fourth quarter solely future legal defense costs vioxx litigation consequently december aggregate amount vioxx reserve approximately million solely future legal defense costs vioxx litigation significant factors considered review vioxx reserve follows actual costs incurred company development companys legal defense strategy structure light scope vioxx litigation including settlement agreement expectation certain lawsuits continue pending number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials vioxx litigation amount vioxx reserve december represents companys best estimate minimum amount defense costs incurred connection remaining aspects vioxx litigation however events additional trials vioxx litigation events could arise course vioxx litigation could affect ultimate amount defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase vioxx reserve time future based upon factors set forth believes would appropriate product liability litigation fosamax previously disclosed old merck defendant product liability lawsuits united states involving fosamax fosamax litigation december approximately cases include approximately plaintiff groups filed pending old merck either federal state court including one case seeks class action certification well damages andor medical monitoring actions plaintiffs allege among things suffered osteonecrosis jaw generally subsequent invasive dental procedures tooth extraction dental implants andor delayed healing association use fosamax addition plaintiffs approximately five percent actions allege sustained stress andor low energy femoral fractures association use fosamax august jpml ordered fosamax product liability cases pending federal courts nationwide transferred consolidated one multidistrict litigation fosamax mdl coordinated pretrial proceedings fosamax mdl transferred judge john keenan us district court southern district new york result jpml order approximately cases judge keenan judge keenan issued case management order various amendments thereto setting forth schedule governing proceedings focused primarily upon resolving class action certification motions completing fact discovery initial group cases october briefing argument plaintiffs motions certification medical monitoring classes completed judge keenan issued order denying motions january january judge keenan issued order dismissing prejudice class claims asserted first four class action lawsuits filed old merck sought personal injury damages andor medical monitoring relief class wide basis daubert motions filed table contents may judge keenan conducted daubert hearing july july judge keenan issued ruling parties respective daubert motions ruling denied plaintiff steering committees motion granted part denied part old mercks motion first mdl trial boles v merck began august ended september september mdl court declared mistrial boles eight person jury could reach unanimous verdict consequently boles case set retried june second mdl case set trial flemings v merck scheduled start january judge keenan granted old mercks motion summary judgment dismissed case november next mdl case set trial maley v merck currently scheduled start april old merck filed motion summary judgment maley mdl court granted part denied part january result company expects trial commence currently scheduled april february judge keenan selected new bellwether case judith graves v merck replace flemings bellwether case mdl court dismissed granted summary judgment favor old merck mdl court set graves trial begin september trial alabama currently scheduled begin may trial florida currently scheduled begin june addition july application made atlantic county superior court new jersey requesting fosamax cases pending new jersey considered mass tort designation centralized management one judge new jersey october new jersey supreme court ordered pending future actions filed new jersey arising use fosamax seeking damages existing dental jawrelated injuries including osteonecrosis jaw solely seeking medical monitoring designated mass tort centralized management purposes judge higbee atlantic county superior court december approximately cases pending old merck new jersey coordinated proceeding july judge higbee entered case management order various amendments thereto setting forth schedule contemplates completing fact discovery initial group cases february followed expert discovery five cases projected trial date july first case tried new jersey coordinated proceeding discovery ongoing fosamax mdl litigation new jersey coordinated proceeding remaining jurisdictions fosamax cases pending company intends defend lawsuits december company remaining reserve approximately million solely future legal defense costs fosamax litigation company spent approximately million added million reserve consequently december company reserve approximately million solely future legal defense costs fosamax litigation significant factors considered establishment reserve fosamax litigation legal defense costs follows actual defense costs incurred thus far development companys legal defense strategy structure light creation fosamax mdl number cases brought company anticipated timing progression related costs pretrial activities fosamax litigation company continue monitor legal defense costs review adequacy associated reserves due uncertain nature litigation company unable reasonably estimate costs beyond third quarter company established reserves potential liability relating fosamax litigation unfavorable outcomes fosamax litigation could material adverse effect companys financial position liquidity results operations nuvaring beginning may number complaints filed various jurisdictions asserting claims companys subsidiaries organon usa inc organon pharmaceuticals usa inc organon international collectively organon scheringplough arising organons marketing sale nuvaring combined hormonal contraceptive vaginal ring plaintiffs contend organon scheringplough failed adequately warn alleged increased risk venous thromboembolism vte posed nuvaring andor downplayed risk vte plaintiffs seek damages injuries allegedly sustained product use including alleged deaths heart attacks strokes majority cases currently pending federal multidistrict litigation venued missouri new jersey state court cases pending states table contents vetsulin december scheringplough animal health named defendant putative class action lawsuit filed us district court northern district ohio lawsuit entitled friedman v scheringplough animal health individual plaintiff seeks represent class people purchased vetsulin household pets suit alleges vetsulin contaminated improperly manufactured vetsulin insulin product administered diabetic dogs cats plaintiff seeks compensatory punitive damages based theories negligence violation consumer sales practices acts breach warranty product liability due allegedly defective manufacturing merck intends defend lawsuit vigorously commercial litigation awp litigation investigations previously disclosed old merck joined ongoing litigation alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used calculations determine public private sector reimbursement levels complaints allege violations federal state law including fraud medicaid fraud consumer protection violations among claims outcome litigations investigations could include substantial damages imposition substantial fines penalties injunctive administrative remedies jpml ordered transfer consolidation pending federal awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions also expanded number manufacturers include like old merck defendants prior pending case may court granted old mercks motion dismiss consolidated class action dismissed old merck class action case old merck many pharmaceutical manufacturers defendants similar complaints pending federal state court including cases brought individually number counties state new york fifty county cases consolidated new york state court old merck dismissed suffolk county case first new york county cases filed addition new york county cases december old merck defendant state cases brought attorneys general eleven states defended february kansas attorney general filed suit old merck several manufacturers awp claims brought attorney general arizona old merck dropped court awp cases pending hawaii listed old merck others set trial mid scheringplough reached settlements claims relating awp august scheringplough five pharmaceutical companies settled claims brought behalf alabama medicaid program combined total million addition july scheringplough reached settlement relator acting behalf united states non intervened awp qui tam action pending us federal district court massachusetts states california florida combined total million settlement resolved claims brought behalf medicaid programs states california florida approved us district court district massachusetts held preclusive claims federal share alleged medicaid overpayment remaining states consistent applicable precedent january us district court district massachusetts held unit scheringplough eight drugmakers overcharged new york city new york counties certain generic drugs court reserved issue damages penalties future proceedings company continues respond litigation brought certain states private payors investigations initiated department health human services department justice several states regarding awp company cooperating investigations centocor distribution agreement may centocor wholly owned subsidiary johnson johnson delivered scheringplough notice initiating arbitration proceeding resolve whether result merger centocor permitted terminate companys rights distribute commercialize remicade simponi sales remicade simponi included companys results postmerger period million million respectively sales remicade recognized scheringplough prior merger table contents billion arbitration process involves number steps including selection independent arbitrators information exchanges hearings final decision reached hearing arbitration scheduled commence late september unfavorable outcome arbitration would material adverse effect companys financial position liquidity results operations information matter see item risk factors governmental proceedings previously disclosed february old merck entered corporate integrity agreement cia us department health human services office inspector general hhsoig fiveyear term cia requires among things old merck maintain ethics training program policies procedures governing promotional practices medicaid price reporting required cia old merck retained independent review organization iro conduct systems review promotional policies procedures conduct sample basis transactional reviews old mercks promotional programs certain medicaid pricing calculations old merck also required provide regular reports certifications hhsoig regarding compliance cia similarly previously disclosed scheringplough scheringplough entered cia hhsoig fiveyear term august entered addendum cia also effective five years requirements old merck scheringplough cias similar although identical failure comply cias requirements result financial penalties exclusion participation federal health care programs company believes promotional practices medicaid price reports meet requirements cias vytorinzetia litigation previously disclosed legacy companies received several letters house committee energy commerce subcommittee oversight investigations oi ranking minority member senate finance committee collectively seeking combination witness interviews documents information variety issues related enhance clinical trial sale promotion vytorin well sales stock corporate officers addition previously disclosed since august old merck scheringplough received three additional letters oi including identical letters dated february seeking certain information documents related seas clinical trial previously disclosed legacy companies received subpoenas new york state attorney generals office letter connecticut attorney general seeking similar information documents july legacy companies announced reached civil settlement attorneys general representing states district columbia resolve previously disclosed investigation group whether legacy companies violated state consumer protection laws marketing vytorin zetia part settlement legacy companies agreed reimburse investigative costs states district columbia totaled million make voluntary assurances compliance related promotion vytorin zetia including agreeing continue comply food drug cosmetic act us food drug administration amendments act laws requiring truthful nonmisleading marketing pharmaceutical products settlement include admission misconduct liability legacy companies furthermore previously disclosed september legacy companies received letters civil division doj informing doj investigating whether conduct relating promotion vytorin caused false claims submitted federal health care programs company cooperating investigations responding inquiries previously disclosed legacy companies become aware served approximately civil class action lawsuits alleging common law state consumer fraud claims connection msp partnerships sale promotion vytorin zetia certain lawsuits alleged personal injuries andor sought medical monitoring lawsuits old merck scheringplough consolidated single multidistrict litigation docket judge cavanaugh district new jersey vytorinzetia marketing sales practices products liability litigation august old merck scheringplough jointly announced cholesterol joint venture entered agreements resolve total fixed amount million civil class table contents action lawsuits msp partnership recorded charges second quarter february judge cavanaugh granted final approval settlements also previously disclosed april old merck shareholder filed putative class action lawsuit federal court eastern district pennsylvania alleging old merck chairman president chief executive officer richard clark violated federal securities laws suit since withdrawn refiled district new jersey consolidated another federal securities lawsuit caption merck co inc vytorin securities litigation amended consolidated complaint filed october names defendants old merck merckscheringplough pharmaceuticals llc certain companys current former officers directors specifically complaint alleges old merck delayed releasing unfavorable results enhance clinical trial regarding efficacy vytorin old merck made false misleading statements expected earnings knowing results vytorin study released sales vytorin would decline old mercks earnings would suffer december old merck defendants moved dismiss lawsuit grounds plaintiffs failed state claim relief granted september court issued opinion order denying defendants motion dismiss lawsuit october old merck defendants filed answer amended consolidated complaint similar consolidated putative class action securities lawsuit pending district new jersey filed scheringplough shareholder scheringplough former chairman president chief executive officer fred hassan caption scheringplough corporationenhance securities litigation amended consolidated complaint filed september names defendants schering plough merckscheringplough pharmaceuticals llc certain companys current former officers directors underwriters participated august public offering scheringploughs common preferred stock december scheringplough defendants filed motions dismiss lawsuit grounds plaintiffs failed state claim relief granted september court issued opinion order denying defendants motion dismiss lawsuit september defendants filed motion reconsideration courts september opinion order denying motion dismiss motion reconsideration fully briefed october decision remains pending defendants filed answer consolidated amended complaint november previously disclosed april member old merck erisa plan filed putative class action lawsuit old merck certain companys current former officers directors alleging breached fiduciary duties erisa since time similar erisa lawsuits filed old merck district new jersey lawsuits consolidated caption merck co inc vytorin erisa litigation consolidated amended complaint filed february names defendants old merck various current former members companys board directors plaintiffs allege erisa plans investment old merck stock imprudent old mercks earnings dependent commercial success cholesterol drug vytorin defendants knew known results scientific study would cause medical community turn less expensive drugs cholesterol management april old merck defendants moved dismiss lawsuit grounds plaintiffs failed state claim relief granted september court issued opinion order denying defendants motion dismiss lawsuit november plaintiffs moved strike certain defendants affirmative defenses motion fully briefed december pending court similar consolidated putative class action erisa lawsuit currently pending district new jersey filed member scheringplough erisa plan schering plough certain current former officers directors alleging breached fiduciary duties erisa caption scheringplough corp enhance erisa litigation consolidated amended complaint filed october names defendants scheringplough various current former members scheringploughs board directors current former members committees scheringploughs board directors november company defendants filed motion dismiss lawsuit grounds plaintiffs failed state claim relief granted plaintiffs opposition table contents motion dismiss filed december motion fully briefed january decision remains pending november stockholder company filed shareholder derivative lawsuit local international brotherhood electrical workers pension fund v clark local district new jersey behalf nominal defendant company shareholders company company certain companys officers directors alleged insiders certain predecessor companies former officers directors alleged insiders alleged breaches fiduciary duties waste unjust enrichment gross mismanagement similar shareholder derivative lawsuit cain v hassan filed scheringplough stockholder currently pending district new jersey amended complaint filed may scheringplough stockholder behalf nominal defendant scheringplough scheringplough shareholders lawsuit scheringplough scheringploughs thencurrent board directors certain scheringploughs current former officer directors alleged insiders plaintiffs local cain v hassan allege defendants withheld enhance study results made false misleading statements thereby deceiving causing harm company scheringplough respectively investing public unjustly enriching insiders wasting corporate assets defendants local intend move dismiss plaintiffs complaint defendants cain v hassan moved dismiss amended complaint july motion fully briefed october decision remains pending company intends defend lawsuits referred section unfavorable outcomes resulting government investigations civil litigations could material adverse effect companys financial position liquidity results operations november individual shareholder previously delivered letter old mercks board directors demanding board take legal action responsible individuals recover amounts paid old merck resolve certain governmental investigations delivered another letter board demanding board subcommittee thereof commence investigation matters raised various civil suits governmental investigations relating vytorin securities class action litigation federal securities litigation following scheringploughs announcement february fda conducting inspections manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices delayed approval clarinex several lawsuits filed scheringplough certain named officers lawsuits allege defendants violated federal securities law allegedly failing disclose material information making material misstatements specifically allege scheringplough failed disclose alleged serious risk new drug application clarinex would delayed result manufacturing issues allege company failed disclose alleged depth severity manufacturing issues complaints consolidated one action us district court district new jersey consolidated amended complaint filed october purporting represent class shareholders purchased shares scheringplough stock may february complaint sought compensatory damages behalf class february court signed order preliminarily approving settlement agreement scheringplough would provide settlement fund amount million resolve claims class funds placed escrow time vast majority settlement covered insurance december district court granted final approval settlement settlement due consummated expiration appeal period final approval decision erisa litigation march scheringplough served putative class action complaint filed us district court new jersey alleging scheringplough employee savings plan plan administrator several current former directors certain former corporate officers breached fiduciary obligations certain participants plan complaint seeks damages amount losses allegedly table contents suffered plan complaint dismissed june plaintiffs appealed august us court appeals third circuit reversed dismissal district court matter remanded back district court proceedings september district court entered order granting part denying part named putative class representatives motion class certification scheringplough thereafter petitioned us district court appeals third circuit leave appeal class certification decision scheringploughs petition granted december december third circuit vacated district courts order remanded case proceedings consistent courts ruling kdur antitrust litigation june january scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relating generic versions kdur scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upshersmith filed abbreviated new drug applications following commencement administrative proceeding united states federal trade commission ftc alleging anticompetitive effects settlements resolved scheringploughs favor alleged class action suits filed federal state courts behalf direct indirect purchasers kdur scheringplough upshersmith lederle suits claim violations federal state antitrust laws well state statutory common law causes action suits seek unspecified damages february special master recommended us district court district new jersey dismiss class action lawsuits summary judgment us district court judge yet ruled recommendation thirdparty payor actions discussed july connection settlement investigation doj us attorneys office eastern district pennsylvania schering plough entered fiveyear cia cia amended august connection million settlement investigation state massachusetts involving certain scheringploughs sales marketing clinical trial practices programs massachusetts investigation several purported class action litigations filed following announcement settlement massachusetts investigation plaintiffs actions seek damages behalf thirdparty payors resulting allegations offlabel promotion improper payments physicians issue massachusetts investigation actions consolidated multidistrict litigation federal district court district new jersey july district court dismissed consolidated class action complaint granted plaintiffs leave refile september plaintiffs filed amended complaints companys motion dismiss complaints pending vaccine litigation previously disclosed old merck party individual class action product liability lawsuits claims united states involving pediatric vaccines eg hepatitis b vaccine contained thimerosal preservative used vaccines december approximately thimerosal related lawsuits pending old merck defendant although vast majority lawsuits currently active defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result exposure thimerosal pediatric vaccines cases currently scheduled trial company defend lawsuits however possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations old merck successful cases type either dismissed stayed ground action prohibited national childhood vaccine injury act vaccine act vaccine act prohibits person filing maintaining civil action state federal court seeking damages vaccine manufacturer vaccinerelated injuries unless petition first filed united states court federal claims hereinafter vaccine court vaccine act filing civil action vaccine manufacturer petitioner must either pursue petition conclusion vaccine court timely table contents file election proceed civil action lieu accepting vaccine courts adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribed time periods old merck party vaccine court proceedings petitions brought united states department health human services company aware approximately cases pending vaccine court involving allegations thimerosalcontaining vaccines andor mmr ii vaccine cause autism spectrum disorders thimerosalcontaining vaccines involved vaccine court proceeding company vaccines company sole source mmr ii vaccine domestically special masters presiding vaccine court proceedings held hearings three test cases involving theory combination mmr ii vaccine thimerosal vaccines causes autism spectrum disorders february special masters issued decisions cases finding theory unsupported valid scientific evidence petitioners three cases therefore entitled compensation two three cases currently appeal special masters held similar hearings three different test cases involving theory thimerosal vaccines alone causes autism spectrum disorders decisions issued second set test cases special masters previously indicated would hold similar hearings involving theory mmr ii alone causes autism spectrum disorders stated longer intend vaccine court indicated intends use evidence presented test case hearings guide adjudication remaining autism spectrum disorder cases patent litigation time time generic manufacturers pharmaceutical products file andas fda seeking market generic forms companys products prior expiration relevant patents owned company generic pharmaceutical manufacturers submitted andas fda seeking market united states generic forms fosamax nexium singulair emend cancidas respectively prior expiration old mercks astrazenecas case nexium patents concerning products addition anda submitted fda seeking market united states generic form zetia anda submitted fda seeking market united states generic form vytorin prior expiration scheringploughs patent concerning product generic companies andas generally include allegations noninfringement invalidity unenforceability patents company filed patent infringement suits federal court companies filing andas generic alendronate fosamax montelukast singulair astrazeneca company filed patent infringement suits federal court companies filing andas generic esomeprazole nexium also company scheringplough filed patent infringement suits federal court companies filing andas generic versions ezetimibe zetia ezetimibesimvastatin vytorin also schering corp schering subsidiary company filed patent infringement suits federal court generic companies filing andas generic versions temodar integrilin levitra nasonex similar patent challenges exist certain foreign jurisdictions company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration dates patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products february scheringplough received notice generic company indicating filed anda zetia challenging us patents listed zetia prior merger company marketed zetia joint venture msp singapore company llc march scheringplough msp singapore company llc filed patent infringement suit glenmark pharmaceuticals inc usa parent corporation glenmark lawsuit automatically stays fda approval glenmarks anda october adverse court decision whichever may occur earlier trial matter scheduled commence may previously disclosed february old merck received notice teva pharmaceuticals inc teva generic company indicating filed anda montelukast challenging us patent listed singulair april old merck filed patent infringement action teva trial matter held february august court issued decision upholding table contents validity old mercks singulair patent ordered tevas anda could approved prior expiry old mercks exclusivity rights august teva appealed decision however january teva withdrew appeal trial courts decision upholding validity old mercks singulair patent addition may united states patent trademark office granted petition article one partners llc reexamine old mercks singulair patent december united states patent trademark office issued notice indicating allow claims companys singulair patent product exclusivity accordingly expected maintained august may federal court canada trial division issued decision refusing bar approval generic alendronate grounds old mercks patent weekly alendronate likely invalid decision appealed generic alendronate launched canada june july old merck sued federal court canada apotex corp apotex seeking damages lost sales generic weekly alendronate due patent proceeding october federal court canada issued decision awarding apotex lost profits generic alendronate product period time held market due old mercks lawsuit june trial court decision upheld part companies sought leave appeal supreme court canada january supreme court canada declined hear appeal leaving intact decision apotex entitled damages discrete period time market entry postponed due litigation launched old merck previously disclosed september old merck appealed decision opposition division european patent office epo revoked companys patent europe covers onceweekly administration alendronate march board appeal epo upheld decision opposition division revoking patent march epo issued another patent europe old merck covers onceweekly administration alendronate terms new patent effective july old merck sued multiple parties european countries asserting european patent covering onceweekly dosing fosamax decisions rendered netherlands belgium invalidating patent countries old merck appealed decisions oppositions filed epo patent hearing held march opposition division epo issued appealable decision revoking patent old merck appealed decision addition previously disclosed japan proceeding filed challenging validity old mercks japanese patent onceweekly administration alendronate patent office invalidated patent decision appeal october us patent dorzolamide covering trusopt cosopt expired old merck experienced significant decline us sales products company involved litigation proceedings corresponding patents canada great britain germany november trial court great britain issued decision finding old mercks cosopt patent invalid canada trial held december regarding companys canadian trusopt cosopt patents company awaiting decision old merck astrazeneca received notice october ranbaxy filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium november old merck astrazeneca sued ranbaxy us district court new jersey previously disclosed astrazeneca old merck ranbaxy entered settlement agreement provides ranbaxy bring generic esomeprazole product market united states may company astrazeneca received cid ftc july regarding settlement agreement ranbaxy company cooperating ftc responding cid old merck astrazeneca received notice january ivax pharmaceuticals inc ivax subsequently acquired teva filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium march old merck astrazeneca sued teva us district court new jersey january astrazeneca old merck tevaivax entered settlement agreement provides tevaivax bring generic esomeprazole product market united states may addition january old merck astrazeneca sued dr reddys laboratories dr reddys district court new jersey based dr reddys filing anda table contents esomeprazole magnesium trial scheduled january respect ivaxs dr reddys andas postponed new trial date set also old merck astrazeneca received notice december sandoz inc sandoz filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium january old merck astrazeneca sued sandoz district court new jersey based sandozs filing anda esomeprazole magnesium addition old merck astrazeneca received notice september lupin ltd lupin filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium october old merck astrazeneca sued lupin district court new jersey based lupins filing anda esomeprazole magnesium january old merck received notice sandoz filed anda challenging five old merck patents listed fda orange book emend february old merck filed patent infringement suit sandoz lawsuit automatically stays fda approval sandozs anda july adverse court decision whichever may occur earlier case scheduled go trial december europe old merck aware various companies seeking registration generic losartan active ingredient cozaar hyzaar old merck patent rights losartan via license ei du pont de nemours company du pont old merck du pont filed patent infringement proceedings various companies portugal spain norway finland belgium netherlands austria october old merck received notice teva parenteral medicines tpm filed anda caspofungin acetate challenging five patents listed fda orange book cancidas november company filed patent infringement suit tpm lawsuit automatically stays fda approval tpms anda april adverse court decision whichever may occur earlier november schering received notice apotex filed anda mometasone furoate nasal spray challenging two patents listed fda orange book nasonex december schering filed patent infringement suit apotex lawsuit automatically stays fda approval apotexs anda may adverse court decision whichever may occur earlier november scheringplough received notice mylan filed anda ezetimibesimvastatin challenging two patents listed fda orange book vytorin december scheringplough filed patent infringement suit mylan lawsuit automatically stays fda approval mylans anda may adverse court decision whichever may occur earlier july schering licensor cancer research technologies limited crt received notice barr laboratories barr subsidiary teva barr filed anda temodar challenging crts patent temozolomide july schering crt filed patent infringement action barr january court issued decision finding crt patent unenforceable grounds prosecution laches inequitable conduct schering crt process appealing decision january schering licensor millennium received notice teva filed anda eptifibatide challenging three millennium patents listed fda orange book integrilin february schering millennium filed patent infringement actions teva lawsuit automatically stays fda approval tevas anda august adverse court decision whichever may occur earlier may schering bayer schering pharma ag bayer healthcare pharmaceuticals received notice teva filed anda vardenofil challenging bayers patent listed fda orange book levitra vardenifil june schering bayer filed patent infringement action teva lawsuit automatically stays fda approval tevas anda november adverse court decision whichever may occur earlier table contents legal proceedings related merger connection merger separate class action lawsuits brought old merck scheringplough challenging merger seeking forms relief previously disclosed lawsuits settled pending court approval settlements approved court resolve release claims could brought shareholder old merck scheringplough challenging aspect proposed merger including merger disclosure claims litigation french matter based complaint french competition authority competitor france pursuant court order french competition authority obtained documents french subsidiary company relating subutex one products subsidiary markets sells resolution matter adverse french subsidiary could result imposition civil fines injunctive administrative remedies july juge des liberts et de la dtention ordered annulment search seizure procedural grounds july french authority appealed order french supreme court may french supreme court overturned annulment remanded case paris court appeal basis juge des liberts et de la dtention examined document assess whether seized whether lawfully seized case pending paris court appeal april competitor also requested interim relief portion granted french competition authority december interim relief required companys french subsidiary publish two specialized newspapers information including generic quantitative qualitative composition pharmaceutical form substitutable subutex february paris court appeal confirmed decision french competition authority january french supreme court confirmed decision french competition authority various legal proceedings principally product liability intellectual property suits involving company pending feasible predict outcome proceedings proceedings discussed item opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company proceedings separate assessment provided item environmental matters company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others final costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying providing costs amounts include table contents reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties previously disclosed approximately plaintiffs filed amended complaint old merck defendants us district court eastern district california asserting claims clean water act resource conservation recovery act well negligence nuisance suit seeks damages personal injury diminution property value medical monitoring alleged real personal property damage associated groundwater soil contamination found site former old merck subsidiary merced california old merck intends defend claims managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year executive officers registrant ages february richard clark age november chairman president chief executive officer merck co inc formerly scheringplough corporation april chairman president chief executive officer old merck may chief executive officer president old merck june president merck manufacturing division old merck responsible companys manufacturing information services operational excellence organizations worldwide adele ambrose age november senior vice president chief communications officer merck co inc formerly scheringplough corporation responsible global communications organization december vice president chief communications officer old merck responsible global communications organization april sabbatical prior april ms ambrose executive vice president public relations investor communications att wireless wireless services provider september april stanley f barshay age november executive vice president president consumer health care merck co inc formerly scheringplough corporation responsible consumer health care organization mr barshay retire effective april prior november mr barshay chairman consumer health care scheringplough corporation since june table contents richard bowles iii age november executive vice president chief compliance officer merck co inc formerly scheringplough corporation responsible companys compliance function including global safety environment systems assurance ethics privacy prior november dr bowles senior vice president global quality operations scheringplough corporation since march john canan age november senior vice president global controller merck co inc formerly scheringplough corporation responsible companys global control organization including accounting controls external reporting financial standards policies january senior vice president controller old merck responsible corporate controllers group september vice president controller old merck responsible corporate controllers group willie deese age november executive vice president president merck manufacturing division mmd merck co inc formerly scheringplough corporation responsible companys global manufacturing procurement distribution logistics functions january executive vice president president mmd old merck responsible companys global manufacturing procurement distribution logistics functions may president mmd old merck responsible companys global manufacturing procurement operational excellence functions january senior vice president global procurement kenneth c frazier age november executive vice president president global human health merck co inc formerly scheringplough corporation responsible companys marketing sales organizations worldwide including global pharmaceutical vaccine franchises august executive vice president president global human health old merck responsible companys marketing sales organizations worldwide including global pharmaceutical vaccine franchises november executive vice president general counsel old merck responsible legal public affairs functions merck company foundation notforprofit charitable organization affiliated company december senior vice president general counsel old merck responsible legal public affairs functions merck company foundation notforprofit charitable organization affiliated company mirian graddickweir age november executive vice president human resources merck co inc formerly scheringplough corporation responsible global human resources organization january executive vice president human resources old merck responsible global human resources organization september senior vice president human resources old merck table contents prior september dr graddickweir executive vice president human resources employee communications att communications services provider held several senior human resources leadership positions att years bridgette heller age effective march executive vice president president consumer health care merck co inc formerly scheringplough corporation responsible consumer health care organization prior march ms heller president johnson johnsons baby global business unit global president baby kids wound care prior joining johnson johnson ms heller founder managing partner heller associates peter n kellogg age november executive vice president chief financial officer merck co inc formerly scheringplough corporation responsible companys worldwide financial organization investor relations corporate development licensing companys joint venture relationships august executive vice president chief financial officer old merck responsible companys worldwide financial organization investor relations corporate development licensing companys joint venture relationships prior august mr kellogg executive vice president finance chief financial officer biogen idec biotechnology company since november merger biogen inc idec pharmaceuticals corporation peter kim age november executive vice president president merck research laboratories merck co inc formerly scheringplough corporation since january responsible companys research development efforts worldwide january executive vice president president merck research laboratories old merck responsible companys research development efforts worldwide january president merck research laboratories old merck responsible companys research development efforts worldwide raul e kohan age november executive vice president president animal health merck co inc formerly scheringplough corporation responsible companys animal health organization october senior vice president president intervetscheringplough animal health scheringplough corporation october deputy head animal health senior vice president corporate excellence administrative services scheringplough corporation february senior vice president president animal health scheringplough corporation prior february mr kohan group head global specialty operations president animal health scheringplough corporation since table contents bruce n kuhlik age november executive vice president general counsel merck co inc formerly scheringplough corporation responsible legal communications public policy functions merck company foundation notforprofit charitable organization affiliated company january executive vice president general counsel old merck responsible legal communications public policy functions merck company foundation notforprofit charitable organization affiliated company august senior vice president general counsel old merck responsible legal communications public policy functions merck company foundation notforprofit charitable organization affiliated company may vice president associate general counsel old merck primary responsibility companys vioxx litigation defense prior may mr kuhlik senior vice president general counsel pharmaceutical research manufacturers america since october michael rosenblatt age december executive vice president chief medical officer merck co inc formerly scheringplough corporation companys primary voice global medical community critical issues patient safety oversee companys global center scientific affairs prior december dr rosenblatt dean tufts university school medicine since j chris scalet age november executive vice president global services chief information officer cio merck co inc formerly scheringplough corporation responsible global shared services across human resources finance site services information services function enterprise business process redesign initiative january executive vice president global services cio old merck responsible global shared services across human resources finance site services information services function enterprise business process redesign initiative january senior vice president global services cio old merck responsible global shared services across human resources finance site services information services function enterprise business process redesign initiative march senior vice president information services cio old merck responsible areas information technology services including application development technical support voice data communications computer operations worldwide mervyn turner age november chief strategy officer senior vice president emerging markets research development merck research laboratories merck co inc formerly schering plough corporation responsible leading formulation execution companys long term strategic plan additional responsibilities licensing external research within merck research laboratories november chief strategy officer senior vice president worldwide licensing external research merck research laboratories old merck october senior vice president worldwide licensing external research old merck officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer board table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol sgp prior merger mrk merger common stock market price information set forth table based historical nyse market prices following table also sets forth calendar periods indicated dividend per share information cash dividends paid per common share year th q rd q nd q st q common stock market prices th q rd q nd q st q high low high low old merck paid quarterly cash dividends per common share annual amount january approximately shareholders record equity compensation plan information following table summarizes information options warrants rights equity compensation companys legacy merck legacy scheringplough equity plans close business december table include information tax qualified plans msd employee savings security plan schering plough employees savings plan number securities number remaining available securities future issuance issued upon weightedaverage equity exercise exercise price compensation plans outstanding outstanding excluding options warrants options warrants securities rights rights reflected column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following shareholderapproved plans merck sharp dohme incentive stock plans merck co inc nonemployee directors stock option plans scheringplough corporation stock incentive plans table contents excludes approximately shares restricted stock units performance share units assuming maximum payouts merck sharp dohme incentive stock plans shares restricted stock units performance share units excluding accrued dividends scheringplough corporation stock incentive plan also excludes shares phantom stock deferred merck co inc deferral program table include information equity compensation plans options warrants rights assumed company connection mergers acquisitions pursuant remain outstanding options warrants rights collectively assumed plans include rosetta inpharmatics inc employee stock option plans total shares merck common stock may purchased assumed plans weighted average exercise price grants may made assumed plans table contents performance graph following graph assumes investment december reinvestment dividends companys common shares sp index composite peer group major usbased pharmaceutical companies abbott laboratories bristolmyers squibb company johnson johnson eli lilly company pfizer inc comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer grp sp merck peer grp sp performance graph reflects scheringploughs tock perf ormanc e ecembe r thr ou gh c lose rg er n ew mer cks sto c k perform ance n vember december assumes cash component merger consideration reinvested new merck stock closing price november compound annual growth rate october wyeth pfizer inc completed previously announced merger pfizerwyeth merger wyeth became whollyowned subsidiary pfizer inc discussed november old merck scheringplough completed merger together pfizerwyeth merger transactions old merck subsequently renamed merck sharp dohme corp became whollyowned subsidiary scheringplough subsequently renamed merck co inc result transactions wyeth old merck longer exist publicly traded entities ceased trading common stock close business respective merger dates wyeth old merck permanently removed peer group index table contents recent sale unregistered securities november january company inadvertently issued total approximately unregistered shares common stock certain former directors former employees old merck upon exercise stock options held aggregate exercise prices paid connection stock option exercises approximately million addition january company inadvertently issued total approximately unregistered shares common stock certain former senior employees old merck upon vesting performance share units held table contents item selected financial data following selected financial data read conjunction item managements discussion analysis financial condition results operations consolidated financial statements notes thereto contained item financial statements supplementary data report merck co inc subsidiaries millions except per share amounts results year sales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates us vioxx settlement agreement charge income expense net income taxes taxes income net income net income attributable noncontrolling interests net income attributable merck co inc preferred stock dividends net income available common shareholders basic earnings per common share available common shareholders earnings per common share assuming dilution available common shareholders cash dividends declared cash dividends paid per common share capital expenditures depreciation average common shares outstanding millions average common shares outstanding assuming dilution millions yearend position working capital property plant equipment net total assets longterm debt total equity yearend statistics number stockholders record number employees amounts include impact merger scheringplough corporation november including recognition gain representing fair value stepup mercks previously held interest merckscheringplough partnership result obtaining controlling interest increased materials production costs result amortization intangible assets inventory stepup also included gain sale mercks interest merial limited favorable impact certain tax items impact restructuring actions additional legal defense costs amounts include gain distribution astrazeneca lp gain related sale remaining worldwide rights aggrastat favorable impact certain tax items impact restructuring actions additional legal defense costs expense contribution merck company foundation amounts include impact us vioxx settlement agreement charge restructuring actions civil governmental investigations charge insurance arbitration settlement gain inprocess research development expense resulting acquisition additional vioxx legal defense costs gains sales assets product divestitures well net gain settlements certain patent disputes amounts include impact restructuring actions inprocess research development expenses resulting acquisitions additional vioxx legal defense costs adoption new accounting standard requiring expensing stock options amounts include impact net tax charge primarily associated american jobs creation act repatriation restructuring actions additional vioxx legal defense costs amount reflects dividends paid common shareholders old merck addition approximately million dividends paid subsequent merger scheringplough million paid prior merger relating common stock preferred stock dividends declared scheringplough table contents item managements discussion analysis financial condition results operations description mercks business november merck co inc old merck scheringplough corporation scheringplough completed previouslyannounced merger merger merger scheringplough acquired shares old merck became whollyowned subsidiary scheringplough renamed merck sharp dohme corp scheringplough continued surviving public company renamed merck co inc new merck company however accounting purposes merger treated acquisition old merck considered accounting acquirer accordingly accompanying financial statements reflect old mercks standalone operations existed prior completion merger results scheringploughs business included new mercks financial statements periods subsequent completion merger therefore new mercks financial results reflect full year legacy scheringplough operations references report accompanying financial statements merck periods prior merger refer old merck periods completion merger new merck company global health care company delivers innovative health solutions medicines vaccines biologic therapies consumer animal products markets directly joint ventures companys operations principally managed products basis comprised one reportable segment pharmaceutical segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventative pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value pharmaceutical vaccine products health care professionals private practice group practices managed care organizations company also animal health operations discover develop manufacture market animal health products including vaccines companys professional representatives communicate safety value companys animal health products veterinarians distributors animal producers additionally company consumer health care operations develop manufacture market overthecounter otc foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets united states canada overview discussed merger completed november merger old merck shareholders received one share common stock new merck share old merck stock owned scheringplough shareholders received share common stock new merck cash share scheringplough stock owned consideration merger valued billion aggregate scheringplough old mercks longterm partner merckscheringplough cholesterol partnership msp partnership cash portion consideration funded combination existing cash including proceeds sale old mercks interest merial limited sale redemption investments issuance debt combined company research development pipeline greater depth breadth many promising drug candidates significantly broader portfolio medicines expanded presence key international markets particularly highgrowth emerging markets company anticipates efficiencies gained merger allow invest promising pipeline candidates well strategic external research development opportunities combination increased companys pipeline early mid late stage product candidates including significant increase number potential medicines company phase iii development table contents candidates additionally number candidates currently review united states internationally merger also expected accelerate expansion therapeutic areas old merck focused recent years addition scheringploughs established presence expertise oncology neuroscience novel biologics merger expected broaden companys commercial portfolio leading franchises key therapeutic areas including cardiovascular respiratory oncology neuroscience infectious diseases immunology womens health additionally combined company expected realize potential benefits animal health business portfolio consumer health brands including claritin coppertone dr scholls many legacy scheringploughs products expected long periods marketing exclusivity leveraging combined companys expanded product offerings company expects benefit additional revenue growth opportunities example combined company expected expanded opportunities lifecycle management introduction potential new combinations formulations existing products two legacy companies also company expanded global presence geographically diverse revenue base scheringploughs significant international presence accelerate old mercks international growth efforts revenue increased driven largely incremental sales resulting inclusion postmerger results legacy scheringplough products remicade treatment inflammatory diseases temodar treatment certain types brain tumors nasonex nasal spray inhaled nasal corticosteroid treatment nasal allergy symptoms pegintron treating chronic hepatitis c well recognition revenue sales zetia vytorin cholesterol modifying medicines prior merger sales zetia vytorin recognized msp partnership results old mercks interest msp partnership recorded equity income affiliates result merger msp partnership whollyowned company therefore revenues products postmerger period reflected sales additionally company recognized sales post merger period legacy scheringplough animal health consumer health care products also contributing sales increase growth januvia janumet treatment type diabetes isentress antiretroviral therapy treatment hiv infection singulair medicine indicated chronic treatment asthma relief symptoms allergic rhinitis varivax vaccine help prevent chickenpox varicella pneumovax vaccine help prevent pneumococcal disease increases partially offset lower sales fosamax treatment prevention osteoporosis fosamax fosamax plus lost market exclusivity substantially formulations united states february april respectively revenue also negatively affected lower sales gardasil vaccine help prevent cervical vulvar vaginal cancers precancerous dysplastic lesions genital warts caused human papillomavirus hpv types cosopttrusopt ophthalmic products lost us market exclusivity october lower revenue companys relationship astrazeneca lp azlp products experiencing declines include rotateq vaccine help protect rotavirus gastroenteritis infants children zocor companys statin modifying cholesterol primaxin treatment bacterial infections result merger company expects achieve substantial cost savings across areas including consolidation sales marketing research development application companys lean manufacturing sourcing strategies expanded operations full integration msp partnership february company announced first phase new global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough businesses merger restructuring program intended optimize cost structure combined company part first phase merger restructuring program end company expects reduce total workforce approximately across areas company worldwide company also plans eliminate vacant positions part first phase program workforce reductions primarily come elimination duplicative positions sales administrative headquarters organizations well consolidation certain manufacturing facilities research development operations company continue hire new employees strategic growth areas business period certain actions ongoing reevaluation manufacturing research development facilities table contents worldwide yet completed included later phases merger restructuring program connection first phase merger restructuring program separation costs companys existing severance programs worldwide recorded fourth quarter extent costs probable reasonably estimable company recorded pretax restructuring costs billion primarily employee separation costs related merger restructuring program fourth quarter first phase merger restructuring program expected completed end total pretax costs estimated billion billion company estimates approximately cumulative pretax costs relate cash outlays primarily related employee separation expense approximately cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested company expects first phase merger restructuring program yield annual savings approximately billion billion anticipated savings relate first phase merger restructuring program therefore portion estimated billion incremental annual savings originally disclosed merger announced company expects additional savings generated subsequent phases merger restructuring program announced later year well non restructuring related activities procurement savings initiatives cost savings expected come areas companys pharmaceutical business addition previously announced ongoing cost reduction initiatives legacy companies result merger company obtained controlling interest msp partnership owned company accordingly company required remeasure mercks previously held equity interest msp partnership mergerdate fair value recognize resulting gain earnings result company recorded gain billion recognized income expense net also old merck sold interest merial limited merial sanofiaventis billion cash sale resulted recognition billion gain reflected income expense net see note consolidated financial statements earnings per common share eps assuming dilution reflect net impact resulting gains related msp partnership sale merial partially offset increased expenses amortization purchase accounting adjustments restructuring mergerrelated costs eps also affected dilutive impact shares issued merger competition health care environment competition markets company conducts business pharmaceutical industry highly competitive highly regulated companys operations may affected technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors new information clinical trials marketed products postmarketing surveillance generic competition companys products mature addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result recognition impairment charge respect certain products competitive pressures intensified pressures industry grown effect operations competitive factors patent disputes predicted pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively longstanding emphasis research development company well positioned compete search technological innovations additional resources meet market challenges include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products external alliances joint ventures licenses refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacement even products protected patents example number table contents compounds available treat particular disease typically increases time result slowed sales growth companys products therapeutic category global efforts toward healthcare cost containment continue exert pressure product pricing access addressing cost containment pressure company makes continuing effort demonstrate medicines provide value patients pay healthcare addition pricing flexibility across companys product portfolio encouraged growing use medicines mitigated effects increasing cost pressures individual medicines outside united states difficult government budgetary environments company worked payers encourage allocation scarce resources optimize healthcare outcomes limiting potentially detrimental effects government policies sales growth access innovative medicines vaccines support discovery development innovative products benefit patients company also working governments many emerging markets eastern europe latin america asia encourage increase investments health thereby improve citizens access medicines addition certain countries within european union eu recognizing economic importance research based pharmaceutical industry value innovative medicines society working industry representatives improve competitive climate variety means including market deregulation company anticipates worldwide trend toward cost containment continue resulting ongoing pressures healthcare budgets united states major healthcare reform introduced passed houses congress final revised bill unifies versions may considered adopted law impact actions well budget pressures governments united states nations predicted time company continues successfully launch new products contribute healthcare debates monitor reforms new products policies strategies enable maintain strong position changing economic environment although one predict outcome legislative regulatory advocacy initiatives company believes well positioned respond evolving healthcare environment market forces access medicines company also committed improving access medicines enhancing quality life people around world cite one example african comprehensive hivaids partnerships botswana partnership government botswana bill melinda gates foundation merck company foundationmerck co inc supporting botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support catalyze access hiv medicines developing countries company makes profit sale current hivaids medicines worlds poorest countries hardest hit pandemic offers hivaids medicines significantly reduced prices mediumincome countries february old merck announced reduced price stocrin least developed countries world hardest hit pandemic actions company working independently partners public private sectors address critical barriers access medicines developing world addressing barriers requires investments education training health infrastructure improve capacity developing countries achieved increased international assistance sustainable financing addition old merck committed providing rotateq vaccine help protect rotavirus gastroenteritis infants children global alliance vaccines immunizationeligible countries prices profit also old merck wellcome trust established msd wellcome trust hilleman laboratories joint venture india develop vaccines millions people poorest areas world government regulation pharmaceutical industry subject regulation regional country state local agencies around world particular importance us food drug administration fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount table contents time resources necessary develop new products bring market united states food drug administration modernization act fda modernization act passed culmination comprehensive legislative reform effort designed streamline regulatory procedures within fda improve regulation drugs medical devices food legislation principally designed ensure timely availability safe effective drugs biologics expediting premarket review process new products key provision legislation reauthorization prescription drug user fee act permits continued collection user fees prescription drug manufacturers augment fda resources earmarked review human drug applications helps provide resources necessary ensure prompt approval safe effective new drugs united states government expanded access senior citizens prescription drug coverage enacting medicare prescription drug improvement modernization act signed law december prescription drug coverage began january legislation supports companys goal improving access medicines expanding insurance coverage preserving marketbased incentives pharmaceutical innovation time legislation helped control cost prescription drug costs competitive pressures encouraging appropriate use medicines mentioned united states major healthcare reform introduced passed houses congress final revised bill unifies versions may considered adopted law us congress also considered may consider proposals increase governments role pharmaceutical pricing medicare program proposals may include removing current legal prohibition secretary health human services intervening price negotiations medicare drug benefit program plans pharmaceutical companies may also include mandating payment rebates pharmaceutical utilization medicare drug benefit plans addition congress may consider proposals allow certain conditions importation medicines countries many years pharmaceutical industry federal state oversight approval process new drugs drug safety advertising promotion drug purchasing reimbursement programs formularies company believes continue able conduct operations including introduction new drugs market regulatory environment company continues work private public payors slow increases healthcare spending also us federal state governments pursued methods directly reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities disproportionate share hospitals hospitals meeting certain criteria provide minimum discounts defined nonfederal average manufacturer price purchases certain components federal government department veterans affairs department defense initiatives states seek rebates beyond minimum required medicaid legislation cases patients beyond eligible medicaid federal vaccines children entitlement program us centers disease control prevention cdc funds purchases recommended pediatric vaccines public sector price immunization medicaideligible uninsured native american certain underinsured children old merck awarded cdc contract supply pediatric vaccines vaccines children program outside united states company encounters similar regulatory legislative issues countries business primary thrust governmental inquiry action toward determining drug safety effectiveness often mechanisms controlling prices reimbursement prescription drugs profits prescription drug companies eu adopted directives concerning classification labeling advertising wholesale distribution approval marketing medicinal products human use companys policies procedures already consistent substance directives consequently believed material effect companys business january european commission ec launched sector inquiry pharmaceutical industry rules eu competition law part inquiry old mercks offices germany inspected authorities beginning january preliminary report ec issued november following public consultation period final report issued july final report confirmed decline number novel medicines reaching market instances delayed market entry generic medicines discussed industry practices may contributed table contents phenomena ec issued inquiries respect subject investigation ec alleged company subsidiaries engaged unlawful practices company subject jurisdiction various regulatory agencies therefore subject potential administrative actions actions may include seizures products civil criminal sanctions certain circumstances company may deem advisable initiate product recalls company believes able compete effectively within environment privacy data protection company subject number privacy data protection laws regulations globally legislative regulatory landscape privacy data protection continues evolve increasing attention privacy data protection issues potential affect directly companys business including recently enacted laws regulations united states internationally requiring notification individuals government authorities security breaches involving certain categories personal information operating results sales worldwide sales totaled billion increase compared foreign exchange unfavorably affected global sales performance revenue increase largely reflects incremental sales resulting inclusion postmerger results legacy scheringplough products remicade temodar nasonex nasal spray pegintron well recognition revenue sales zetia vytorin prior merger sales zetia vytorin recognized msp partnership results old mercks interest msp partnership recorded equity income affiliates result merger msp partnership whollyowned company therefore revenues products postmerger period reflected sales additionally company recognized sales postmerger period legacy scheringplough animal health consumer healthcare products also contributing sales increase growth januvia janumet isentress singulair varivax pneumovax increases partially offset lower sales fosamax fosamax plus lost market exclusivity substantially formulations united states february april respectively revenue also negatively affected lower sales gardasil cosopttrusopt lost us market exclusivity october lower revenue companys relationship azlp products experiencing declines include rotateq zocor primaxin domestic sales increased compared foreign sales rose driven primarily incremental sales resulting inclusion postmerger results legacy scheringplough products domestic sales increase also driven higher sales januvia janumet isentress singulair increases partially offset lower sales fosamax fosamax plus cosopttrusopt gardasil rotateq foreign sales growth reflects strong performance januvia janumet isentress partially offset lower sales fosamax fosamax plus vaccines foreign sales represented total sales worldwide sales totaled billion decline compared foreign exchange favorably affected global sales performance revenue decline largely reflects lower sales fosamax fosamax plus also contributing decline lower sales zocor vasotecvaseretic sales certain vaccines including hepatitis haemophilus influenzae type b hib vaccines partially offsetting declines higher sales januvia janumet isentress cozaarhyzaar rotateq singulair foreign sales represented total sales table contents sales companys products follows millions pharmaceutical bone respiratory immunology dermatology singulair fosamax propecia remicade arcoxia nasonex clarinex asmanex cardiovascular vytorin zetia integrilin diabetes obesity januvia janumet infectious disease isentress primaxin cancidas invanz crixivanstocrin pegintron avelox rebetol mature brands cozaarhyzaar zocor vasotecvaseretic proscar claritin rx proventil neurosciences ophthalmology maxalt cosopttrusopt remeron subutexsuboxone oncology emend temodar caelyx intron vaccines proquadmmr iivarivax gardasil rotateq pneumovax zostavax womens health endocrine follistimpuregon nuvaring pharmaceutical segment revenues total segment revenues sales legacy scheringplough products reflect results postmerger period december sales msp partnership products zetia vytorin represent sales postmerger period december prior merger sales zetia vytorin primarily recognized msp partnership results old mercks interest msp partnership recorded equity income affiliates sales zetia vytorin reflect old mercks sales products latin america part msp partnership amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd pharmaceutical primarily includes sales human pharmaceutical products including products within franchises listed separately reflects nonreportable segments including animal health consumer health care revenue companys relationship azlp primarily relating sales nexium well prilosec revenue azlp billion billion billion respectively revenues primarily comprised miscellaneous corporate revenues thirdparty manufacturing sales sales related divested products businesses supply sales included segment results table contents pharmaceutical segment revenues bone respiratory immunology dermatology worldwide sales singulair leukotriene receptor antagonist chronic treatment asthma relief symptoms allergic rhinitis grew reaching billion primarily driven favorable pricing strong performance japan asia pacific global sales singulair rose billion reflecting higher sales outside united states including volume growth europe japan positive effect foreign exchange partially offset lower sales domestically singulair continues number one prescribed product us respiratory market us sales singulair billion patent provides us marketing exclusivity singulair expires august company expects within two years following patent expiration lose substantially us sales singulair declines coming first full year following patent expiration addition patent singulair expire number major european markets august company expects sales singulair markets decline significantly thereafter worldwide sales fosamax fosamax plus marketed fosavance throughout eu fosamac japan treatment case fosamax prevention osteoporosis decreased billion declined billion since substantially formulations medicines lost us market exclusivity company experiencing significant declines sales united states within fosamax product franchise company expects declines continue international sales remicade treatment inflammatory diseases million postmerger period december remicade marketed company outside united states except japan certain asian markets products compete remicade launched past several years october ec approved simponi golimumab oncemonthly subcutaneous treatment certain inflammatory diseases company launched simponi canada germany denmark launches international markets ongoing planned see note consolidated financial statements discussion arbitration proceedings involving remicadesimponi global sales nasonex nasal spray inhaled nasal corticosteroid treatment nasal allergy symptoms million postmerger period december global sales clarinex marketed aerius many countries outside united states nondrowsy antihistamine million postmerger period december products included bone respiratory immunology dermatology franchise include among others propecia product treatment male pattern hair loss arcoxia treatment arthritis pain asmanex orally inhaled steroid asthma cardiovascular sales zetia cholesterol absorption inhibitor vytorin combination product containing active ingredients zetia zocor million million respectively postmerger period december prior merger sales products recognized msp partnership results old mercks interest msp partnership recorded equity income affiliates result merger msp partnership whollyowned company therefore revenues products reflected sales discussion performance zetia vytorin prior closing merger see selected joint venture affiliate information global sales integrilin injection legacy scheringplough product treatment patients acute coronary syndrome sold company united states canada million postmerger period december june launches tredaptive began international markets december merck launched tredaptive countries including major european markets tredaptive lipidmodifying therapy patients mixed dyslipidemia primary hypercholesterolemia tredaptive also known trademark cordaptive certain countries approved countries outside united states united states remains investigational table contents diabetes obesity global sales januvia mercks dipeptidyl peptidase dpp inhibitor treatment type diabetes billion billion million januvia approved fda october ec march dpp inhibitors represent class prescription medications improve blood sugar control patients type diabetes enhancing natural body system called incretin system helps regulate glucose affecting beta cells alpha cells pancreas januvia received regulatory approval japan china ec approved restricted first line use januvia treatment type diabetes approval sitagliptin indicated improve glycemic control diet exercise alone provide adequate glycemic control metformin inappropriate due contraindications intolerance sitagliptin diabetes treatment dpp inhibitor class restricted first line indication eu worldwide sales janumet mercks oral antihyperglycemic agent combines sitagliptin mercks dpp inhibitor januvia metformin single tablet target three key defects type diabetes million compared million million janumet initially approved adjunct diet exercise improve blood sugar control adult patients type diabetes adequately controlled metformin sitagliptin alone patients already treated combination sitagliptin metformin february fda approval market janumet initial treatment type diabetes received july janumet approved marketing eu iceland norway ec approved use januvia tablets janumet tablets addon insulin treatment type diabetes sitagliptin diabetes treatment dpp inhibitor class indication use addon insulin eu united states supplemental new drug application concerning use januvia janumet combination insulin accepted fda currently review infectious disease worldwide sales isentress antiretroviral therapy treatment hiv infection million million million sales growth reflects positive performance united states well internationally due part strong launches certain countries including france spain italy isentress available major international markets october fda granted isentress accelerated approval use combination antiretroviral agents treatment hiv infection treatment experienced adult patients evidence viral replication hiv strains resistant multiple antiretroviral agents isentress first medicine approved class antiretroviral drugs called integrase inhibitors isentress works inhibiting insertion hiv dna human dna integrase enzyme inhibiting integrase performing essential function limits ability virus replicate infect new cells january fda granted traditional approval isentress following review week data benchmrk clinical trials july fda approved expanded indication isentress include use treatment adult patients starting hiv therapy first time treatment nave well treatment experienced adult patients september isentress granted expanded license ec use combination antiretroviral medicinal products treatment hiv infection adult patients including treatmentnave adult patients well treatmentexperienced adult patients commissions decision applicable countries members eu well iceland norway additionally october merck announced isentress indicated use treatmentnave adults canada sales primaxin antibacterial product declined million compared results reflect competitive pressures also reflect supply constraints patents primaxin expired worldwide multiple generics approved europe accordingly company experiencing decline sales product company expects decline continue sales primaxin essentially flat compared table contents worldwide sales pegintron treating chronic hepatitis c million postmerger period december products contained infectious diseases franchise include among others cancidas antifungal product crixivan stocrin antiretroviral therapies treatment hiv infection avelox fluoroquinolone antibiotic treatment certain respiratory skin infections invanz treatment certain infections mature brands mercks mature brands human health pharmaceutical products approaching expiration marketing exclusivity longer protected patents developed markets continue core part companys offering markets around world global sales cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatment hypertension billion comparable sales reflecting unfavorable effect foreign exchange offset strong performance products united states hyzaar japan marketed preminent global sales cozaar hyzaar grew billion driven strong performance hyzaar japan well positive effect foreign exchange cozaar hyzaar among leading medicines angiotensin receptor blocker class patents provide us market exclusivity cozaar hyzaar expire april addition patent cozaar expire number major european markets march hyzaar lost patent protection number major european markets february company anticipates significant decline future cozaarhyzaar sales since multiple sources generics expected medicines time patent expiry worldwide sales zocor statin modifying cholesterol declined zocor lost us market exclusivity june also lost market exclusivity major international markets products contained mature brands franchise include among others prescription claritin treatment seasonal outdoor allergies yearround indoor allergies vasotecvaseretic hypertension andor heart failure proscar urology product treatment symptomatic benign prostate enlargement neurosciences ophthalmology sales cosopt trusopt mercks largestselling ophthalmic products declined million compared patent provided us market exclusivity cosopt trusopt expired october cosopt also lost market exclusivity number major european markets trusopt lose market exclusivity number major european markets april company expects sales markets decline significantly thereafter sales cosopt trusopt declined compared saphris asenapine mercks sublingual tablet acute treatment schizophrenia adults acute treatment manic mixed episodes associated bipolar disorder approved fda august full launch underway company filed two supplemental new drug applications fda saphris adjunct therapy patients mania maintenance therapy patients schizophrenia application asenapine also review eu companys muscle relaxant reversal drug bridion currently approved countries including japan launched countries around world saflutan tafluprost launched number countries including united kingdom spain additional launches countries expected next year pending regulatory approvals saflutan preservative free synthetic analogue prostaglandin f reduction elevated intraocular pressure appropriate patients primary openangle glaucoma ocular hypertension tafluprost phase iii development united states april old merck santen pharmaceutical co ltd santen announced worldwide licensing agreement tafluprost see research development update table contents also old merck divested us marketing rights timoptic product franchise aton pharma inc timoptic product franchise includes ophthalmic products treat elevated intraocular pressure patients ocular hypertension openangle glaucoma oncology sales temodar treatment certain types brain tumors million postmerger period december temodar lost patent exclusivity eu january company announced us district court district delaware ruled company patent infringement suit teva pharmaceuticals usa inc see note consolidated financial statements decision appealed effects ruling uncertain matter appeal products oncology franchise include emend treatment chemotherapy induced nausea vomiting caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma marketing rights caelyx return johnson johnson december vaccines following discussion vaccines include sales vaccines sold major european markets sanofi pasteur msd spmsd companys joint venture sanofi pasteur results included equity income affiliates see selected joint venture affiliate information supply sales spmsd however included worldwide sales gardasil recorded merck declined billion declined billion gardasil worlds topselling hpv vaccine indicated girls women years age prevention cervical vulvar vaginal cancers precancerous dysplastic lesions genital warts caused hpv types gardasil also approved united states use boys men ages years age prevention genital warts caused hpv types sales performance driven largely declines united states continue affected saturation yearold female cohort due rapid early uptake ongoing challenges vaccinating yearold female age group sales include million revenue result government purchases us centers disease control preventions cdc strategic national stockpile sales performance reflects lower sales domestically partially offset growth outside united states sales include initial purchases many states cdc vaccines children program company party certain third party license agreements respect gardasil including crosslicense settlement agreement glaxosmithkline result agreements company pays royalties worldwide gardasil sales vary country included materials production costs october fda approved gardasil use boys men making gardasil hpv vaccine approved use males later october merck announced cdcs advisory committee immunization practices acip supports permissive use gardasil boys men ages means gardasil may given males ages reduce likelihood acquiring genital warts acip also voted recommend funding provided use gardasil males vaccines children program january fda issued second complete response letter regarding supplemental biologics license application sbla use gardasil women ages fda completed review response old merck provided july fdas first complete response letter issued june recommended old merck submit additional data month study completed initial sbla included data collected average months enrollment study number prespecified endpoints met merck provided response fda fourth quarter class response generally carries month review time point fda accepted file complete response letter affect current indications gardasil females ages global sales rotateq vaccine help protect rotavirus gastroenteritis infants children recorded merck declined million reflecting moderate impact competition table contents united states greater impact public sector worldwide sales rotateq grew million primarily driven continued uptake united states successful launches around world sales included purchases million support cdc strategic national stockpile old merck received regulatory approvals united states certain markets increase manufacturing capacity companys varicella zoster virus vzv containing vaccines company manufacturing bulk varicella producing doses varivax zostavax proquad pediatric combination vaccine help protect measles mumps rubella varicella one vzvcontaining vaccines currently available ordering however orders transitioned appropriate mmr ii varivax total sales recorded merck proquad million million merck anticipates proquad available us market mercks sales varivax vaccine help prevent chickenpox varicella billion million million varivax vaccine available united states help protect chickenpox due unavailability proquad sales reflect million revenue result government purchases cdcs strategic national stockpile varivax benefited acips june second dose recommendation mercks sales mmr ii vaccine help protect measles mumps rubella million million million sales varivax mmr ii affected unavailability proquad combined sales proquad mmr ii varivax increased declined sales zostavax vaccine help prevent shingles herpes zoster recorded merck million million million sales years affected supply issues normal shipping schedules zostavax united states resumed june company anticipates zostavax available united states customers likely experience back orders zostavax throughout year international launches zostavax delayed vaccine first medical option prevention shingles sales pneumovax vaccine help prevent pneumococcal disease million compared million million increase due favorable pricing united states higher demand associated flu pandemic september old merck announced entered exclusive agreement csl biotherapies csl subsidiary csl limited market distribute afluria csls seasonal influenza flu vaccine united states flu seasons terms agreement company assume responsibility aspects commercialization afluria united states csl supply afluria merck retain responsibility marketing vaccine outside united states afluria indicated active immunization persons age months older influenza disease caused influenza virus subtypes type b present vaccine efforts resolve manufacturing issues related hibcontaining vaccines pedvaxhib comvax ongoing since december january pedvaxhib became fully available united states routine vaccination well booster dose catchup vaccination timing availability outside united states dependent upon local regulatory requirements market return comvax dependent upon supply situation companys hibcontaining vaccine hepatitis b vaccine pediatricadolescent formulation vaqta vaccine hepatitis currently available company continuing prioritize pediatricadolescent formulation merck anticipates adult formulation available outside united states supply vaqta limited availability vary region pediatricadolescent formulation recombivax hb vaccine hepatitis b became available december company anticipate availability adult formulation first half company anticipates dialysis formulation become available end table contents womens health endocrine global sales follistimpuregon fertility treatment million postmerger period december follistimpuregon lost market exclusivity eu august worldwide sales nuvaring contraceptive product million postmerger period december january merck received ec approval elonva elonva indicated controlled ovarian stimulation combination gnrh antagonist development multiple follicles women participating assisted reproductive technology program ec approval merck receives marketing authorization elonva unified labeling valid european union member states elonva first class sustained follicle stimulant due ability initiate sustain multiple follicular growth entire week single subcutaneous injection recommended dose elonva may replace first seven injections daily recombinant follicle stimulating hormone rfsh preparation controlled ovarian stimulation treatment cycle january company azlp teva pharmaceuticals inc acquired ivax pharmaceuticals inc entered settlement agreement resolve patent litigation respect esomeprazole nexium provides tevaivax bring generic esomeprazole product market united states may old merck azlp entered similar agreement ranbaxy laboratories ltd ranbaxy provides ranbaxy bring generic esomeprazole product market united states may company faces challenges respect outstanding patent infringement matters esomeprazole see note consolidated financial statements animal health global sales animal health products include livestock poultry companion animal aquaculture products prevent treat animal diseases totaled million postmerger period december animal health sales affected intense competition frequent introduction generic products consumer health care global sales consumer health care products include otc foot care sun care products million postmerger period december consumer health care product sales affected competition frequent competitive product introductions consumer spending patterns consumer health care products include dr scholls foot care products claritin nondrowsy antihistamines miralax treatment occasional constipation coppertone sun care products december merck announced fda approved zegerid otc overthecounter treatment frequent heartburn agreement santarus inc specialty pharmaceutical company developed currently markets prescription zegerid scheringplough healthcare products consumer healthcare division merck responsible development manufacturing commercialization zegerid otc products heartburnrelated indications united states canada table contents costs expenses millions change c hange materials production marketing administrative research development restructuring costs equity income affiliates us vioxx settlement agreement charge income expense net greater materials production materials production costs billion compared billion materials production costs include expenses related sale legacy schering plough products postmerger period additionally costs unfavorably affected billion amortization purchase accounting adjustments scheringploughs inventories billion expense amortization intangible assets recognized merger also included materials production costs million costs associated restructuring activities substantially represents accelerated depreciation associated planned sale closure manufacturing facilities see note consolidated financial statements materials production costs declined compared decline sales primarily reflecting lower restructuring costs included materials production costs million restructuring costs comprised million accelerated depreciation million costs primarily asset writeoffs compares restructuring costs million representing million accelerated depreciation million asset impairments gross margin compared additional amortization expense result merger restructuring charges reflected periods noted unfavorable impact percentage points percentage points percentage points gross margin reflects changes product mix including decline fosamax fosamax plus sales result loss us market exclusivity manufacturing efficiencies gross margin reflects slight unfavorable impact changes product mix positive impact manufacturing efficiencies marketing administrative marketing administrative expenses increased driven largely inclusion expenses related scheringplough activities postmerger period additionally million mergerrelated costs recognized consisting transaction costs directly related merger including advisory legal fees integration costs increases partially offset initiatives reduce cost base place prior consummation merger separation costs associated sales force reductions incurred reflected restructuring costs discussed addition marketing administrative expenses benefited foreign exchange marketing administrative expenses included million million respectively additional reserves solely future vioxx legal defense costs expenses also reflect million additional reserves solely future legal defense costs fosamax litigation see note consolidated financial statements information vioxx fosamax litigation related matters marketing administrative expenses declined compared included marketing administrative expenses million million respectively additional reserves solely future vioxx legal defense costs also included costs million additional reserves solely future legal defense costs fosamax litigation addition marketing table contents administrative expenses included million gain insurance arbitration award related vioxx product liability litigation coverage addition lower expenses future legal defense costs decline marketing administrative expenses compared also reflects efforts reduce cost base research development research development expenses increased compared due part incremental expenditures associated inclusion scheringploughs results postmerger period additionally expenses reflect million costs associated restructuring activities including closure sale research facilities connection restructuring program substantially represent accelerated depreciation see note consolidated financial statements addition research development expenses compared reflect increase development spending support continued advancement research pipeline including investments latestage clinical trials research development expenses declined compared expenses reflect million costs related restructuring activities expenses reflect million inprocess research development expense related novacardia acquisition research development expenses compared reflect increase development spending support continued advancement research pipeline sharebased compensation total pretax sharebased compensation expense million million million december million total pretax unrecognized compensation expense related nonvested stock option restricted stock unit performance share unit awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses restructuring costs restructuring costs billion billion million respectively restructuring costs recorded billion related merger restructuring program million related restructuring program million related legacy scheringplough productivity transformation program restructuring costs recorded million related restructuring program remainder associated restructuring program separation costs billion million million respectively incurred associated actual headcount reductions well estimated expenses existing severance programs headcount reductions probable could reasonably estimated merck eliminated positions related restructuring program positions approximately related restructuring program related restructuring program positions position eliminations comprised actual headcount reductions elimination contractors vacant positions also included restructuring costs curtailment settlement termination charges pension postretirement benefit plans shutdown costs segment reporting restructuring costs unallocated expenses additional costs associated companys restructuring activities included materials production costs research development expenses equity income affiliates equity income affiliates reflects performance companys joint ventures partnerships decline primarily driven lower equity income msp partnership whollyowned company result merger therefore results reflected consolidated results company beginning date merger decreased equity income merial due sale old mercks interest september partially offset higher partnership returns azlp decline equity income affiliates reflects decreased equity income msp partnership lower partnership returns azlp partially offset higher equity income merial spmsd decrease equity income msp partnership primarily result lower revenues vytorin zetia following announcements enhance seas clinical trial results lower partnership returns azlp table contents primarily attributable first quarter partial redemption old mercks interest certain azlp product rights resulted reduction priority return variable returns based part upon sales certain former astra usa inc products higher equity income merial primarily reflects higher sales biological products increase equity income spmsd largely attributable higher sales gardasil joint venture territories outside united states see selected joint venture affiliate information us vioxx settlement agreement charge november old merck entered agreement settlement agreement law firms comprise executive committee plaintiffs steering committee federal multidistrict vioxx litigation well representatives plaintiffs counsel state coordinated proceedings resolve state federal myocardial infarction mi ischemic stroke claims filed date old merck united states settlement agreement old merck paid aggregate fixed amount billion two funds qualifying claims consisting billion qualifying mi claims million qualifying claims entered resolution process settlement program million paid funds remainder consequence settlement agreement pretax charge billion recorded see note consolidated financial statements income expense net included income expense net billion gain related mercks previously held interest msp partnership result merger company obtained controlling interest msp partnership owned company previously company noncontrolling interest business combination acquirer holds noncontrolling equity investment acquiree immediately obtaining control acquiree referred step acquisition acquirer required remeasure previously held equity interest acquiree acquisitiondate fair value recognize resulting gain loss earnings additionally billion gain recognized sale old mercks interest merial see note consolidated financial statements also included income expense net million investment portfolio recognized net gains million charge related settlement vioxx thirdparty payor litigation united states see note consolidated financial statements included income expense net aggregate gain distribution azlp billion see note consolidated financial statements gain million related sale remaining worldwide rights aggrastat million expense contribution merck company foundation million investment portfolio recognized net losses million charge related resolution investigation whether old merck violated state consumer protection laws respect sales marketing vioxx merck experienced decline interest income compared primarily result lower interest rates change investment portfolio mix toward cash shorterdated securities anticipation merger merck recognized higher interest expense largely due million commitment fees incremental interest expense related financing merger change income expense net compared primarily due aggregate gain azlp billion impact million charge related resolution certain civil governmental investigations gain million related sale remaining worldwide rights aggrastat partially offset million expense contribution merck company foundation increase exchange losses million higher recognized losses million net investment portfolio million charge related resolution investigation whether old merck violated consumer protection laws respect sales marketing vioxx fluctuation exchange losses gains primarily due higher cost foreign currency contracts due lower us interest rates unfavorable impacts periodtoperiod changes foreign currency exchange rates net long net short foreign currency positions considering net monetary assets related foreign currency contracts table contents segment profits millions pharmaceutical segment profits nonreportable segment profits income income taxes segment profits comprised segment revenues less certain elements materials production costs operating expenses including components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker merck allocate production costs standard costs research development expenses general administrative expenses well cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits gain related msp partnership amortization purchase accounting adjustments gain disposition merial gain distribution azlp restructuring costs us vioxx settlement agreement charge taxes paid joint venture level portion equity income additionally segment profits reflect expenses corporate manufacturing cost centers miscellaneous income expense unallocated items reflected table also included miscellaneous corporate profits operating profits related divested products businesses supply sales adjustments eliminate effect double counting certain items income expense pharmaceutical segment profits rose largely driven inclusion legacy scheringplough results postmerger period pharmaceutical segment profits decreased largely driven lower sales fosamax fosamax plus zocor decreased equity income msp partnership taxes income effective income tax rate effective tax rate reflects favorable impacts increased income lower tax jurisdictions includes favorable impact msp partnership gain higher expenses certain jurisdictions including amortization purchase accounting adjustments restructuring costs effective income tax rate also benefited tax settlements including previously announced settlement canada revenue agency cra favorable impacts partially offset unfavorable effect gain sale old mercks interest merial taxable united states combined federal state tax rate approximately net favorable impact items effective tax rate approximately percentage points effective tax rate reflects net favorable impact compared statutory rate approximately percentage points includes favorable impacts relating tax settlements resulted reduction liability unrecognized tax benefits approximately million realization foreign tax credits favorable tax impact foreign exchange rate changes fourth quarter particularly strengthening japanese yen us dollar partially offset unfavorable impact resulting azlp gain fully taxable united states combined federal state tax rate approximately first quarter old merck decided distribute certain prior years foreign earnings united states result utilization foreign tax credits foreign tax credits arose result tax payments made outside united states prior years became realizable first quarter based change old mercks decision distribute foreign earnings effective tax rate reflects reduction domestic pretax income primarily resulting us vioxx settlement agreement charge related change mix domestic foreign pretax income net income earnings per common share net income available common shareholders billion compared billion billion earnings per common share assuming dilution available common shareholders eps compared increases net income earnings per share largely driven gain associated msp partnership recognized conjunction merger well gain recorded sale old mercks interest merial partially offset incremental charges associated merger including amortization intangible assets table contents inventory stepup recognition mergerrelated costs eps also affected dilutive impact shares issued merger increases net income earnings per share compared primarily attributable gain distribution azlp impacts us vioxx settlement agreement civil governmental investigations charges addition increases reflect positive impact certain tax items lower inprocess research development costs lower expenses legal defense costs partially offset higher restructuring costs lower equity earnings well recognition insurance arbitration gain nongaap income nongaap eps nongaap income nongaap eps alternative views companys performance used management merck providing management believes information enhances investors understanding companys results nongaap income nongaap earnings per share exclude certain items nature items impact analysis underlying business performance trends excluded items certain purchase accounting items related merger restructuring activities merger related costs certain items excluded items significant components understanding assessing financial performance therefore information nongaap income non gaap eps considered addition lieu net income earnings per share prepared accordance generally accepted accounting principles united states gaap additionally since nongaap income nongaap eps measures determined accordance gaap standardized meaning prescribed gaap therefore may comparable calculation similar measures companies nongaap income nongaap eps important internal measures company senior management receives monthly analysis operating results includes nongaap income nongaap eps performance company measured basis along performance metrics senior managements annual compensation derived part using nongaap income nongaap eps table contents reconciliation gaap financial measures nongaap financial measures follows millions pretax income reported gaap increase decrease excluded items purchase accounting restructuring activities mergerrelated costs items gain related msp partnership gain merial gain distribution azlp us vioxx settlement agreement charge civil governmental investigations charge insurance arbitration gain taxes income reported gaap tax benefit expense excluded items nongaap taxes income nongaap net income eps assuming dilution reported gaap eps impact excluded items nongaap eps assuming dilution purchase accounting adjustments nongaap income nongaap eps exclude certain amounts recorded connection merger see note consolidated financial statements amounts include amortization intangible assets inventory stepup restructuring activities nongaap income nongaap eps exclude restructuring activities including restructuring activities related merger see note consolidated financial statements amounts include employee separation costs accelerated depreciation associated facilities sold closed company undertaken restructurings different types covered periods therefore charges considered nonrecurring however management excludes amounts nongaap income nongaap eps believes helpful understanding performance continuing business mergerrelated costs nongaap income nongaap eps exclude transaction costs associated directly merger well integration costs costs excluded management believes costs unique merger transaction representative ongoing normal business activities integration costs associated merger occur several years however impacts within year vary integration progresses certain items nongaap income nongaap eps exclude certain items items represent substantive unusual items evaluated individual basis evaluation considers quantitative table contents qualitative aspect unusual nature generally represent items either result nature magnitude management would anticipate would occur part companys normal business regular basis certain items include among items gain fair value adjustment mercks existing interest msp partnership result merger gain divestiture interest merial gain distribution azlp certain legal settlements research development chart reflecting companys current research pipeline february set forth item business research development research development update connection merger company assessing pipeline identify promising highpotential compounds development company completed prioritization clinical development programs company continuing work prioritization value adding programs related currently marketed products preclinicaldiscovery programs company anticipates full prioritization process completed first half connection process company may recognize non cash impairment charges cancellation certain legacy scheringplough pipeline programs measured fair value capitalized connection merger noncash impairment charges anticipated excluded companys nongaap earnings could material companys future gaap earnings company currently number candidates regulatory review united states internationally additionally company drug candidates phase iii development mk vernakalant iv investigational candidate treatment atrial fibrillation currently undergoing regulatory review eu april old merck cardiome pharma corp cardiome announced collaboration license agreement development commercialization vernakalant provides merck exclusive rights outside united states canada mexico intravenous formulation vernakalant see vernakalent oral currently phase ii development merck exclusive global rights oral formulation vernakalent maintenance normal heart rhythm patients atrial fibrillation sch mff combination two previously approved drugs treatment asthma mometasone asmanex formoterol foradil company aiming create new option patients bringing two key treatments together july scheringplough announced filed new drug application nda fda mff mff also currently regulatory review eu sch nomace oral contraceptive combines selective progestin estradiol estrogen women produce naturally drug currently regulatory review eu phase iii development us market sch saphris asenapine central nervous system compound bipolar disorder schizophrenia currently undergoing regulatory review eu fda approved saphris august sch bridion sugammadex medication designed rapidly reverse effects certain muscle relaxants used part general anesthesia ensure patients remain immobile surgical procedures differs reversal agents administered muscle relaxant begins wear bridion received regulatory approval eu australia new zealand japan regulatory review markets including united states prior merger scheringplough received complete response letter fda bridion following communication fda company assessing agencys feedback order determine new timetable response sch boceprevir hepatitis c protease inhibitor currently development boceprevir fully enrolled phase iii program company expects conclude mid company expects submit nda fda boceprevir end treatmentexperienced treatmentnave patients hepatitis c table contents mk ridaforolimus novel mtor mammalian target rapamycin inhibitor evaluated treatment cancer drug candidate jointly developed commercialized ariad pharmaceuticals inc agreement entered phase iii study succeed patients metastatic softtissue bone sarcomas underway company continues anticipate filing nda ridaforolimus fda subject review results planned interim analysis succeed sch allergy immunotherapy sublingual tablet ait grass pollen allergy developed company november sch met primary endpoint phase iii study adult subjects united states history grass pollen induced rhinoconjunctivitis without asthma investigational grass ait treatment designed work inducing protective immune response grass pollen allergy providing sustained prevention allergy symptoms treating symptoms underlying cause disease sch ait ragweed allergy also phase iii development us market sch vorapaxar thrombin receptor antagonist antiplatelet protease activated receptor inhibitor studied prevention treatment thrombosis november merck announced completion patient enrollment patients tra ptimi clinical trial phase iii randomized doubleblind placebocontrolled multinational study trial assess ability sch prevent major cardiovascular events added current antiplatelet regimens aspirin aspirin plus adp inhibitor patients previously experienced heart attack stroke peripheral arterial disease sch also studied treatment patients acute coronary syndrome ongoing phase iii thrombin receptor antagonist clinical event reduction acute coronary syndrome trial led duke clinical research institute company anticipates filing nda vorapaxar fda mk tafluprost preservative free synthetic analogue prostaglandin f reduction elevated intraocular pressure appropriate patients primary openangle glaucoma ocular hypertension april old merck santen announced worldwide licensing agreement tafluprost see previously disclosed old merck submitted filing nda fda mkc ezetimibe combined atorvastatin investigational medication treatment dyslipidemia fda refused file application fda identified additional manufacturing stability data needed company assessing fdas response anticipates filing mkc candidate currently phase iii clinical development combines januvia pioglitazone another type diabetes therapy company continues anticipate filing nda mkc fda mk odanacatib oral onceweekly investigational treatment osteoporosis osteoporosis disease reduces bone density strength results increased risk bone fractures odanacatib cathepsin k inhibitor selectively inhibits cathepsin k enzyme cathepsin k known play central role function osteoclasts cells break existing bone tissue particularly protein components bone inhibition cathepsin k novel approach treatment osteoporosis september data phase iib clinical study odanacatib presented st annual meeting american society bone mineral research showed stopping treatment two years increases lower back lumbar spine bone mineral density bmd reversed next year bmd hip femoral neck remained levels observed start study additionally three years treatment odanacatib mg demonstrated increases bmd key fracture sites minimal impact formation new bone measured biochemical markers bone turnover odanacatib currently phase iii clinical trials evaluated largescale global outcomes study determine effects vertebral hip nonvertebral fractures company continues anticipate filing nda fda v ninevalent hpv vaccine development expand protection cancercausing hpv types phase iii clinical program underway merck anticipates filing biologics license application bla fda table contents mka drug candidate combines extendedrelease er niacin novel flushing inhibitor laropiprant mka demonstrated ability lower ldlcholesterol ldlc bad cholesterol raise hdlcholesterol hdlc good cholesterol lower triglycerides significantly less flushing traditional extended release niacin alone high ldl c low hdlc elevated triglycerides risk factors associated heart attacks strokes april old merck received nonapprovable action letter fda response nda mka meeting discuss letter fda stated additional efficacy safety data required suggested old merck wait results treatment hdl reduce incidence vascular events hpsthrive cardiovascular outcomes study expected completed company anticipates filing nda fda mk mka approved countries outside united states treatment dyslipidemia particularly patients combined mixed dyslipidemia characterized elevated levels ldlc triglycerides low hdlc patients primary hypercholesterolemia heterozygous familial nonfamilial marketed tredaptive cordaptive certain countries tredaptive used patients combination statins cholesterol lowering effects statin monotherapy inadequate tredaptive used monotherapy patients statins considered inappropriate tolerated mkb drug candidate combines novel approach raising hdlc lowering triglycerides er niacin combined laropiprant proven benefits simvastatin one combination product merck seek approval mkb united states files complete response relating mka mk anacetrapib inhibitor cholesteryl ester transfer protein shown promise lipid management raising hdlc reducing ldlc without raising blood pressure november merck announced phase iib study patients primary hypercholesterolemia mixed hyperlipidemia treated anacetrapib monotherapy co administered atorvastatin persistent lipid effects higher dose arms monotherapy coadministration treatment groups eight weeks stopping active therapy anacetrapib effect cetp inhibition cardiovascular risk yet established phase iii trial titled define ongoing evaluate safety efficacy anacetrapib patients coronary heart disease company anticipates filing nda fda beyond previously disclosed old merck announced delaying filing us application telcagepant mk companys investigational calcitonin gene related peptide cgrpreceptor antagonist intermittent treatment acute migraine decision based findings phase iia exploratory study small number patients taking telcagepant twice daily three months prevention migraine found marked elevations liver transaminases daily dosing regimen prevention study different dosing regimen used phase iii studies telcagepant intermittently administered one two doses treat individual migraine attacks occurred studies telcagepant acute intermittent treatment migraine continue following meetings regulatory agencies end merck planning conduct additional safety study part overall phase iii program telcagepant results study inform planned filings approval sch acadesine potential firstin class adenosine regulating agent ischemia reperfusioninjury patients undergoing heart bypass surgery patient enrollment red cabg phase iii clinical trial initiated sch vicriviroc treatment hiv infection treatment experienced evaluated two phase iii studies patient population announced january primary efficacy endpoint met merck submit nda fda vicriviroc treatmentexperienced hivinfected patients time continue evaluate vicriviroc firstline therapy treatmentnaive patients previously disclosed cubist pharmaceuticals inc cubist entered license agreement old merck development commercialization cubicin daptomycin injection mk japan merck develop commercialize cubicin whollyowned subsidiary banyu pharmaceutical co ltd cubist commercializes cubicin united states mk currently phase iii development table contents mk orexin receptor antagonist potential new approach treatment chronic insomnia currently phase iii development sch elonva corifollitropin alpha injection approved ec controlled ovarian stimulation combination gnrh antagonist development multiple follicles women participating assisted reproductive technology program currently phase iii development united states merck terminated internal clinical development program esmirtazapine sch hot flashes insomnia strategic reasons previously disclosed old merck announced preliminary results pivotal phase iii study rolofylline mk investigational medicine treatment acute heart failure showed rolofylline meet primary secondary efficacy endpoints old merck terminated clinical development program rolofylline inprocess research development connection merger company recorded fair value human animal health research projects underway scheringplough approximately billion consideration transferred merger allocated pharmaceutical segment iprd projects billion allocated animal health operating segment iprd projects significant projects include bridion vorapaxar boceprevir phase iii clinical development well ezetimibeatorvastatin combination product projects discussed detail also noted company expects file ndas fda boceprevir vorapaxar ezetimibeatorvastatin combination product fair values identifiable intangible assets related iprd determined using income approach fair value estimated based assets probability adjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using discount rates range actual cash flows likely different assumed additional research development required programs reach technological feasibility costs complete research projects depend whether projects brought final stages development ultimately submitted fda regulatory agencies approval december estimated costs complete projects phase iii development human health analogous stage development animal health approximately billion iprd projects subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates time periods receive approvals fda regulatory agencies subject uncertainty significant delays approval process companys failure obtain approval delay prevent company realizing revenues products additionally certain iprd programs fail abandoned development result companys portfolio prioritization process otherwise company realize future cash flows estimated recorded iprd merger date company may also recover research development expenditures made since merger develop program circumstances occur companys future operating results could adversely affected acquisitions research collaborations license agreements merck continues remain focused augmenting internal efforts capitalizing growth opportunities drive near longterm growth transactions across broad range therapeutic categories well early stage technology transactions completed merck actively table contents monitoring landscape growth opportunities meet companys strategic criteria highlights activities include december merck avecia investments limited announced definitive agreement merck would acquire biologics business avecia group total purchase price million avecia biologics contract manufacturing organization specific expertise microbialderived biologics terms agreement merck would acquire avecia biologics limited avecia assets including avecias process development scaleup manufacturing quality business support operations located billingham united kingdom transaction closed february accordingly results operations acquired business included mercks results operations beginning acquisition date july old merck portola pharmaceuticals inc portola signed exclusive global collaboration license agreement development commercialization betrixaban mk investigational oral factor xa inhibitor anticoagulant currently phase ii clinical development prevention stroke patients atrial fibrillation return exclusive worldwide license betrixaban old merck paid portola initial fee million closing recorded research development expense portola eligible receive additional cash payments totaling million upon achievement certain development regulatory commercialization milestones well doubledigit royalties worldwide sales betrixaban approved company assume development commercialization costs including costs phase iii clinical trials portola retained option cofund phase iii clinical trials return additional royalties b copromote betrixaban merck united states term agreement commenced august unless terminated earlier continue remaining royalty payment obligations country time agreement expire entirety country agreement may terminated either party event material uncured breach bankruptcy party agreement may terminated merck event parties merck decide cease development betrixaban safety efficacy addition merck may terminate agreement time upon days prior written notice portola may terminate agreement event merck challenges portola patent covering betrixaban upon termination agreement depending upon circumstances parties varying rights obligations respect continued development commercialization betrixaban case termination cause merck certain royalty obligations april old merck medarex inc medarex massachusetts biologic laboratories mbl university massachusetts medical school announced exclusive worldwide license agreement cda cdb mka also known mdxmdx mblcdamblcdb investigational fully human monoclonal antibody combination developed target neutralize clostridium difficile toxins b treatment c difficile infection cda cdb codeveloped medarex mbl terms agreement merck gained worldwide rights develop commercialize cda cdb medarex mbl received aggregate upfront payment million upon closing recorded research development expense potentially eligible receive additional cash payments million aggregate upon achievement certain milestones associated development approval drug candidate covered agreement upon commercialization medarex mbl also eligible receive doubledigit royalties product sales milestones certain sales targets met term agreement commenced closing date unless terminated earlier continue remaining royalty payment obligations country time agreement expire entirety country either party may terminate agreement uncured material breach party bankruptcy insolvency party merck may terminate agreement time upon providing days prior written notice medarex mbl also april old merck santen pharmaceutical co ltd santen announced worldwide licensing agreement tafluprost mk prostaglandin analogue investigation united states tafluprost preserved preservativefree formulations received marketing approval reduction elevated intraocular pressure openangle glaucoma ocular hypertension several european nordic countries well japan filed approval additional european asia pacific markets terms agreement old merck paid fee capitalized amortized materials table contents production costs life underlying patent pay milestones royalty payments based future sales tafluprost preserved preservativefree formulations exchange exclusive commercial rights tafluprost western europe excluding germany north america south america africa santen retain commercial rights tafluprost countries eastern europe northern europe asia pacific including japan merck provide promotion support santen germany poland tafluprost approved united states santen option copromote agreement old merck santen expires countrybycountry basis last occur expiry last expire valid patent claim b expiration last expire royalty merck may terminate agreement time upon days prior written notice also time upon days prior written notice merck determines product presents issues safety tolerability addition merck may terminate agreement event enumerated agreements santen co ownerlicensor certain intellectual property terminate expire materially adversely affects merck either merck santen materially breaches agreement fails cure receiving notice nonbreaching party may terminate agreement agreement provides termination noninsolvent party due bankruptcy party finally agreement terminate term merck develops commercializes competitive product term defined agreement addition april old merck cardiome pharma corp cardiome announced collaboration license agreement development commercialization vernakalant mk investigational candidate treatment atrial fibrillation agreement provides merck exclusive global rights oral formulation vernakalant vernakalant oral maintenance normal heart rhythm patients atrial fibrillation provides merck affiliate merck sharp dohme switzerland gmbh exclusive rights outside united states canada mexico intravenous iv formulation vernakalant vernakalant iv rapid conversion acute atrial fibrillation normal heart rhythm terms agreement old merck paid cardiome initial fee million upon closing recorded research development expense addition cardiome eligible receive million payments based achievement certain milestones associated development approval vernakalant products including million submission regulatory approval europe vernakalant iv old merck paid result submission million initiation planned phase iii program vernakalant oral million milestones associated approvals subsequent indications intravenous oral formulations also cardiome receive tiered royalty payments sales approved products potential receive million milestone payments based achievement significant sales thresholds cardiome retained option copromote vernakalant oral merck hospitalbased sales force united states merck responsible future costs associated development manufacturing commercialization candidates merck granted cardiome secured interestbearing credit facility million cardiome may access tranches several years commencing cardiomes codevelopment partner north america astellas pharma us inc submitted nda fda kynapid vernakalant hydrochloride injection december included results two pivotal phase iii clinical trials december cardiovascular renal drugs advisory committee recommended fda approve vernakalant iv rapid conversion atrial fibrillation august fda issued approvable action letter requesting additional information phase iib doubleblind placebocontrolled randomized doseranging clinical trial patients risk recurrent atrial fibrillation showed mg dose vernakalant oral significantly reduced rate atrial fibrillation relapse compared placebo agreement continues effect expiration cardiomes copromotion rights royalty milestone payment obligations agreement may terminated event insolvency material uncured breach either party additionally collaboration may terminated merck event merck determines good faith advisable continue development commercialization vernakalant product result serious safety issue addition merck may terminate agreement time upon months prior written notice cardiome may terminate agreement event merck challenges cardiome patent covering vernakalant upon termination agreement depending upon circumstances parties varying rights obligations respect continued development commercialization vernakalant cases continuing royalty obligations table contents march old merck acquired insmed incs insmed portfolio followon biologic therapeutic candidates commercial manufacturing facilities located boulder colorado terms agreement old merck paid insmed aggregate million cash acquire rights boulder facilities insmeds pipeline followon biologic candidates insmeds followon biologics portfolio includes two clinical candidates mk investigational recombinant granulocytecolony stimulating factor gcsf evaluated ability prevent infections patients cancer receiving chemotherapy mk pegylated recombinant gcsf designed allow less frequent dosing transaction accounted business combination accordingly assets acquired liabilities assumed recorded respective fair values acquisition date determination fair value requires management make significant estimates assumptions connection acquisition substantially purchase price allocated insmeds followon biologics portfolio mk mk indefinitelived intangible asset recorded fair value determined based upon present value expected future cash flows new product candidates resulting insmeds followon biologics portfolio adjusted probability estimated technical marketing success utilizing income approach reflecting appropriate riskadjusted discount rates ongoing activity related mk mk expected material companys research development expense remaining net assets acquired material milestone royalty obligations associated acquisition transaction closed march accordingly results operations acquired business included mercks results operations beginning april company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources disease areas unmet medical needs scientific opportunity commercial opportunity merck managing research development portfolio across diverse approaches discovery development balancing investments appropriately novel innovative targets potential major impact human health developing bestinclass approaches delivering maximum value new medicines vaccines new indications new formulations another important component companys sciencebased diversification based expanding companys portfolio modalities include small molecules vaccines also biologics peptides rnai merck moved diversify portfolio creating new division merck bioventures potential harness market opportunity presented biological medicine patent expiries delivering high quality followon biologic products enhance access patients worldwide company continue pursue appropriate external licensing opportunities integration plans research development focused integrating research operations legacy companies including providing effective transition employees realizing projected merger synergies form cost savings revenue growth opportunities maintaining momentum companys latestate pipeline merck continued implementing new model basic research global operating strategy legacy merck research laboratories sites new model align franchise function well align resources disease area priorities balance capacity across discovery phases allow company act upon programs highest probability success additionally across disease area priorities companys strategy designed expand access worldwide external science incorporate external research key component companys early discovery pipeline order translate basic research productivity latestage clinical success companys clinical pipeline includes candidates multiple disease areas including anemia atherosclerosis cancer diabetes heart disease hypertension infectious diseases inflammatoryautoimmune diseases migraine neurodegenerative diseases ophthalmics osteoporosis psychiatric diseases respiratory disease womens health company supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies table contents selected joint venture affiliate information expand research base realize synergies combining capabilities opportunities assets previous years old merck formed number joint ventures see note consolidated financial statements merckscheringplough partnership old merck scheringplough collectively partners entered agreement create equallyowned partnership develop market united states new prescription medicines cholesterol management agreement generally provided equal sharing development costs copromotion approved products company cholesterolmanagement partnership expanded include countries world excluding japan ezetimibe first new class cholesterollowering agents launched united states zetia marketed ezetrol outside united states combination product containing active ingredients zetia zocor approved united states vytorin marketed inegy outside united states vytorin combination tablet cholesterol treatment provide ldl cholesterol lowering dual inhibition cholesterol production absorption cholesterol agreements provided sharing operating income generated msp partnership based upon percentages vary product sales level country us market partners shared profits zetia vytorin sales equally exception first million annual zetia sales scheringplough received greater share profits operating income included expenses partners contractually agreed share portion manufacturing costs specifically identified promotion costs including directtoconsumer advertising direct identifiable outofpocket promotion agreed upon costs specific services ongoing clinical research market support market research market expansion well specialty sales force physician education programs expenses incurred support msp partnership shared partners marketing administrative expenses including certain sales force costs well certain manufacturing costs included equity income affiliates however costs reflected overall results legacy company certain research development expenses generally shared equally partners adjusting earned milestones result merger msp partnership owned company results msp partnership date merger reflected equity income affiliates results sales msp partnership products merger consolidated mercks results sales joint venture products follows millions premerger postmerger total vytorin zetia amounts exclude sales products partners outside msp partnership following previously announced enhance seas clinical trial results discussed sales vytorin zetia declined previously disclosed january legacy companies announced results effect combination ezetimibe highdose simvastatin vs simvastatin alone atherosclerotic process patients heterozygous familial hypercholesterolemia enhance clinical trial imaging trial patients heterozygous familial hypercholesterolemia rare genetic condition causes high levels ldl bad cholesterol greatly increases risk premature coronary artery disease previously reported despite fact ezetimibesimvastatin mg vytorin significantly lowered ldl bad cholesterol simvastatin mg alone significant difference treatment ezetimibesimvastatin simvastatin alone prespecified primary endpoint change thickness carotid artery walls two years measured ultrasound improved reduction highrisk subjects presenting acute coronary syndrome improveit trial underway designed provide cardiovascular outcomes data ezetimibesimvastatin patients acute coronary syndrome incremental benefit ezetimibe table contents simvastatin cardiovascular morbidity mortality demonstrated simvastatin established january fda announced completed review final clinical study report enhance fda stated results enhance change position elevated ldl cholesterol risk factor cardiovascular disease lowering ldl cholesterol reduces risk cardiovascular disease july efficacy safety results simvastatin ezetimibe aortic stenosis seas study announced seas designed evaluate whether intensive lipid lowering vytorin mg would reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patients asymptomatic mild moderate aortic stenosis indication statin therapy vytorin failed meet primary end point reduction major cardiovascular events study patients group took vytorin mg higher incidence cancer group took placebo also nonsignificant increase deaths cancer patients group took vytorin versus took placebo cancer cancer deaths distributed across major organ systems company believes cancer finding seas likely anomaly taken light available data support association vytorin august fda announced investigating results seas trial december fda announced completed review data seas trial well review interim data study heart renal protection sharp improveit trials based currently available information fda indicated believed unlikely vytorin zetia increase risk cancerrelated death sharp trial expected completed improveit trial scheduled completion improveit trial blinded interim efficacy analysis conducted data safety monitoring board trial approximately endpoints accrued interim analysis expected conducted company committed working regulatory agencies evaluate available data interpretations data however company believe changes clinical use vytorin warranted see note consolidated financial statements information respect litigation involving partners msp partnership related sale promotion zetia vytorin results old mercks interest msp partnership completion merger recorded equity income affiliates equity income billion billion billion financial statements msp partnership included item financial statement schedules astrazeneca lp old merck entered agreement astra ab astra develop market astras products royaltybearing license old mercks total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami old merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining old merck astra completed restructuring ownership operations joint venture whereby old merck acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights table contents maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns ongoing revenue based sales current future kbi products revenue billion billion billion respectively primarily relating sales nexium well prilosec addition merck earns certain partnership returns recorded equity income affiliates returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings returns aggregated million million million respectively astrazeneca merger triggered partial redemption march old mercks interest certain azlp product rights upon redemption old merck received billion azlp amount based primarily multiple old mercks average annual variable returns derived sales former astra usa inc products three years prior redemption limited partner share agreed value pretax gain billion partial redemption recorded partial redemption old mercks interest product rights result change old mercks limited partnership interest conjunction restructuring astra purchased option asset option payment million recorded deferred income buy old mercks interest kbi products excluding gastrointestinal medicines nexium prilosec nonppi products astrazeneca exercise asset option first half exercise price million represents net present value march projected future pretax revenue received old merck nonppi products appraised value february astrazeneca notified company exercising asset option old merck also right require astra purchase interest appraised value february old merck advised astrazeneca would exercise asset option thus million remains deferred recognized asset option consummated addition old merck granted astra option shares option buy old mercks common stock interest kbi therefore old mercks interest nexium prilosec exercisable two years astras exercise asset option astra also exercise shares option combined annual sales two products fall minimum amount provided case long astrazenecas asset option exercised exercise price shares option based net present value estimated future net sales nexium prilosec determined time exercise subject certain trueup mechanisms astrazeneca merger constituted trigger event kbi restructuring agreements result merger exchange old mercks relinquishment rights future astra products existing pending us patents time merger astra paid million advance payment advance payment deferred remained subject trueup calculation trueup amount directly dependent fair market value march astra product rights retained old merck calculated trueup amount million returned azlp march pretax gain million recognized related residual advance payment balance provisions kbi restructuring agreements trigger event occurred sum limited partner share agreed value appraised value trueup amount guaranteed minimum billion distribution limited partner share agreed value less payment trueup amount resulted cash receipts old merck billion aggregate pretax gain billion included income expense net astrazenecas purchase old mercks interest nonppi products contingent upon exercise asset option astrazeneca therefore payment appraised value may may occur also march billion outstanding loan astra plus interest redemption date settled result transactions old merck received net proceeds azlp billion table contents merial limited old merck rhnepoulenc sa sanofiaventis combined animal health businesses form merial limited merial fully integrated animal health company standalone joint venture owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species september old merck sold interest merial sanofiaventis billion cash sale resulted recognition billion gain reflected income expense net also connection sale merial old merck sanofiaventis scheringplough signed call option agreement terms call option agreement following closing merger sanofiaventis option require company combine intervetscheringplough animal health business merial form animal health joint venture would owned equally company sanofiaventis part call option agreement value merial fixed billion minimum total value received company affiliates contributing intervetscheringplough combined entity would billion subject customary transaction adjustments consisting floor valuation intervetschering plough fixed minimum billion subject potential upward revision based valuation exercise two parties additional payment sanofiaventis million based valuation exercise intervetscheringplough customary transaction adjustments merial intervetscheringplough combined payment may required paid either party make joint venture equally owned company sanofiaventis payment would trueup value contributions equal formation new animal health joint venture sanofiaventis subject customary closing conditions including antitrust review united states europe prior closing merger agreements provided old merck certain rights terminate call option fee million recognition termination fee deferred fourth quarter conditions could triggered payment lapsed sales joint venture products follows millions fipronil products biological products avermectin products products amounts include sales september divestiture date sanofi pasteur msd old merck pasteur merieux connaught sanofi pasteur sa established owned joint venture market vaccines europe collaborate development combination vaccines distribution europe sales joint venture products follows millions gardasil influenza vaccines viral vaccines hepatitis vaccines rotateq vaccines table contents johnson johnsonmerck consumer pharmaceuticals company old merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned joint venture subsequently expanded canada significant joint venture products pepcid ac overthecounter form companys ulcer medication pepcid well pepcid complete overthecounter product combines companys ulcer medication antacids sales joint venture products follows millions gastrointestinal products products capital expenditures capital expenditures billion billion billion expenditures united states million million million expenditures included million production facilities million research development facilities million environmental projects million administrative safety general site projects approximately represents capital investments related multiyear initiative standardize companys information systems depreciation expense billion billion billion billion billion billion respectively applied locations united states total depreciation expense included accelerated depreciation million million million respectively associated restructuring activities see note consolidated financial statements analysis liquidity capital resources mercks strong financial profile enables fully fund research development focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders selected data millions working capital total debt total liabilities equity cash provided operations total debt billion cash portion consideration merger funded combination existing cash including proceeds sale old mercks interest merial discussed sale redemption shortterm investments issuance debt preparation merger old merck closed underwritten public offering billion senior unsecured notes discussed additionally significant portion longterm investments december liquidated anticipation merger cash provided operating activities billion billion billion continues companys primary source funds finance operating needs capital expenditures treasury stock purchases dividends paid shareholders cash provided operating activities reflects billion payments vioxx settlement funds million payment made connection previously disclosed settlement cra cash provided operating activities reflects billion received connection partial redemption old mercks partnership interest azlp representing table contents distribution old mercks accumulated earnings investment azlp since inception cash provided operating activities also affected million payment made connection previously disclosed resolution investigations civil claims federal state authorities relating certain past marketing selling activities million payments vioxx settlement funds cash provided operating activities reflects payment made previously disclosed settlement internal revenue service irs cash provided investing activities billion compared cash used investing activities billion change primarily driven release restricted cash primarily due release pledged collateral certain vioxxrelated matters lower purchases securities investments proceeds disposition old mercks interest merial increases cash used investing activities partially offset use cash fund merger well distribution azlp representing return old mercks investment azlp cash used investing activities billion compared billion lower use cash investing activities primarily reflects distribution azlp billion payment connection december acquisition sirna therapeutics inc partially offset higher net purchases securities investments higher capital expenditures increase restricted assets cash used financing activities billion compared billion reflecting issuance billion senior unsecured notes purchases treasury stock lower payments debt partially offset net decrease shortterm borrowings cash used financing activities billion compared billion reflecting higher purchases treasury stock lower proceeds exercise stock options higher payments debt connection settlement note due astra partially offset net increase shortterm borrowings dividends paid stockholders billion billion december total worldwide cash investments billion including billion cash cash equivalents shortterm investments million longterm investments addition company million cash investments restricted certain collateral arrangements discussed working capital levels adequate meet operating requirements company august old merck executed billion letter credit agreement financial institution satisfied certain conditions set forth us vioxx settlement agreement see note consolidated financial statements old merck pledged collateral financial institution approximately billion pursuant terms letter credit agreement although amount assets pledged collateral set letter credit agreement assets held custody third party assets managed old merck old merck considered assets pledged letter credit agreement restricted letter credit amount required collateral balances declined payments first million settlement agreement made december billion recorded within deferred income taxes current assets billion classified assets remaining payments vioxx settlement funds made pursuant us vioxx settlement agreement accordingly letter credit agreement terminated collateral released previously disclosed irs completed examination old mercks tax returns years result examination old merck made aggregate payment billion february payment offset tax refund million received amounts previously paid matters ii federal tax benefit approximately million related interest included payment resulting net cash cost old merck approximately billion impact years subsequent items reviewed part examination included payment although years remain open respects closing irs examination material impact results operations amounts previously accrued previously disclosed october cra issued old merck notice reassessment containing adjustments related certain intercompany pricing matters february old merck cra negotiated settlement agreement regard matters accordance settlement old merck paid additional tax approximately million us dollars interest approximately million us dollars table contents additional amounts penalties due assessment settlement accounted first quarter old merck previously established reserves matters significant portion taxes paid expected creditable us tax purposes resolution matters material effect financial position liquidity respect associated collateral discussed addition july november cra proposed additional adjustments respectively relating intercompany pricing matters adjustments would increase canadian tax due approximately million us dollars plus million us dollars interest december possible cra propose similar adjustments later years company disagrees positions taken cra believes without merit company intends contest assessments cra appeals process courts necessary management believes resolution matters material effect companys financial position liquidity connection appeals process matters discussed old merck pledged collateral two financial institutions one provided guarantee cra quebec ministry revenue representing portion tax interest assessed result settlement noted guarantees required appeal disputes reduced eliminated approximately million associated collateral released certain cash investments continue collateralized guarantees required appeal canadian tax disputes collateral included deferred income taxes current assets assets consolidated balance sheet totaled approximately million billion december respectively irs examining old mercks federal income tax returns addition various state foreign tax examinations progress significant tax jurisdictions us state foreign companys income tax returns open examination period second quarter irs completed examination scheringploughs federal income tax returns company seeking resolution issue raised examination irs administrative appeals process july scheringplough made payment million irs pertaining examination companys income tax returns remain open irs tax years irs commenced examination federal income tax returns examination expected completed significant tax jurisdictions us state foreign companys income tax returns open examination period companys contractual obligations december follows payments due period millions total thereafter purchase obligations loans payable current portion longterm debt longterm debt interest related debt obligations unrecognized tax benefits operating leases december companys consolidated balance sheet reflects liabilities unrecognized tax benefits interest penalties billion including million reflected current liability due high degree uncertainty regarding timing future cash outflows liabilities unrecognized tax benefits beyond one year reasonable estimate period cash settlement years beyond made table contents purchase obligations consist primarily goods services enforceable legally binding include obligations minimum inventory contracts research development advertising amounts reflected research development obligations include contingent milestone payments loans payable current portion longterm debt also reflects million longdated notes subject repayment option holders annual basis required funding obligations relating companys pension postretirement benefit plans expected material however company currently anticipates contributing approximately million million respectively pension plans postretirement benefit plans june old merck closed underwritten public offering billion senior unsecured notes consisting billion aggregate principal amount notes due billion aggregate principal amount notes due billion aggregate principal amount notes due million aggregate principal amount notes due interest notes payable semiannually notes series redeemable whole part time companys option redemption prices specified notes associated prospectus proceeds notes used fund portion cash consideration merger december company filed securities registration statement securities exchange commission sec automatic shelf registration process available wellknown seasoned issuers effective three years also connection merger march old merck entered financing commitment letter jpmorgan chase bank na jp morgan securities inc collectively jpmorgan jpmorgan committed provide billion financing may old merck entered billion day senior unsecured interim term loan facility bridge loan facility billion day asset sale revolving credit facility asset sale facility billion day corporate revolving credit facility incremental facility connection billion offering bridge loan facility terminated commitment lenders day asset sale facility reduced upon completion sale merial sanofiaventis see note consolidated financial statements asset sale facility terminated incremental facility available backstop commercial paper general corporate purposes facility drawn expire november merck incurred commitment fees approximately million associated facilities amortized commitment period april old merck amended billion year revolving credit facility maturing april allow facility remain place merger companys existing billion credit facility maturing august remains outstanding facilities provide backup liquidity companys commercial paper borrowing facility general corporate purposes company drawn funding either facility also connection merger effective november new merck executed full unconditional guarantee existing debt old merck old merck executed full unconditional guarantee existing debt new merck excluding commercial paper including payments principal interest companys longterm credit ratings assigned moodys investors service standard poors aa stable outlook aa positive outlook respectively ratings continue allow access capital markets flexibility obtaining funds competitive terms company continues maintain conservative financial profile company places cash investments instruments meet high credit quality standards specified investment policy guidelines guidelines also limit amount credit exposure one issuer despite strong financial profile certain contingent events realized discussed note consolidated financial statements could material adverse impact companys liquidity capital resources company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations november february board directors declared quarterly dividend per share companys common stock first second quarter respectively declared table contents quarterly dividend per share mandatory convertible preferred stock first second quarter respectively november board directors approved purchases time billion mercks common stock treasury purchases treasury stock made old merck purchased billion billion treasury stock respectively previous program approved old mercks board directors july financial instruments market risk disclosures company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management significant portion companys revenues denominated foreign currencies merck relies sustained cash flows generated foreign sources support longterm commitment us dollarbased research development extent dollar value cash flows diminished result strengthening dollar companys ability fund research dollarbased strategic initiatives consistent level may impaired company established revenue hedging balance sheet risk management programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates us functional currency entities objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company partially hedge forecasted foreign currency denominated third party intercompany distributor entity sales expected occur planning cycle typically three years future company layer hedges time increasing portion third party intercompany distributor sales hedged gets closer expected date forecasted foreign currency denominated sales probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged risk manner company manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows offset decline expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase value anticipated foreign currency cash flows company also utilizes forward contracts revenue hedging program us dollar strengthens relative currency hedged anticipated sales increase fair value forward contracts offsets decrease expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens decrease fair value forward contracts offsets increase value anticipated foreign currency cash flows weaker us dollar would result net benefit market value mercks hedges would declined million million respectively uniform weakening us dollar december market value determined using foreign exchange option pricing model holding factors except exchange rates constant merck principally uses purchased local currency put options uniform weakening us dollar yield largest overall potential loss market value options sensitivity measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes table contents threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows us dollar functional currency companys foreign subsidiaries primary objective balance sheet risk management program protect us dollar value foreign currency denominated net monetary assets effects volatility foreign exchange might occur prior conversion us dollars instances merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange amount us dollar cash flows derived net assets us dollar functional currency companys foreign subsidiaries merck executes spot trades convert foreign currencies us dollars based shortterm forecast needs us dollar proceeds invested required companys foreign subsidiaries merck routinely enters contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level applicable company uses forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly strengthened currency exposures company december income taxes would declined million company net long position relative major foreign currencies consideration forward contracts uniform strengthening us dollar yield largest overall potential net loss earnings due exchange december old merck net short position relative major foreign currencies consideration forward contracts therefore uniform weakening us dollar would reduced income taxes million measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows venezuelan economy recently determined hyperinflationary requires company remeasure local currency operations us dollars accordingly accordance us gaap company remeasure monetary assets liabilities operations earnings first quarter effective january venezuelan government devalued currency bsf per us dollar twotiered official exchange rate essentials rate bsf per us dollar nonessentials rate bsf per us dollar companys products expected classified essentials anticipates majority transactions settled essential rate bsf per us dollar actions adverse effect companys results operations financial position cash flows interest rate risk management addition revenue hedging balance sheet risk management programs company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party seven payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes two swaps maturing notional amounts million effectively convert companys million fixedrate notes due floating rate instruments five swaps maturing notional amounts million effectively convert million companys billion fixedrate notes due floating rate instruments fair value changes notes attributable changes benchmark interest rate recorded interest expense offset fair value changes swap table contents contracts old merck terminated four interest rate swap contracts notional amounts million terminated one interest rate swap contract notional amount million swaps effectively converted billion fixedrate notes due million fixedrate notes due variable rate debt result swap terminations old merck received million cash excluding accrued interest material corresponding gains related basis adjustment debt associated terminated swap contracts deferred amortized reduction interest expense remaining term notes cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly affected changes interest rates market value companys medium longterm fixedrate investments modestly affected changes us interest rates changes medium longterm us interest rates significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value mercks investments debt related swap contracts change interest rates indicated one percentage point increase interest rates december would positively affected net aggregate market value instruments million million respectively one percentage point decrease december would negatively affected net aggregate market value million million respectively increased sensitivity interest rate movements prior year attributable sale redemption longterm fixed rate investments fund merger well increase debt included existing scheringplough debt well debt issued fund merger fair value mercks debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair values mercks investments determined using combination pricing duration models critical accounting policies matters companys consolidated financial statements include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection mergers acquisitions including fair value determinations assets liabilities additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements mergers acquisitions january new guidance issued fasb adopted changes way acquisition method applied business combination also changes way assets liabilities recognized purchase accounting prospective basis acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies recognized fair value fair value reasonably estimated acquisition date fair value asset acquired liability assumed arises contingency determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred company determines asset acquired meet definition business acquisition method accounting transaction table contents accounted acquisition assets rather business combination therefore goodwill recorded fair value intangible assets including acquired inprocess research development based significant judgments made management accordingly significant items company typically obtains assistance third party valuation specialists amounts allocated acquired inprocess research development capitalized accounted similar indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make separate determination useful life asset begin amortization valuations useful life assumptions based information available near merger acquisition date based expectations assumptions deemed reasonable management judgments made determining estimated fair values assigned assets acquired liabilities assumed well asset lives materially affect companys results operations fair values identifiable intangible assets related currently marketed products product rights primarily determined using income approach fair value estimated based assets discounted projected net cash flows companys estimates market participant net cash flows consider historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain marketing regulatory approvals ability manufacture commercialize products extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probability adjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate fair values identifiable intangible assets related iprd determined using income approach fair value estimated based assets probability adjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using appropriate discount rate revenue recognition revenues sales products recognized time delivery title risk loss passes customer recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale provision aggregate indirect customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases directly intermediary wholesaler contracted customer generally purchases product contracted price plus markup wholesaler wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision based expected payments driven patient usage contract performance benefit provider customers company uses historical customer segment mix adjusted known events order estimate expected provision amounts accrued aggregate indirect customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers customers amounts accrued adjustments recorded trends significant events indicate change estimated provision appropriate table contents company continually monitors provision aggregate indirect customer discounts material adjustments estimates associated aggregate indirect customer discount provision summarized information changes aggregate indirect customer discount accrual follows millions balance january current provision scheringplough accrual assumed merger adjustments prior years payments balance december accruals chargebacks reflected direct reduction accounts receivable accruals rebates current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million million respectively december million million respectively december company maintains returns policy allows customers return product within specified period prior subsequent expiration date generally three six months twelve months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market additional generic competition changes formularies launch overthecounter products among others product returns provision well actual returns less net sales distribution programs us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories specified levels terms programs allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing product returns information provided wholesaler distribution programs includes items sales trends inventory onhand onorder quantity product returns wholesalers generally provide mentioned data company regulatory requirement report lot level information manufacturers level information needed determine remaining shelf life original sale date inventory given current wholesaler inventory levels generally less month company believes collection order lot information across wholesale customers would limited use estimating sales discounts returns inventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support estimated initial market demand typically capitalization inventory begin related product candidates phase iii clinical trials considered high probability regulatory approval company monitors status respective product within regulatory approval process however company generally disclose specific timing regulatory approval company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory affected stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support realization inventory value inventory shelf life sufficient meet initial product launch requirements inventories produced preparation product launches capitalized december significant table contents contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable december old merck aggregate reserve approximately billion vioxx reserve settlement program future legal defense costs worldwide related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation see note consolidated financial statements merck spent approximately million aggregate legal defense costs worldwide including approximately million fourth quarter related vioxx litigation addition old merck paid additional billion settlement funds connection settlement program also merck recorded charges million including million fourth quarter solely future legal defense costs vioxx litigation consequently december aggregate amount vioxx reserve approximately million solely future legal defense costs vioxx litigation significant factors considered review vioxx reserve follows actual costs incurred company development companys legal defense strategy structure light scope vioxx litigation including settlement agreement expectation certain lawsuits continue pending number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials vioxx litigation amount vioxx reserve december represents companys best estimate minimum amount defense costs incurred connection remaining aspects vioxx litigation however events additional trials vioxx litigation events could arise course vioxx litigation could affect ultimate amount defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase vioxx reserve time future based upon factors set forth believes would appropriate two us vioxx product liability lawsuits trials scheduled company predict timing trials related vioxx litigation company believes meritorious defenses vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits included settlement program company established reserves potential liability relating vioxx lawsuits included settlement program reserve established connection resolution shareholder derivative lawsuits see note consolidated financial statements vioxx investigations unfavorable outcomes vioxx litigation could material adverse effect companys financial position liquidity results operations december old merck remaining reserve approximately million solely future legal defense costs fosamax litigation merck spent approximately million added million reserve consequently december company reserve approximately million solely future legal defense costs fosamax litigation significant factors considered establishment reserve fosamax litigation legal defense costs follows actual costs incurred company thus far development companys legal defense strategy structure light creation fosamax multidistrict litigation number cases brought company anticipated timing progression related costs pretrial activities table contents fosamax litigation company continue monitor legal defense costs review adequacy associated reserves due uncertain nature litigation company unable estimate costs beyond third quarter company established reserves potential liability relating fosamax litigation unfavorable outcomes fosamax litigation could material adverse effect companys financial position liquidity results operations company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted site investigations feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying providing costs past old merck performed worldwide survey assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated definitive information became available course investigations andor remedial efforts site estimates refined accruals established adjusted accordingly estimates related accruals continue refined annually similar process followed legacy scheringplough sites company believes compliance issues associated applicable environmental laws regulations would material adverse effect company expenditures remediation environmental liabilities million estimated million years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year sharebased compensation company expenses sharebased payment awards employees including grants stock options requisite service period based grant date fair value awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options pensions postretirement benefit plans net pension postretirement benefit cost totaled million million million increase compared primarily due million costs associated scheringplough benefit plans date merger december decrease compared primarily due lower amortization actuarial net losses higher expected return plan assets partially offset increase termination benefits attributable restructuring actions pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated measurement dates modified reflect table contents prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due december discount rates companys us pension postretirement benefit plans ranged compared range december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data well actual returns companys plan assets using reference information company develops forwardlooking return expectations asset category weighted average expected longterm rate return target portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate result analysis companys expected rate return range compared range us pension postretirement benefit plans company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact net pension postretirement benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact net pension postretirement benefit cost required funding obligations relating companys pension postretirement benefit plans expected material preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions recorded component accumulated comprehensive income expected returns pension plans based calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns recognized marketrelated value assets ratably fiveyear period also net loss amounts accumulated comprehensive income excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees amortization net losses companys us plans december expected increase net pension postretirement benefit cost approximately million annually restructuring costs restructuring costs recorded connection restructuring programs designed reduce cost structure increase efficiency enhance competitiveness result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place connection actions management also assesses recoverability longlived assets employed business certain instances asset lives shortened based changes expected useful lives affected assets severance related costs reflected within restructuring costs assetrelated charges reflected within materials production costs research development expenses depending upon nature asset table contents impairments longlived assets company assesses changes economic regulatory legal conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets company periodically evaluates whether current facts circumstances indicate carrying values longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows approach company tests goodwill impairment least annually using fair value based test goodwill represents excess consideration transferred fair value net assets businesses purchased assigned reporting units acquired intangibles excluding inprocess research development recorded fair value amortized straightline basis estimated useful lives events circumstances warrant review company assess recoverability future operations using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated cash flows company tests indefinitelived intangibles including inprocess research development impairment least annually onestep test compares fair value indefinite lived intangible asset assets carrying value impairment testing purposes company may combine separately recorded indefinitelived intangible assets one unit account based relevant facts circumstances generally company combine indefinitelived intangible assets testing purposes operate single asset essentially inseparable fair value less carrying amount impairment loss recognized within companys operating results impairments investments company reviews investments impairments based determination whether decline market value investment carrying value otherthan temporary company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investments april new authoritative guidance fasb adopted amended otherthantemporary recognition guidance debt securities pursuant new guidance otherthantemporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized comprehensive income taxes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual onetime item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys tax provision evaluating tax positions recognition measurement tax position based managements best judgment given facts circumstances information available reporting date company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax table contents position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements likely threshold met period tax position taken company may subsequently recognize benefit tax position tax matter effectively settled statute limitations expires likely threshold met subsequent period see note consolidated financial statements tax regulations require items included tax return different times items reflected financial statements timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income taxes would payable upon distribution earnings recently issued accounting standards june fasb issued amendment accounting disclosure requirements transfers financial assets effective january amendment eliminates concept qualifying specialpurpose entity changes requirements derecognizing financial assets requires enhanced disclosures provide financial statement users greater transparency transfers financial assets including securitization transactions entitys continuing involvement exposure risks related transferred financial assets effect adoption companys financial position results operations expected material also june fasb amended existing accounting disclosure guidance consolidation variable interest entities effective january amended guidance requires enhanced disclosures intended provide users financial statements transparent information enterprises involvement variable interest entity effect adoption companys financial position results operations expected material october fasb issued new guidance revenue recognition multiple deliverables effective revenue arrangements entered materially modified fiscal years beginning june although early adoption permitted guidance eliminates residual method current guidance replaces relative selling price method allocating revenue multiple deliverable arrangement selling price deliverable shall determined using vendor specific objective evidence selling price exists otherwise thirdparty evidence selling price shall used neither exists deliverable vendor shall use best estimate selling price deliverable adoption guidance also require expanded qualitative quantitative disclosures company currently assessing impact adoption financial position results operations january fasb amended existing disclosure guidance fair value measurements effective january except disclosures purchases sales issuances settlements roll forward activity level fair value measurements effective january among things updated guidance requires additional disclosure amounts significant transfers level level measurements requires certain level disclosures gross basis additionally updates amend existing guidance require greater level disaggregated information robust disclosures valuation techniques inputs fair value measurements since amended guidance requires additional disclosures adoption affect companys financial position results operations table contents cautionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms k q k item risk factors annual report company discusses detail various important risk factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties item quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations table contents item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income equity cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses materials production marketing administrative research development restructuring costs equity income affiliates us vioxx settlement agreement charge income expense net income taxes taxes income net income less net income attributable noncontrolling interests net income attributable merck co inc preferred stock dividends net income available common shareholders basic earnings per common share available common shareholders earnings per common share assuming dilution available common shareholders accompanying notes integral part consolidated financial statement table contents consolidated balance sheet merck co inc subsidiaries december millions except per share amounts assets current assets cash cash equivalents shortterm investments accounts receivable net allowance doubtful accounts inventories excludes inventories classified assets see note deferred income taxes current assets total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less allowance depreciation goodwill intangibles net assets liabilities equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable mandatory convertible preferred stock par value authorized shares issued outstanding shares total current liabilities longterm debt deferred income taxes noncurrent liabilities merck co inc stockholders equity common stock par value par value authorized shares shares issued shares paidin capital retained earnings accumulated comprehensive loss less treasury stock cost shares shares total merck co inc stockholders equity noncontrolling interests total equity accompanying notes integral part consolidated financial statement table contents consolidated statement equity merck co inc subsidiaries years ended december millions except per share amounts accumulated non common paidin retained comprehensive treasury controlling stock capital earnings loss stock interests total balance january net income attributable merck co inc total comprehensive income net tax comprehensive income net tax cumulative effect adoption guidance accounting unrecognized tax benefits cash dividends declared common stock per share treasury stock shares purchased acquisition novacardia inc net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc total comprehensive loss net tax comprehensive income net tax cash dividends declared common stock per share treasury stock shares purchased net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc total comprehensive loss net tax comprehensive income net tax scheringplough merger cancellations treasury stock preferred stock conversions cash dividends declared common stock per share net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december accompanying notes integral part consolidated financial statement table contents consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities net income adjustments reconcile net income net cash provided operating activities gain related merckscheringplough partnership gain disposition interest merial limited gain distribution astrazeneca lp equity income affiliates dividends distributions equity affiliates us vioxx settlement agreement charge depreciation amortization deferred income taxes sharebased compensation inprocess research development taxes paid internal revenue service settlement net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities cash flows investing activities capital expenditures purchases securities investments proceeds sales securities investments proceeds sale interest merial limited scheringplough merger net cash acquired acquisitions businesses net cash acquired distribution astrazeneca lp increase restricted assets net cash provided used investing activities cash flows financing activities net change shortterm borrowings proceeds issuance debt payments debt purchases treasury stock dividends paid stockholders dividends paid proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents net increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental cash flow information see note accompanying notes integral part consolidated financial statement table contents notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations november merck co inc old merck scheringplough corporation scheringplough completed previouslyannounced merger merger merger scheringplough acquired shares old merck became whollyowned subsidiary scheringplough renamed merck sharp dohme corp scheringplough continued surviving public company renamed merck co inc new merck company however accounting purposes merger treated acquisition old merck considered accounting acquirer accordingly accompanying financial statements reflect old mercks standalone operations existed prior completion merger references financial statements merck periods prior merger refer old merck periods completion merger new merck results scheringploughs business included new mercks financial statements periods subsequent completion merger therefore new mercks financial results reflect full year legacy scheringplough operations merger resulted inclusion scheringploughs assets liabilities merger date respective fair values limited exceptions accordingly merger materially affected mercks results operations financial position see note company global health care company delivers innovative health solutions medicines vaccines biologic therapies consumer animal products markets directly joint ventures companys operations principally managed products basis comprised one reportable segment pharmaceutical segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value pharmaceutical vaccine products health care professionals private practice group practices managed care organizations company also animal health operations discover develop manufacture market animal health products including vaccines companys professional representatives communicate safety value companys animal health products veterinarians distributors animal producers additionally company consumer health care operations develop manufacture market overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets united states canada summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained intercompany balances transactions eliminated controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside shareholders interests shown noncontrolling interests equity investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis mergers acquisitions january new guidance issued financial accounting standards board fasb adopted changes way acquisition method applied table contents business combination acquisition method accounting requires assets acquired liabilities assumed recorded date merger acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies recognized fair value fair value reasonably estimated acquisition date fair value asset acquired liability assumed arises contingency determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements results operations date merger acquisition company determines assets acquired meet definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded foreign currency translation international subsidiaries local currencies determined functional currencies net assets subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included accumulated comprehensive income loss aoci reflected separate component equity subsidiaries operate highly inflationary economies subsidiaries us dollar determined functional currency nonmonetary foreign currency assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income expense net cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories inventories valued lower cost market cost substantial majority domestic pharmaceutical vaccine inventories determined using lastin firstout lifo method financial reporting tax purposes cost inventories determined using firstin firstout fifo method inventories consist currently marketed products certain products awaiting regulatory approval evaluating recoverability inventories produced preparation product launches company considers probability revenue obtained future sale related inventory together status product within regulatory approval process investments investments marketable debt equity securities classified availableforsale reported fair value fair value companys investments determined using quoted market prices active markets identical assets liabilities quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities changes fair value considered temporary reported net tax aoci declines fair value equity securities considered otherthantemporary impairment losses charged income expense net company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investment april new guidance issued fasb adopted amended otherthantemporary recognition guidance debt securities pursuant new guidance otherthantemporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings recorded income expense net limited portion attributed table contents credit loss remaining portion otherthantemporary impairment related factors recognized aoci realized gains losses debt equity securities included income expense net revenue recognition revenues sales products recognized time delivery title risk loss passes customer recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale accruals chargebacks reflected direct reduction accounts receivable accruals rebates recorded current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million million respectively december million million respectively december company recognizes revenue sales vaccines federal government placement stockpiles related pediatric vaccine stockpile accordance securities exchange commission sec interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings software capitalization company capitalizes certain costs incurred connection obtaining developing internaluse software including external direct costs material services payroll costs employees directly involved software development capitalized software costs included property plant equipment amortized beginning asset substantially ready use capitalized software costs associated companys multiyear implementation enterprisewide resource planning system amortized years december approximately million million respectively remaining unamortized capitalized software costs associated initiative capitalized software costs amortized periods ranging years costs incurred preliminary project stage postimplementation stage well maintenance training costs expensed incurred goodwill goodwill represents excess consideration transferred fair value net assets businesses purchased goodwill assigned reporting units evaluated impairment least annual basis using fair value based test goodwill increased substantially result merger see notes acquired intangibles acquired intangibles include products product rights tradenames patents recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives ranging years see note events circumstances warrant review company assess recoverability future operations acquired intangibles using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated future cash flows acquired intangibles balances increased substantially result merger see notes inprocess research development inprocess research development iprd represents fair value assigned incomplete research projects company acquires business combinations time acquisition reached technological feasibility transactions closed prior fair value projects expensed upon acquisition transactions closed fair value research projects recorded intangible assets consolidated balance sheet rather expensed amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project table contents merck make determination useful life intangible asset begin amortization company tests indefinitelived intangibles including inprocess research development impairment least annually onestep test compares fair value indefinitelived intangible asset assets carrying value iprd increased result merger see notes research development research development expensed incurred upfront milestone payments due third parties connection research development collaborations prior regulatory approval expensed incurred payments due third parties upon subsequent regulatory approval capitalized amortized shorter remaining license product patent life nonrefundable advance payments goods services used future research development activities expensed activity performed goods received rather payment made sharebased compensation company expenses sharebased payments employees including grants stock options requisite service period based grant date fair value awards restructuring costs company records liabilities costs associated exit disposal activities period liability incurred costs onetime termination benefits employee required render service termination order receive benefits recognized ratably future service period employee termination costs primarily recorded actions probable estimable contingencies legal defense costs company records accruals contingencies legal defense costs expected incurred connection loss contingency probable liability incurred amount reasonably estimated taxes income deferred taxes recognized future tax effects temporary differences financial income tax reporting based enacted tax laws rates company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements company recognizes interest penalties exchange gains losses associated uncertain tax positions component taxes income consolidated statement income use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection mergers acquisitions including fair value determinations assets liabilities additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation recently adopted accounting standards several new accounting standards issued fasb adopted january new guidance business combinations adopted changes way acquisition method applied business combination guidance requires acquirer recognize assets acquired liabilities assumed acquisition date fair values limited exceptions additionally guidance requires contingent consideration recorded fair value acquisition date acquired inprocess research development capitalized recorded intangible assets acquisition table contents date also requires transaction costs costs restructure acquired company expensed april additional guidance issued amending accounting contingencies business combination companys business combination transactions accounted new guidance including merger see note january new guidance accounting reporting disclosure noncontrolling interests adopted requires among things noncontrolling interests recorded equity consolidated financial statements adoption new guidance resulted reclassification billion noncontrolling interests formerly referred minority interests separate component equity consolidated balance sheet see note additionally net income attributable noncontrolling interests shown separately parent net income consolidated statement income prior periods restated reflect presentation disclosure requirements new guidance january new guidance adopted requiring enhanced disclosures derivative instruments hedging activities allow better understanding effects entitys financial position financial performance cash flows among things new guidance requires disclosure fair values derivative instruments associated gains losses tabular format see note since new guidance requires additional disclosures derivatives hedging activities adoption affect mercks financial position results operations january new guidance adopted clarifies unvested sharebased payment awards contain nonforfeitable rights dividends dividend equivalents whether paid unpaid considered participating securities shall included computation earnings per share pursuant two class method effect adoption material mercks results operations provisions guidance retrospective therefore prior periods restated see note january new guidance adopted defines collaborative arrangements establishes reporting requirements transactions participants collaborative arrangement participants arrangement third parties effect adoption material mercks financial position results operations see note associated disclosures companys collaborative arrangements january new guidance adopted clarifies accounting certain transactions impairment considerations involving equity method investments effective prospective basis january new guidance adopted clarifies defensive intangible asset intangible asset entity intend actively use intends hold prevent others obtaining access asset accounted separate unit accounting assigned useful life reflects entitys consumption expected benefits related asset guidance effective prospective basis april new guidance adopted establishes general standards accounting disclosure events occur balance sheet date financial statements issued available issued guidance subsequently amended february longer require disclosure date entity evaluated subsequent events effect adoption material april new guidance adopted provides additional guidelines estimating fair value significant decrease volume level activity asset liability relation normal market activity asset liability similar assets liabilities addition new guidance includes guidelines identifying circumstances indicate transaction asset liability orderly case entity shall place little weight transaction price indicator fair value effect adoption mercks financial position results operations material april new guidance adopted amended otherthantemporary recognition guidance debt securities impairment model equity securities affected impairment exists current fair value individual security less amortized cost basis pursuant new guidance otherthantemporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security table contents likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized comprehensive income loss determining credit losses occurred company evaluates whether expected cash flows received sufficient recover amortized cost basis security new guidance material effect upon adoption period adoption december december company adopted new guidance amending existing authoritative literature provides guidance employers disclosures plan assets defined pension postretirement benefit plans amended guidance requires disclosures plan assets including investment allocation decisions made major categories plan assets inputs valuation techniques used measure fair value plan assets effect fair value measurements using significant unobservable inputs level changes plan assets period significant concentrations risk within plan assets since amended guidance required additional disclosures companys pension postretirement plan assets see note adoption affect companys financial position results operations recently issued accounting standards fasb issued several new accounting pronouncements yet effective company june fasb issued amendment accounting disclosure requirements transfers financial assets effective january amendment eliminates concept qualifying specialpurpose entity changes requirements derecognizing financial assets requires enhanced disclosures provide financial statement users greater transparency transfers financial assets including securitization transactions entitys continuing involvement exposure risks related transferred financial assets effect adoption companys financial position results operations expected material also june fasb amended existing accounting disclosure guidance consolidation variable interest entities effective january amended guidance requires enhanced disclosures intended provide users financial statements transparent information enterprises involvement variable interest entity effect adoption companys financial position results operations expected material october fasb issued new guidance revenue recognition multiple deliverables effective revenue arrangements entered materially modified fiscal years beginning june although early adoption permitted guidance eliminates residual method current guidance replaces relative selling price method allocating revenue multiple deliverable arrangement selling price deliverable shall determined using vendor specific objective evidence selling price exists otherwise thirdparty evidence selling price shall used neither exists deliverable vendor shall use best estimate selling price deliverable adoption guidance also require expanded qualitative quantitative disclosures company currently assessing impact adoption financial position results operations january fasb amended existing disclosure guidance fair value measurements effective january except disclosures purchases sales issuances settlements roll forward activity level fair value measurements effective january among things updated guidance requires additional disclosure amounts significant transfers level level measurements requires certain level disclosures gross basis additionally updates amend existing guidance require greater level disaggregated information robust disclosures valuation techniques inputs fair value measurements since amended guidance requires additional disclosures adoption impact companys financial position results operations table contents merger scheringplough corporation november old merck scheringplough completed merger merger scheringplough acquired shares old merck became whollyowned subsidiary scheringplough renamed merck sharp dohme corp scheringplough continued surviving public company renamed merck co inc however accounting purposes merger treated acquisition old merck considered accounting acquirer terms merger agreement issued outstanding share schering plough common stock converted right receive combination cash share common stock new merck issued outstanding share old merck common stock automatically converted share common stock new merck based closing price old merck stock november consideration received scheringplough shareholders valued per share billion aggregate cash portion consideration funded combination existing cash including sale old mercks interest merial limited sale redemption investments issuance debt see note upon completion merger issued outstanding share scheringplough mandatory convertible preferred stock scheringplough preferred stock converted accordance terms preferred stock remained outstanding one share merck mandatory convertible preferred stock preferred stock rights set forth new merck certificate incorporation see note rights substantially similar rights scheringplough preferred stock merger expanded companys pipeline product candidates broadened companys commercial portfolio expanded global presence increased manufacturing capabilities additionally company expects realize substantial cost savings synergies including opportunities consolidation sales marketing research development calculation consideration transferred scheringplough common stock shares outstanding november net treasury shares units merger consideration arising conversion preferred stock shares units eligible cash per shareunit cash consideration outstanding sharesunits preferred stock makewhole dividend payments value scheringplough deferred stock units settled cash total cash consideration shares units eligible common stock exchange ratio per shareunit equivalent new merck shares shares issued settle certain performancebased awards new merck shares issued old merck common stock share price november common stock equity consideration fair value preferred stock converted fair value sharebased compensation awards employee benefit related amounts payable result merger total consideration transferred upon completion merger period days thereafter holders preferred stock entitled convert share preferred stock number units merger consideration equal make whole conversion rate determined table contents accordance terms preferred stock amount represents units merger consideration relating preferred stock converted holders day period following merger represents present value remaining future dividend payments conversion date mandatory conversion date august paid holders preferred stock elected convert connection merger using discount rate stipulated terms preferred stock represents cash consideration paid holders scheringplough deferred stock units issued prior converted right receive cash specified merger agreement attributable precombination services represents fair value scheringplough stock option performance share unit deferred stock unit replacement awards attributable precombination service issued holders awards merger fair value outstanding scheringplough stock options performance share units awards prior immediately vested effective time merger attributed precombination service included consideration transferred stock option performance share unit deferred stock unit awards immediately vest upon completion merger awards fair value awards attributed precombination services included part consideration transferred fair value attributed postcombination service recognized compensation cost requisite service period postcombination financial statements new merck preliminary allocation consideration transferred net assets acquired following amounts represent preliminary determination fair value identifiable assets acquired liabilities assumed merger final determination fair value certain assets liabilities completed may result adjustments preliminary values presented cash cash equivalents inventories current assets property plant equipment identifiable intangible assets products product rights year weighted average useful life inprocess research development iprd tradenames year weighted average useful life noncurrent assets current liabilities deferred income tax liabilities longterm debt noncurrent liabilities total identifiable net assets goodwill estimated consideration transferred connection merger company obtained controlling interest merckscheringplough partnership table reflects scheringploughs share fair value merckscheringplough partnerships net assets including intangibles inventories reflected table mercks share fair value merckscheringplough partnerships net assets recorded connection fair value adjustment mercks previously held equity interest partnership see merckscheringplough partnership iprd represents fair value assigned incomplete research projects time merger reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination useful life asset begin amortization see inprocess research development goodwill recognized largely attributable anticipated synergies expected arise merger approximately billion goodwill allocated pharmaceutical segment remainder goodwill allocated nonreportable segments goodwill deductible tax purposes order allocate merger consideration company estimated fair value assets liabilities scheringplough contingent assets liabilities recognized fair value merger date fair value contingencies could determined contingent liabilities recorded table contents extent amounts probable reasonably estimable see note accounting financial reporting purposes fair value defined price would received upon sale asset amount paid transfer liability orderly transaction market participants measurement date market participants assumed buyers sellers principal advantageous market asset liability additionally fair value measurements asset assume highest best use asset market participants use different estimates judgments could yield different results fair values identifiable intangible assets related currently marketed products product rights primarily determined using income approach fair value estimated based assets discounted projected net cash flows companys estimates market participant net cash flows considered historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain marketing regulatory approvals ability manufacture commercialize products extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probability adjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate inprocess research development connection merger company recorded fair value human animal health research projects approximately billion consideration transferred merger allocated human health iprd projects billion allocated animal health iprd projects amounts capitalized accounted similar indefinite lived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination useful life asset begin amortization fair values identifiable intangible assets related iprd determined using income approach fair value estimated based assets probability adjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using discount rates range actual cash flows likely different assumed iprd projects subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates significant projects include bridion vorapaxar boceprevir phase iii clinical development well ezetimibeatorvastatin combination product bridion sugammadex medication designed rapidly reverse effects certain muscle relaxants used part general anesthesia bridion received regulatory approval european union eu several countries around world date regulatory review markets including united states vorapaxar studied prevention treatment atherothrombosis boceprevir hepatitis c protease inhibitor currently development ezetimibe combined atorvastatin investigational medication treatment dyslipidemia merckscheringplough partnership upon consummation merger company obtained controlling interest merckscheringplough partnership msp partnership owned company previously company noncontrolling interest result obtaining controlling interest company required remeasure mercks previously held equity interest msp partnership mergerdate fair value recognized resulting gain billion earnings income expense net conjunction remeasurement company recorded intangible assets approximately billion included iprd approximately billion stepup inventories table contents mergerrelated costs mergerrelated costs expensed incurred year ended december merck incurred million transaction costs directly related merger including advisory legal fees million integration costs billion restructuring costs including exit costs connection merger see note costs recognized within marketing administrative expenses restructuring costs additionally million interest costs recognized connection debt issued partially fund merger see note supplemental pro forma data scheringploughs results operations included new mercks financial statements periods subsequent completion merger scheringplough contributed revenues billion estimated losses billion new merck period consummation merger december following unaudited supplemental pro forma data presents consolidated information merger completed january years ended december unaudited sales earnings attributable merck co inc earnings available merck co inc common shareholders basic earnings per common share available common shareholders earning per common share assuming dilution available common shareholders unaudited supplemental pro forma data reflect application following adjustments consolidation msp partnership owned company corresponding gain resulting companys remeasurement previously held equity interest msp partnership additional depreciation amortization expense would recognized assuming fair value adjustments inventory property plant equipment intangible assets additional interest expense financing costs would incurred borrowing arrangements loss interest income cash shortterm investments used fund merger transaction costs associated merger conversion portion outstanding preferred stock unaudited supplemental pro forma financial information reflect potential realization cost savings relating integration two companies pro forma data considered indicative results would occurred merger related borrowings consummated january indicative future results restructuring merger restructuring program february company announced first phase new global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough businesses merger restructuring program intended optimize cost structure combined company part first phase merger restructuring program end company expects reduce total workforce approximately across areas company worldwide company also plans eliminate vacant positions part first phase program workforce reductions primarily come elimination duplicative positions sales administrative headquarters organizations well consolidation certain manufacturing facilities research development operations company continue hire new employees strategic growth areas business period certain actions ongoing reevaluation manufacturing research development facilities table contents worldwide yet completed included later phases merger restructuring program connection merger restructuring program separation costs companys existing severance programs worldwide recorded fourth quarter extent costs probable reasonably estimable company recorded pretax restructuring costs billion primarily employee separation costs related merger restructuring program fourth quarter first phase merger restructuring program expected completed end total pretax costs estimated billion billion costs voluntary programs enhancement programs recorded relevant criteria met company estimates approximately cumulative pretax costs relate cash outlays primarily related employee separation expense approximately cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested global restructuring program october old merck announced global restructuring program restructuring program reduce cost structure increase efficiency enhance competitiveness part restructuring program company expects eliminate approximately positions active employees vacancies across areas company worldwide end total reductions occur united states part restructuring program company streamlining management layers reducing total number senior midlevel executives globally december approximately positions eliminated connection restructuring program comprised employee separations elimination contractors vacant positions merck rolling new customercentric selling model designed provide merck meaningful competitive advantage help physicians patients payers improve patient outcomes company operating new commercial selling models united states markets around world company also making greater use outside technology resources centralizing common sales marketing activities consolidating streamlining operations mercks manufacturing division focus capabilities core products outsource noncore manufacturing merck continued implementing new model basic research global operating strategy legacy merck research laboratories sites new model align franchise function well align resources disease area priorities balance capacity across discovery phases allow company act upon programs highest probability success additionally across disease area priorities companys strategy designed expand access worldwide external science incorporate external research key component companys early discovery pipeline order translate basic research productivity latestage clinical success basic research facilities pomezia italy tsukuba japan sold operations conducted basic research facility seattle closed merck also sold closed certain facilities sold related assets connection restructuring program connection restructuring program separation costs existing severance programs worldwide recorded third quarter extent costs probable estimable old merck commenced accruing costs related onetime termination benefits offered employees restructuring program fourth quarter necessary criteria met pretax restructuring costs million million respectively recorded related restructuring program since inception restructuring program december merck recorded total pretax accumulated costs billion restructuring program expected completed end total pretax costs estimated billion billion company estimates twothirds cumulative pretax costs relate cash outlays primarily employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested global restructuring program november old merck announced global restructuring program restructuring program designed reduce cost structure increase efficiency enhance competitiveness substantially complete end segment reporting restructuring charges unallocated expenses table contents following table summarizes charges related merger restructuring program restructuring program activities type cost separation accelerated year ended december costs depreciation total merger restructuring program materials production research development restructuring costs restructuring program materials production research development restructuring costs year ended december restructuring program materials production research development restructuring costs restructuring program materials production research development restructuring costs year ended december restructuring program materials production research development restructuring costs separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated approximately positions eliminated approximately related restructuring program approximately related merger restructuring program certain employees anticipated separated part planned restructuring actions restructuring program instead transferred buyer conjunction sale facility accordingly accrual separation costs associated employees reversed resulting reduction expenses approximately positions eliminated approximately related restructuring program related restructuring program approximately table contents positions eliminated connection restructuring program position eliminations comprised actual headcount reductions elimination contractors vacant positions accelerated depreciation costs primarily relate manufacturing research facilities sold closed part programs sites continue operate respective closure dates since future cash flows sufficient recover respective book values merck required accelerate depreciation site assets rather write immediately site assets include manufacturing research facilities equipment activity includes million million million respectively asset abandonment shutdown related costs additionally activity includes million million million respectively related curtailment settlement termination charges pension postretirement benefit plans see note activity also reflects pretax losses resulting sales facilities related assets million pretax gains sales million adjustments recorded amounts material period following table summarizes charges spending relating merger restructuring program restructuring program activities separation accelerated costs depreciation total merger restructuring program restructuring reserves january expense payments receipts net noncash activity restructuring reserves december restructuring program restructuring reserves january expense payments receipts net noncash activity restructuring reserves december expense payments receipts net noncash activity restructuring reserves december restructuring program restructuring reserves january expense payments receipts net noncash activity restructuring reserves december payments receipts net restructuring reserves december cash outlays associated first phase merger restructuring program expected substantially completed end cash outlays associated remaining restructuring reserve restructuring program expected completed end cash outlays associated remaining restructuring reserve restructuring program expected completed end includes proceeds sales facilities connection restructuring actions table contents legacy scheringplough program prior merger scheringplough commenced productivity transformation program designed reduce avoid costs increase productivity postmerger period december company recorded million costs related program including million employee separation costs included restructuring costs million accelerated depreciation costs included materials production costs remaining reserve associated program million december approximately positions eliminated connection program postmerger period december acquisitions research collaborations license agreements december merck avecia investments limited announced definitive agreement merck would acquire biologics business avecia group total purchase price million avecia biologics contract manufacturing organization specific expertise microbialderived biologics terms agreement merck would acquire avecia biologics limited avecia assets including avecias process development scaleup manufacturing quality business support operations located billingham united kingdom transaction closed february accordingly results operations acquired business included mercks results operations acquisition date september old merck announced entered exclusive agreement csl biotherapies csl subsidiary csl limited market distribute afluria csls seasonal influenza flu vaccine united states flu seasons terms agreement merck assume responsibility aspects commercialization afluria united states csl supply afluria merck retain responsibility marketing vaccine outside united states afluria indicated active immunization persons ages months older influenza disease caused influenza virus subtypes type b present vaccine july old merck portola pharmaceuticals inc portola signed exclusive global collaboration license agreement development commercialization betrixaban mk investigational oral factor xa inhibitor anticoagulant currently phase ii clinical development prevention stroke patients atrial fibrillation return exclusive worldwide license betrixaban old merck paid portola initial fee million closing recorded research development expense portola eligible receive additional cash payments totaling million upon achievement certain development regulatory commercialization milestones well doubledigit royalties worldwide sales betrixaban approved merck assume development commercialization costs including costs phase iii clinical trials portola retained option cofund phase iii clinical trials return additional royalties b copromote betrixaban merck united states term agreement commenced august unless terminated earlier continue remaining royalty payment obligations country time agreement expire entirety country agreement may terminated either party event material uncured breach bankruptcy party agreement may terminated merck event parties merck decide cease development betrixaban safety efficacy addition merck may terminate agreement time upon days prior written notice portola may terminate agreement event merck challenges portola patent covering betrixaban upon termination agreement depending upon circumstances parties varying rights obligations respect continued development commercialization betrixaban case termination cause merck certain royalty obligations april old merck medarex inc medarex massachusetts biologic laboratories mbl university massachusetts medical school announced exclusive worldwide license agreement cda cdb mka also known mdxmdx mblcdamblcdb investigational fully human monoclonal antibody combination developed target neutralize clostridium difficile toxins b treatment c difficile infection cda cdb codeveloped medarex mbl terms agreement merck gained worldwide rights develop commercialize cda cdb medarex mbl received aggregate upfront payment million upon closing recorded research development expense potentially eligible receive additional cash table contents payments million aggregate upon achievement certain milestones associated development approval drug candidate covered agreement upon commercialization medarex mbl also eligible receive doubledigit royalties product sales milestones certain sales targets met term agreement commenced closing date unless terminated earlier continue remaining royalty payment obligations country time agreement expire entirety country either party may terminate agreement uncured material breach party bankruptcy insolvency party merck may terminate agreement time upon providing days prior written notice medarex mbl also april old merck santen pharmaceutical co ltd santen announced worldwide licensing agreement tafluprost mk prostaglandin analogue investigation united states tafluprost preserved preservativefree formulations received marketing approval reduction elevated intraocular pressure openangle glaucoma ocular hypertension several european nordic countries well japan filed approval additional european asia pacific markets terms agreement merck paid fee capitalized amortized materials production costs life underlying patent pay milestones royalty payments based future sales tafluprost preserved preservativefree formulations exchange exclusive commercial rights tafluprost western europe excluding germany north america south america africa santen retain commercial rights tafluprost countries eastern europe northern europe asia pacific including japan merck provide promotion support santen germany poland tafluprost approved united states santen option copromote agreement merck santen expires countrybycountry basis last occur expiry last expire valid patent claim b expiration last expire royalty merck may terminate agreement time upon days prior written notice also time upon days prior written notice merck determines product presents issues safety tolerability addition merck may terminate agreement event enumerated agreements santen coownerlicensor certain intellectual property terminate expire materially adversely affects merck either merck santen materially breaches agreement fails cure receiving notice nonbreaching party may terminate agreement agreement provides termination noninsolvent party due bankruptcy party finally agreement terminate term merck develops commercializes competitive product term defined agreement addition april old merck cardiome pharma corp cardiome announced collaboration license agreement development commercialization vernakalant mk investigational candidate treatment atrial fibrillation agreement provides merck exclusive global rights oral formulation vernakalant vernakalant oral maintenance normal heart rhythm patients atrial fibrillation provides merck affiliate merck sharp dohme switzerland gmbh exclusive rights outside united states canada mexico intravenous iv formulation vernakalant vernakalant iv rapid conversion acute atrial fibrillation normal heart rhythm terms agreement old merck paid cardiome initial fee million upon closing recorded research development expense addition cardiome eligible receive million payments based achievement certain milestones associated development approval vernakalant products including million submission regulatory approval europe vernakalant iv old merck paid result submission million initiation planned phase iii program vernakalant oral million milestones associated approvals subsequent indications intravenous oral formulations also cardiome receive tiered royalty payments sales approved products potential receive million milestone payments based achievement significant sales thresholds cardiome retained option copromote vernakalant oral merck hospitalbased sales force united states merck responsible future costs associated development manufacturing commercialization candidates merck granted cardiome secured interestbearing credit facility million cardiome may access tranches several years commencing cardiomes codevelopment partner north america astellas pharma us inc submitted nda fda kynapid vernakalant hydrochloride injection december included results two pivotal phase iii clinical trials december cardiovascular renal drugs advisory committee recommended fda approve vernakalant iv rapid conversion atrial fibrillation table contents august fda issued approvable action letter requesting additional information phase iib doubleblind placebocontrolled randomized doseranging clinical trial patients risk recurrent atrial fibrillation showed mg dose vernakalant oral significantly reduced rate atrial fibrillation relapse compared placebo agreement continues effect expiration cardiomes copromotion rights royalty milestone payment obligations agreement may terminated event insolvency material uncured breach either party additionally collaboration may terminated merck event merck determines good faith advisable continue development commercialization vernakalant product result serious safety issue addition merck may terminate agreement time upon months prior written notice cardiome may terminate agreement event merck challenges cardiome patent covering vernakalant upon termination agreement depending upon circumstances parties varying rights obligations respect continued development commercialization vernakalant cases continuing royalty obligations march old merck acquired insmed incs insmed portfolio followon biologic therapeutic candidates commercial manufacturing facilities located boulder colorado terms agreement old merck paid insmed aggregate million cash acquire rights boulder facilities insmeds pipeline followon biologic candidates insmeds followon biologics portfolio includes two clinical candidates mk investigational recombinant granulocytecolony stimulating factor gcsf evaluated ability prevent infections patients cancer receiving chemotherapy mk pegylated recombinant gcsf designed allow less frequent dosing transaction accounted business combination accordingly assets acquired liabilities assumed recorded respective fair values acquisition date determination fair value requires management make significant estimates assumptions connection acquisition substantially purchase price allocated insmeds followon biologics portfolio mk mk indefinitelived intangible asset recorded fair value determined based upon present value expected future cash flows new product candidates resulting insmeds followon biologics portfolio adjusted probability estimated technical marketing success utilizing income approach reflecting appropriate riskadjusted discount rates ongoing activity related mk mk expected material companys research development expense remaining net assets acquired material milestone royalty obligations associated acquisition transaction closed march accordingly results operations acquired business included mercks results operations beginning april september old merck japan tobacco inc jt signed worldwide licensing agreement develop commercialize jtt mk investigational oral osteoanabolic bone growth stimulating agent treatment osteoporosis disease reduces bone density strength results increased risk bone fractures jtt investigational oral calcium sensing receptor antagonist currently evaluated jt phase ii clinical trials japan effect increasing bone density phase clinical trials outside japan terms agreement merck gained worldwide rights except japan develop commercialize jtt certain related compounds jt received upfront payment million recorded research development expense eligible receive additional cash payments upon achievement certain milestones associated development approval drug candidate covered agreement jt also eligible receive royalties sales drug candidates receive marketing approval license agreement merck jt remain effect expiration royalty milestone obligations may terminated event uncured material breach party agreement may also terminated merck without cause initial commercial sale jtt giving six months prior notice jt thereafter giving one year prior notice thereof jt license agreement may also terminated immediately merck merck determines due safety andor efficacy concerns based available scientific evidence cease development jtt andor withdraw jtt market permanent basis september old merck completed acquisition novacardia inc novacardia privately held clinicalstage pharmaceutical company focused cardiovascular disease old merck acquired outstanding equity novacardia total purchase price million including million table contents cash investments hand closing paid issuance million shares old merck common stock former novacardia shareholders based old mercks average closing stock price five days prior closing acquisition connection acquisition old merck recorded charge million inprocess research development associated rolofylline mk novacardias investigational phase iii compound acute heart failure acquisition date technological feasibility established alternative future use existed charge deductible tax purposes recorded research development expense determined based upon present value expected future cash flows resulting technology adjusted estimated probability technical marketing success time utilizing income approach reflecting appropriate risk adjusted discount rate remaining purchase price allocated cash investments million deferred tax asset relating net operating loss carryforward million net assets million novacardia development stage company commenced planned principal operations transaction accounted acquisition assets rather business combination therefore goodwill recorded novacardias results operations included mercks consolidated financial results since acquisition date june old merck announced preliminary results pivotal phase iii study rolofylline showed rolofylline meet primary secondary efficacy endpoints old merck terminated clinical development program rolofylline also old merck gtx inc gtx entered agreement providing research development global strategic collaboration selective androgen receptor modulators sarms new class drugs potential treat agerelated muscle loss sarcopenia well musculoskeletal conditions merck discontinued internal development mk sarm agreement currently discussing next steps gtx also old merck ariad pharmaceuticals inc ariad entered global collaboration jointly develop commercialize ridaforolimus mk ariads novel mtor inhibitor use cancer collaborations generally continue effect expiration royalty milestone payment obligations collaborations may generally terminated event insolvency material uncured breach either party additionally collaboration agreement merck gtx may terminated merck upon days notice gtx time december collaboration agreement merck ariad may terminated merck upon failure mk meet certain developmental safety requirements event merck concludes advisable continue development mk use cancer indication addition merck may terminate ariad collaboration agreement third anniversary effective date providing least months prior written notice upon termination ariad collaboration agreement depending upon circumstances parties varying rights obligations respect continued development commercialization mk continuing royalty obligations collaborative arrangements company continues strategy establishing external alliances complement substantial internal research capabilities including research collaborations licensing preclinical clinical compounds technology platforms drive near longterm growth company supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies across broad range therapeutic areas arrangements often include upfront payments royalty profit share payments contingent upon occurrence certain future events linked success asset development well expense reimbursements payments third party discussed note january new guidance issued fasb adopted defines collaborative arrangements establishes reporting requirements transactions participants collaborative arrangement participants arrangement third parties company reviewed third party arrangements determine arrangement within scope new guidance arrangement unique nature companys significant arrangements discussed table contents cozaarhyzaar old merck ei dupont de nemours company dupont agreed form longterm research marketing collaboration develop class therapeutic agents high blood pressure heart disease discovered dupont called angiotensin ii receptor antagonists include cozaar hyzaar return old merck provided dupont marketing rights united states canada prescription medicines sinemet sinemet cr pursuant agreement dupont company exclusive licensing agreement market cozaar hyzaar registered trademarks dupont return royalties profit share payments dupont patents provide us marketing exclusivity cozaar hyzaar expire april addition patent cozaar expire number major european markets march hyzaar lost patent protection number major european markets february remicadesimponi subsidiary scheringplough entered licensing agreement centocor inc centocor johnson johnson company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi golimumab fully human monoclonal antibody company exclusive marketing rights products outside united states japan certain asian markets december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade simponi extending companys rights exclusively market remicade match duration companys exclusive marketing rights simponi addition scheringplough centocor agreed share certain development costs relating simponis autoinjector delivery system october european commission approved simponi treatment rheumatoid arthritis immune system disorders two presentations novel autoinjector prefilled syringe result companys marketing rights products extend years first commercial sale simponi eu following receipt pricing reimbursement approval within eu operating expenses subject certain adjustments company entitled receive approximate share profits companys distribution companys marketing territory beginning share profits change time share profits products share profits remain fixed thereafter remainder term company may independently develop market simponi crohns disease indication territories option centocor participate see note discussion arbitration involving remicadesimponi product rights financial instruments derivative instruments hedging activities company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management significant portion companys revenues denominated foreign currencies merck relies sustained cash flows generated foreign sources support longterm commitment us dollarbased research development extent dollar value cash flows diminished result strengthening dollar companys ability fund research dollarbased strategic initiatives consistent level may impaired company established revenue hedging balance sheet risk management programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates us functional currency entities objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange decrease us dollar value future cash flows derived foreign currency table contents denominated sales primarily euro japanese yen achieve objective company partially hedge forecasted foreign currency denominated third party intercompany distributor entity sales expected occur planning cycle typically three years future company layer hedges time increasing portion third party intercompany distributor entity sales hedged gets closer expected date forecasted foreign currency denominated sales probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged risk manner company manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows offset decline expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase value anticipated foreign currency cash flows company also utilizes forward contracts revenue hedging program us dollar strengthens relative currency hedged anticipated sales increase fair value forward contracts offsets decrease expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens decrease fair value forward contracts offsets increase value anticipated foreign currency cash flows derivative instruments designated cash flow hedges fair value contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet accordingly effective portion unrealized gains losses contracts recorded aoci reclassified sales hedged anticipated revenue recognized hedge relationship highly effective hedge ineffectiveness de minimis cash flows contracts reported operating activities consolidated statement cash flows us dollar functional currency companys foreign subsidiaries primary objective balance sheet risk management program protect us dollar value foreign currency denominated net monetary assets effects volatility foreign exchange might occur prior conversion us dollars instances merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange amount us dollar cash flows derived net assets us dollar functional currency companys foreign subsidiaries merck executes spot trades convert foreign currencies us dollars based shortterm forecast needs us dollar proceeds invested required companys foreign subsidiaries merck routinely enters contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level foreign currency denominated monetary assets liabilities remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year applicable company uses forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates derivative contracts designated qualify fair value hedges accordingly changes fair value hedged securities due fluctuations spot rates recorded income expense net table contents offset fair value changes forward contracts attributable spot rate fluctuations changes contracts fair value due spotforward differences excluded designated hedge relationship recognized income expense net amounts well hedge ineffectiveness significant years ended december cash flows contracts reported operating activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes eurodenominated term loan designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses eurodenominated debt instruments included foreign currency translation adjustment within comprehensive income interest rate risk management december company party seven payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes two swaps maturing notional amounts million effectively convert companys million fixedrate notes due floating rate instruments five swaps maturing notional amounts million effectively convert million companys billion fixedrate notes due floating rate instruments interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes benchmark interest rate recorded interest expense offset fair value changes swap contracts old merck terminated four interest rate swap contracts notional amounts million terminated one interest rate swap contract notional amount million swaps effectively converted billion fixedrate notes due million fixedrate notes due variable rate debt result swap terminations old merck received million cash excluding accrued interest material corresponding gains related basis adjustment debt associated terminated swap contracts deferred amortized reduction interest expense remaining term notes cash flows contracts reported operating activities consolidated statement cash flows presented table fair value derivatives segregated derivatives designated hedging instruments designated hedging instruments december f air va lue de rivative us dollar balance sheet caption asset liability notional derivatives designated hedging instruments foreign exchange contracts current deferred income taxes current assets foreign exchange contracts noncurrent assets foreign exchange contracts current accrued current liabilities interest rate swaps noncurrent assets derivatives designated hedging instruments foreign exchange contracts current deferred income taxes current assets foreign exchange contracts current accrued current liabilities table contents table provides information location pretax gain loss amounts derivatives designated fair value hedging relationship ii designated cash flow hedging relationship iii designated hedging relationship year ended december amount amount amount amount pretax pretax gain loss gain loss gain loss gain loss recognized recognized reclassified recognized earnings earnings aoci oci derivatives hedged item earnings derivatives derivatives designated fair value hedging relationships interest rate swap contracts foreign exchange contracts derivatives designated cash flow hedging relationships foreign exchange contracts derivatives designated hedging relationship foreign exchange contracts recognized income expense net recognized sales derivative contracts mitigate changes value remeasured foreign currency denominated monetary assets liabilities attributable changes foreign currency exchange rates december company estimates million pretax net unrealized loss derivatives maturing within next months hedge foreign currency denominated sales period reclassified aoci sales amount ultimately reclassified sales may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity fair value measurements fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs may used measure fair value level quoted prices active markets identical assets liabilities companys level assets include equity securities traded active exchange market level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities companys level assets liabilities primarily include debt securities quoted prices traded less frequently exchangetraded instruments corporate notes bonds us foreign government agency securities certain mortgagebacked assetbacked securities municipal securities commercial paper derivative contracts whose values determined using pricing models inputs observable market derived principally corroborated observable market data level unobservable inputs supported little market activity financial instruments whose values determined using pricing models discounted cash flow methodologies similar techniques well instruments determination fair value requires significant judgment estimation companys level assets mainly include certain mortgagebacked asset table contents backed securities well certain corporate notes bonds limited market activity december million approximately companys investment securities categorized level assets pledged certain collateral arrangements see note assets classified level december acquired old merck elected redeemedinkind shortterm fixed income fund restricted cash redemptions described inputs used measure financial assets liabilities fall within one level described categorization based lowest level input significant fair value measurement instrument financial assets liabilities measured fair value recurring basis financial assets liabilities measured fair value recurring basis summarized fair value measu rem ents us ing fa ir value urement using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total december december assets investments us government agency securities corporate notes bonds municipal securities mortgagebacked securities commercial paper assetbacked securities foreign government bonds equity securities debt securities assets securities held employee compensation assets derivative assets purchased currency options forward exchange contracts interest rate swaps total assets liabilities derivative liabilities written currency options forward exchange contracts total liabilities substantially assetbacked securities highlyrated standard poors rating aaa moodys investors service rating aaa secured primarily credit card auto loan home equity receivables weightedaverage lives primarily years less mortgagebacked securities represent aaarated securities issued unconditionally guaranteed payment principal interest us government agencies assets represent portion pledged collateral discussed note december level assets comprised million assetbacked securities million mortgage backed securities million corporate notes bonds december level assets comprised million corporate notes bonds million municipal securities million commercial paper million mortgagebacked securities million us government agency securities million assetbacked securities fair value determination derivatives includes assessment credit risk counterparties derivatives companys credit risk effects significant table contents december company approximately billion cash equivalents level valuation techniques financial assets considered level fair values determined using pricing models discounted cash flow methodologies similar techniques least one significant model assumption input unobservable level financial assets also include certain investment securities limited market activity determination fair value requires significant judgment estimation companys level investment securities december primarily include certain mortgagebacked assetbacked securities well certain corporate notes bonds decrease observability market pricing investments securities valued primarily using pricing models management understands methodologies models incorporate transaction details contractual terms maturity timing amount future cash inflows well assumptions liquidity credit valuation adjustments marketplace participants december table provides summary changes fair value including net transfers andor financial assets measured fair value recurring basis using significant unobservable inputs level available forsale debt investments assets total securities assets total beginning balance january net transfers level purchases sales settlements net total realized unrealized gains losses included earnings comprehensive income ending balance december losses recorded earnings level assets still held december transfers level deemed occur beginning quarter transaction takes place amounts recorded income expense net january old merck million invested shortterm fixed income fund fund due market liquidity conditions cash redemptions fund restricted result restriction cash redemptions old merck consider fund traded active market observable pricing january amounts categorized level january old merck elected redeemedinkind fund received share underlying securities fund result majority underlying securities transferred level determined securities observable markets december million investment securities associated redemptioninkind classified level securities contained least one significant input unobservable securities account entire balance companys level assets december level investments aggregate amount million longer pledged collateral reclassified assets availableforsale investments financial instruments measured fair value companys financial instruments measured fair value recurring basis recorded amounts approximate fair value due liquid shortterm nature cash cash equivalents receivables payables table contents estimated fair value loans payable longterm debt including current portion december billion compared carrying value billion december billion compared carrying value billion fair value estimated using quoted dealer prices summary december gross unrealized gains losses availableforsale investments including pledged collateral recorded aoci follows decem r december fair amortized gross unrealized fair amortized gross unrealized value cost gains losses value cost gains losses us government agency securities corporate notes bonds municipal securities mortgagebacked securities assetbacked securities foreign government bonds commercial paper debt securities equity securities december gross unrealized gains gross unrealized losses related amounts pledged collateral see note million million respectively december gross unrealized gains gross unrealized losses related amounts pledged collateral million million respectively availableforsale debt securities included shortterm investments totaled million december remaining debt securities million mature within five years debt securities pledged collateral included current assets december debt securities pledged collateral maturing within five years totaled million letter credit august old merck executed billion letter credit agreement financial institution satisfied certain conditions set forth us vioxx settlement agreement see note old merck pledged collateral financial institution approximately billion pursuant terms letter credit agreement although amount assets pledged collateral set letter credit agreement assets held custody third party assets managed old merck old merck considered assets pledged letter credit agreement restricted letter credit amount required collateral balances declined payments first million settlement agreement made december billion recorded within deferred income taxes current assets billion classified assets old merck made remaining payments vioxx settlement funds pursuant us vioxx settlement agreement accordingly letter credit agreement terminated collateral released concentrations credit risk ongoing basis company monitors concentrations credit risk associated corporate issuers securities financial institutions conducts business credit exposure limits established limit concentration single issuer institution cash investments placed instruments meet high credit quality standards specified companys investment policy guidelines derivative financial instruments executed international swaps derivatives association master agreements master agreements several companys financial institution counterparties also include credit support annexes annexes contain provisions require collateral exchanged depending value derivative assets liabilities companys credit rating credit rating counterparty december cash cash equivalents includes cash collateral million table contents received various counterparties corresponding offset included accrued current liabilities company advanced cash collateral counterparties december companys four largest us customers mckesson corporation cardinal health inc amerisourcebergen corporation medco health solutions inc represented aggregate approximately onefifth accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost reduction lifo costs recognized inventories assets increase inventories primarily due merger including billion december remaining purchase accounting adjustments inventories adjustments recognized component materials production costs related inventories sold inventories valued lifo method comprised approximately inventories december respectively amounts recognized assets comprised almost entirely raw materials work process inventories goodwill intangibles result merger see note company recorded billion goodwill billion acquired identifiable intangible assets including acquired iprd company recorded additional billion intangible assets conjunction remeasurement mercks previously held equity interest msp partnership following table summarizes goodwill activity segment pharmaceutical total goodwill balance january goodwill balance december additions goodwill balance december table contents intangibles december consisted gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net products product rights inprocess research development tradenames total identifiable intangible assets amounts capitalized inprocess research development accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project company make separate determination useful life assets begin amortization aggregate amortization expense million million million estimated aggregate amortization expense next five years follows billion billion billion billion billion joint ventures equity method affiliates equity income affiliates reflects performance companys joint ventures equity method affiliates comprised following years ended december merckscheringplough astrazeneca lp primarily reflects results merial limited disposition september sanofi pasteur msd johnson johnsonmerck consumer pharmaceuticals company merckscheringplough partnership old merck scheringplough collectively partners entered agreement create equallyowned partnership develop market united states new prescription medicines cholesterol management agreement generally provided equal sharing development costs copromotion approved products company cholesterolmanagement partnership expanded include countries world excluding japan ezetimibe first new class cholesterollowering agents launched united states zetia marketed ezetrol outside united states combination product containing active ingredients zetia zocor approved united states vytorin marketed inegy outside united states cholesterol agreements provided sharing operating income generated msp partnership based upon percentages varied product sales level country us market partners shared profits zetia vytorin sales equally exception first million annual zetia sales scheringplough received greater share profits operating income included expenses partners contractually agreed share portion manufacturing costs specifically identified promotion costs including directtoconsumer advertising direct identifiable outofpocket promotion agreed upon costs specific services ongoing clinical research market support market research market expansion well specialty sales force physician education programs expenses incurred support msp partnership shared partners marketing administrative expenses including certain sales force costs well certain manufacturing costs included equity income affiliates table contents however costs reflected overall results company certain research development expenses generally shared equally partners adjusting earned milestones result merger see note msp partnership owned company results msp partnership date merger reflected equity income affiliates activity resulting sale msp partnership products merger consolidated mercks results see note information respect litigation involving msp partnership partners related sale promotion zetia vytorin summarized financial information msp partnership follows period january years ended november december sales vytorin zetia materials production costs expense net income taxes mercks share income taxes december total assets total liabilities old mercks share msp partnerships income taxes differs equity income recognized msp partnership primarily due timing recognition certain transactions old erck msp partnership periods presented including milestone payments amounts comprised almost entirely current balances astrazeneca lp old merck entered agreement astra ab astra develop market astras products royaltybearing license old mercks total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami old merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining old merck astra completed restructuring ownership operations joint venture whereby old merck acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner table contents make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns ongoing revenue based sales current future kbi products revenue billion billion billion respectively primarily relating sales nexium well prilosec addition merck earns certain partnership returns recorded equity income affiliates reflected table returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings astrazeneca merger triggered partial redemption march old mercks interest certain azlp product rights upon redemption old merck received billion azlp amount based primarily multiple old mercks average annual variable returns derived sales former astra usa inc products three years prior redemption limited partner share agreed value old merck recorded billion pretax gain partial redemption partial redemption old mercks interest product rights result change old mercks limited partnership interest conjunction restructuring astra purchased option asset option payment million recorded deferred income buy old mercks interest kbi products excluding gastrointestinal medicines nexium prilosec nonppi products astrazeneca exercise asset option first half exercise price million represents net present value march projected future pretax revenue received old merck nonppi products appraised value february astrazeneca notified company exercising asset option old merck also right require astra purchase interest appraised value february old merck advised astrazeneca would exercise asset option thus million remains deferred recognized asset option consummated addition old merck granted astra option shares option buy old mercks common stock interest kbi therefore old mercks interest nexium prilosec exercisable two years astras exercise asset option astra also exercise shares option combined annual sales two products fall minimum amount provided case long astrazenecas asset option exercised exercise price shares option based net present value estimated future net sales nexium prilosec determined time exercise subject certain trueup mechanisms astrazeneca merger constituted trigger event kbi restructuring agreements result merger exchange old mercks relinquishment rights future astra products existing pending us patents time merger astra paid million advance payment advance payment deferred remained subject trueup calculation trueup amount directly dependent fair market value march astra product rights retained old merck calculated trueup amount million returned azlp march old merck recognized pretax gain million related residual advance payment balance provisions kbi restructuring agreements trigger event occurred sum limited partner share agreed value appraised value trueup amount guaranteed minimum billion distribution limited partner share agreed value less payment trueup amount resulted cash receipts old merck billion aggregate pretax gain billion included income expense net astrazenecas purchase old mercks interest nonppi products contingent upon exercise asset option astrazeneca therefore payment appraised value may may occur also march billion outstanding loan astra plus interest redemption date settled result transactions old merck received net proceeds azlp billion table contents summarized financial information azlp follows years ended december sales materials production costs expense net income taxes december current assets noncurrent assets total liabilities current merial limited old merck rhnepoulenc sa sanofiaventis combined animal health businesses form merial limited merial fully integrated animal health company standalone joint venture owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species september old merck sold interest merial sanofiaventis billion cash sale resulted recognition billion gain reflected income expense net also connection sale merial old merck sanofiaventis scheringplough signed call option agreement terms call option agreement following closing merger sanofiaventis option require company combine intervetscheringplough animal health business merial form animal health joint venture would owned equally company sanofiaventis part call option agreement value merial fixed billion minimum total value received company contributing intervetscheringplough combined entity would billion subject customary transaction adjustments consisting floor valuation intervetscheringplough fixed minimum billion subject potential upward revision based valuation exercise two parties additional payment sanofiaventis million based valuation exercise intervetscheringplough customary transaction adjustments merial intervetscheringplough combined payment may required paid either party make joint venture equally owned company sanofiaventis payment would trueup value contributions equal formation new animal health joint venture sanofiaventis subject customary closing conditions including antitrust review united states europe prior closing merger agreements provided old merck certain rights terminate call option fee million recognition termination fee deferred fourth quarter conditions could triggered payment lapsed amount reflected income expense net merial sales billion period january september divestiture date billion billion sanofi pasteur msd old merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe joint venture vaccine sales billion billion billion johnson johnsonmerck consumer pharmaceuticals company old merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned venture subsequently expanded canada significant joint venture products pepcid ac overthecounter form companys ulcer table contents medication pepcid well pepcid complete overthecounter product combines companys ulcer medication antacids sales products marketed joint venture million million million investments affiliates accounted using equity method including joint ventures totaled billion december billion december amounts reported assets amounts due joint ventures included deferred income taxes current assets million december million december summarized information affiliates excluding msp partnership azlp disclosed separately follows years ended december sales materials production costs expense net income taxes december current assets noncurrent assets current liabilities noncurrent liabilities includes information merial divestiture september loans payable longterm debt commitments loans payable december included million eurodenominated notes due shortterm foreign borrowing million also included loans payable december million longdated notes subject repayment option holders beginning reclassified longterm debt additionally loans payable december included million longdated notes subject repayment option holders annual basis loans payable december included billion commercial paper borrowings million longdated notes subject repayment option holders annual basis million shortterm foreign borrowing table contents longterm debt december consisted eurodenominated notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due floating rate eurodenominated term loan due notes due debentures due notes due debentures due notes due debentures due company party interest rate swap contracts effectively convert fixedrate notes million fixedrate notes floatingrate instruments see note presented table december consisted primarily million million borrowings variable rates averaging respectively borrowings million subject repayment option holders beginning years also included foreign borrowings varying rates june old merck closed underwritten public offering billion senior unsecured notes consisting billion aggregate principal amount notes due billion aggregate principal amount notes due billion aggregate principal amount notes due million aggregate principal amount notes due interest notes payable semiannually notes series redeemable whole part time companys option redemption prices specified notes associated prospectus proceeds notes used fund portion cash consideration merger connection merger company recorded longterm debt fair value billion december included million representing remaining excess fair value recorded value debt amortized interest expense remaining lives underlying debt obligations eurodenominated notes due eurodenominated notes due notes due notes due notes due notes due redeemable whole part mercks option time redemption prices specified notes associated prospectus respect eurodenominated notes notes notes change control triggering event defined therein occurs certain circumstances defined notes associated prospectus holders notes right require merck repurchase part notes cash payment equal aggregate principal amount notes repurchased plus accrued unpaid interest date purchase table contents notes due notes due subject interest rate adjustment provisions event rating assigned particular series notes either moodys investors service inc standard poors rating services dropped predetermined level prior merger interest rate adjustment triggered consequently time merger notes due paying interest rate notes due paying interest rate following closing merger ratings series notes upgraded pursuant terms indenture interest rates payable notes reverted back stated amounts effective december interest rate adjustment provisions notes longer apply also connection merger effective november new merck executed full unconditional guarantee existing debt old merck old merck executed full unconditional guarantee existing debt new merck excluding commercial paper including payments principal interest aggregate maturities longterm debt next five years follows million billion million billion billion also connection merger march old merck entered financing commitment letter jpmorgan chase bank na jp morgan securities inc collectively jpmorgan jpmorgan committed provide billion financing may old merck entered billion day senior unsecured interim term loan facility bridge loan facility billion day asset sale revolving credit facility asset sale facility billion day corporate revolving credit facility incremental facility connection billion offering bridge loan facility terminated commitment lenders day asset sale facility reduced upon completion sale merial sanofiaventis see note asset sale facility terminated incremental facility available backstop commercial paper general corporate purposes facility drawn expire november merck incurred commitment fees approximately million associated facilities amortized commitment period april old merck amended billion year revolving credit facility maturing april allow facility remain place merger companys existing billion credit facility maturing august remains outstanding facilities provide backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding either facility rental expense operating leases net sublease income million million million minimum aggregate rental commitments noncancellable leases follows million million million million thereafter million company significant capital leases contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made result number factors product liability insurance become less available cost increased significantly company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits table contents coverage available insurance certain product liabilities effective august including liability legacy merck products first sold date company continue evaluate insurance needs costs availability benefits product liability insurance future vioxx litigation product liability lawsuits previously disclosed individual putative class actions filed old merck state federal courts alleging personal injury andor economic loss respect purchase use vioxx actions filed federal court coordinated multidistrict litigation us district court eastern district louisiana mdl district judge eldon e fallon number actions filed state court coordinated separate coordinated proceedings state courts new jersey california texas counties philadelphia pennsylvania washoe clark counties nevada december company served aware named defendant approximately pending lawsuits include approximately plaintiff groups alleging personal injuries resulting use vioxx approximately putative class actions alleging personal injuries andor economic loss actions discussed paragraph lawsuits collectively referred vioxx product liability lawsuits lawsuits approximately lawsuits representing approximately plaintiff groups slated federal mdl approximately lawsuits representing approximately plaintiff groups included coordinated proceeding new jersey superior court judge carol e higbee plaintiff groups described currently vioxx settlement program described december plaintiff groups otherwise eligible settlement program participated claims remain pending old merck addition claims approximately plaintiff groups eligible settlement program remain pending old merck number plaintiff groups subject various motions dismiss failure comply courtordered deadlines since december certain plaintiff groups since dismissed addition claims plaintiffs dismissed december vast majority dismissed result settlement process discussed november old merck announced entered agreement settlement agreement law firms comprise executive committee plaintiffs steering committee psc federal vioxx mdl well representatives plaintiffs counsel texas new jersey california state coordinated proceedings resolve state federal myocardial infarction mi ischemic stroke claims filed date united states settlement agreement applies us legal residents allege mi occurred united states settlement agreement provided old merck pay fixed aggregate amount billion two funds billion mi claims million claims interim final payments made certain qualifying claimants expected remainder full billion distributed first half company completed making payments settlement funds two us vioxx product liability lawsuits currently scheduled trial old merck previously disclosed outcomes several vioxx product liability lawsuits tried prior cases went trial mcdarby matter resolved fourth quarter leaving two unresolved posttrial appeals ernst v merck garza v merck previously reported september old merck filed notice appeal august jury verdict favor plaintiff texas state court case ernst v merck may texas court appeals reversed trial courts judgment issued judgment favor old merck court appeals found evidence legally insufficient issue causation plaintiff filed motion rehearing en banc court appeals june response plaintiffs motion rehearing court appeals issued new opinion reversing jurys verdict rendered judgment old merck september plaintiff table contents filed second motion rehearing en banc court appeals denied november december plaintiff filed another motion rehearing court appeals denied plaintiff filed petition review supreme court texas february previously reported april garza v merck jury state court rio grande city texas returned verdict favor family decedent leonel garza jury awarded total million compensatory damages mr garzas widow three sons jury also purported award million punitive damages even though texas law case potential punitive damages capped may san antonio court appeals reversed judgment rendered judgment favor old merck december court appeals rehearing vacated prior ruling issued replacement new ruling court ordered takenothing judgment old merck design defect claim reversed remanded new trial strict liability claim juror misconduct january old merck filed petition review texas supreme court texas supreme court granted old mercks petition review oral argument held january lawsuits approximately claims individual private thirdparty payors filed new jersey court federal court mdl september old merck announced finalized settlement agreement previously disclosed resolve pending lawsuits usbased private thirdparty payors tpps sought reimbursement covering vioxx purchased plan members certain claimants participated resolution well agreement provided old merck admit wrongdoing fault settlement agreement old merck paid fixed total million amount includes settlement fund divided among tpps insurers employee benefit plans union welfare funds participating resolution accordance formula based product volume provision potential payment attorneys fees return settling tpps dismiss lawsuits release claims old merck stipulated dismissals settled ttp actions filed new jersey mdl december old merck recorded charge million second quarter related settlement paid million fourth quarter since settlement one additional tpp case filed pending mdl proceeding separately also still pending various us courts putative class actions purportedly brought behalf individual purchasers users vioxx seeking reimbursement alleged economic loss mdl proceeding class actions remain old merck moved dismiss master complaint includes cases mdl court yet ruled motion march new jersey superior court denied plaintiffs motion class certification martinkleinman v merck putative consumer class action plaintiffs moved leave appeal decision new jersey supreme court november january new jersey supreme court denied plaintiffs request appellate review denial class certification june missouri state court certified class missouri plaintiffs seeking reimbursement outofpocket costs relating vioxx plaintiffs allege personal injuries taking vioxx missouri court appeals affirmed trial courts certification class may missouri supreme court denied old mercks application review decision september trial set april addition indiana plaintiffs filed motion certify class indiana vioxx purchasers case pending circuit court marion county indiana discovery case ongoing briefing complete plaintiffs motion certify class kentucky vioxx purchasers circuit court pike county kentucky hearing matter held february judge cook county illinois consolidated three putative class actions brought vioxx purchasers plaintiffs actions recently voluntarily dismissed lawsuits plaintiffs also filed class action california state court seeking certification class california thirdparty payors endusers trial court denied motion class certification april court appeal affirmed ruling december january plaintiffs filed petition review california supreme court table contents old merck also named defendant twentyone separate lawsuits brought government entities including attorneys general thirteen states five counties city new york private citizens brought qui tam taxpayer derivative suits actions allege old merck misrepresented safety vioxx seek recovery cost vioxx purchased reimbursed government entity agencies ii reimbursement sums paid government entity agencies medical services treatment persons injured vioxx iii damages various common law theories andor iv remedies various state statutory theories including state consumer fraud andor fair business practices medicaid fraud statutes including civil penalties nine thirteen cases pending mdl proceeding two subject conditional orders transferring mdl proceeding two remanded state court one lawsuits brought counties class action filed santa clara county california behalf similarly situated california counties old mercks motion summary judgment granted november case brought attorney general texas scheduled go trial early texas attorney general appeal michigan attorney general case old merck currently seeking appellate review trial courts order denying old mercks motion dismiss trial court entered stay proceedings including discovery pending result appeal finally attorney general actions mdl described previous paragraph discovery phase louisiana attorney general case currently scheduled trial mdl court april shareholder lawsuits previously disclosed addition vioxx product liability lawsuits old merck various current former officers directors defendants various putative class actions individual lawsuits federal securities laws state securities laws vioxx securities lawsuits vioxx securities lawsuits pending federal court transferred judicial panel multidistrict litigation jpml us district court district new jersey district judge stanley r chesler inclusion nationwide mdl shareholder mdl judge chesler consolidated vioxx securities lawsuits purposes putative class action requested damages behalf purchasers old merck stock may october alleged defendants made false misleading statements regarding vioxx violation sections b securities exchange act sought unspecified compensatory damages costs suit including attorneys fees complaint also asserted claims section securities exchange act certain defendants relating sales old merck stock sections securities act certain defendants based statements registration statement certain prospectuses filed connection old merck stock investment plan dividend reinvestment plan april judge chesler granted defendants motion dismiss complaint prejudice plaintiffs appealed judge cheslers decision us court appeals third circuit september third circuit issued opinion reversing judge cheslers order remanding case district court old merck filed petition writ certiorari united states supreme court january supreme court granted may oral argument held november decision expected first half petition certiorari pending plaintiffs filed consolidated fifth amended class action complaint district court old merck filed motion dismiss complaint may following district court proceedings stayed pending outcome supreme court appeal motion dismiss district court withdrawn without prejudice old mercks right refile motion pending outcome supreme court appeal october dutch pension fund filed complaint district new jersey alleging violations federal securities laws well violations state law old merck certain officers pursuant case management order governing shareholder mdl case based allegations vioxx securities lawsuits consolidated vioxx securities lawsuits defendants motion dismiss pension funds complaint filed august september dutch pension fund filed amended complaint rather responding defendants motion dismiss addition six new complaints filed district new jersey behalf various foreign institutional investors also alleging violations federal securities laws well violations state law old merck certain officers stipulation table contents defendants required respond complaints resolution motion dismiss consolidated securities action addition previously disclosed various putative class actions filed federal court employee retirement income security act erisa old merck certain current former officers directors vioxx erisa lawsuits together vioxx securities lawsuits vioxx derivative lawsuits described vioxx shareholder lawsuits transferred shareholder mdl consolidated purposes consolidated complaint asserts claims breach fiduciary duty behalf certain old mercks current former employees participants certain old mercks retirement plans complaint makes similar allegations respect vioxx allegations contained vioxx securities lawsuits july judge chesler granted part denied part defendants motion dismiss erisa complaint october plaintiffs moved certification class individuals participants beneficiaries old mercks retirement savings plans time october september whose plan accounts included investments old merck common stock fund andor old merck common stock february court denied motion certification class one count granted motion remaining counts court also excluded class definition individuals injured connection investments old merck stock ii executed post separation settlement agreements released claims erisa march judge chesler denied defendants motion judgment pleadings may judge chesler entered order denying plaintiffs motion partial summary judgment certain individual defendants filed december previously disclosed october two individual shareholders made demand old mercks board take legal action mr raymond gilmartin former chairman president chief executive officer individuals allegedly causing damage old merck respect allegedly improper marketing vioxx december special committee board directors retained honorable john martin jr debevoise plimpton llp conduct independent investigation among things allegations set forth demand judge martins report made public september based special committees recommendation made careful consideration martin report impact derivative litigation would old merck board rejected demand october two shareholders filed shareholder derivative lawsuit purportedly old mercks behalf state court atlantic county new jersey current former officers directors old merck plaintiffs alleged boards rejection demand unreasonable improper defendants breached various duties old merck allowing vioxx marketed parties reached proposed settlement february court issued order preliminarily approving settlement requiring notice proposed settlement made mercks shareholders setting hearing consider final approval settlement march february merck notified shareholders proposed settlement terms proposed settlement merck agreed make certain corporate governance changes supplement policies procedures previously established company agreed pay award fees expenses plaintiffs attorneys amount determined court exceed million addition merck plaintiffs individual defendants exchange full mutual releases claims could asserted derivative actions proposed settlement constitute admission liability wrongful conduct merck defendants named actions approved court proposed settlement also resolve federal consolidated shareholder derivative action described previously disclosed various shareholder derivative actions filed federal court transferred shareholder mdl consolidated purposes judge chesler vioxx derivative lawsuits may judge chesler granted defendants motion dismiss grounds plaintiffs failed demonstrate demand excused denied plaintiffs request leave amend complaint plaintiffs appealed arguing judge chesler erred denying plaintiffs leave amend complaint documents acquired stipulation parties july united states court appeals third circuit reversed district courts decision grounds judge chesler allowed plaintiffs seek leave amend complaint using documents acquired stipulation remanded case district courts consideration whether even additional materials plaintiffs proposed amendment table contents would futile plaintiffs filed brief support request leave amend complaint along proposed amended complaint november court denied motion june dismissed case one plaintiffs appealed judge cheslers decision united states court appeals third circuit oral argument appeal held july november decision issued appeal stayed pending approval settlement reached derivative action pending new jersey superior court would resolve state federal shareholder derivative claims relating vioxx international lawsuits previously disclosed addition lawsuits discussed old merck named defendant litigation relating vioxx various countries collectively vioxx foreign lawsuits europe well canada brazil argentina australia turkey israel philippines singapore november superior court quebec authorized institution class action behalf individuals quebec consumed vioxx suffered damages arising ingestion may plaintiffs served introductory motion class action based upon authorization case remains preliminary stages litigation may provincial court queens bench saskatchewan canada entered order certifying class vioxx users canada except quebec old merck appealed certification order march court appeal granted old mercks appeal quashed certification order october supreme court canada dismissed plaintiffs appeal application decided review judgment saskatchewan court appeal july superior court ontario denied old mercks motion stay class proceedings ontario decided certify overlapping class vioxx users canada except quebec saskatchewan allege negligence entitlement elect waive tort february ontario divisional court dismissed appeal order denying stay may ontario court appeal denied leave appeal october supreme court canada dismissed old mercks application decided review judgment ontario court appeal court appeal saskatchewan quashed multijurisdictional certification order entered province old merck applied ontario court appeal leave appeal ontario certification order leave appeal granted appeal filed may accordance courts decision old merck sought leave appeal divisional court denied december procedural decisions canadian litigation address merits plaintiffs claims litigation canada remains early stage trial representative action australia commenced march federal court australia named plaintiff alleges suffered mi seeks represent others australia ingested vioxx suffered mi thrombotic stroke unstable angina transient ischemic attack peripheral vascular disease march trial judge entered order directing advance issues proceeding issues determined trial issues fact law named plaintiffs individual case issues fact law trial judge finds hearing evidence common claims group members named plaintiff alleged represents trial representative action concluded june trial judge reserved decision insurance previously disclosed company directors officers insurance coverage applicable vioxx securities lawsuits vioxx derivative lawsuits stated upper limits approximately million company fiduciary insurance vioxx erisa lawsuits stated upper limits approximately million result previously disclosed arbitration additional insurance coverage claims also available needed upperlevel excess policies provide coverage variety risks disputes insurers availability companys insurance coverage claims likely additional disputes amounts actually recovered policies discussed paragraph may less stated upper limits table contents investigations previously disclosed old merck received subpoenas us department justice doj requesting information related old mercks research marketing selling activities respect vioxx federal health care investigation criminal statutes investigation includes subpoenas witnesses appear grand jury previously disclosed march old merck received letter us attorneys office district massachusetts identifying target grand jury investigation regarding vioxx previously disclosed investigations conducted local authorities certain cities europe order determine whether criminal charges brought concerning vioxx company cooperating governmental entities respective investigations vioxx investigations company predict outcome inquiries however could result potential civil andor criminal remedies addition old merck received subpoena september state california attorney general seeking documents information related placement vioxx californias medical formulary company cooperating attorney general responding subpoena reserves discussed november old merck entered settlement agreement law firms comprise executive committee psc federal vioxx mdl well representatives plaintiffs counsel texas new jersey california state coordinated proceedings resolve state federal mi claims filed date united states result entering settlement agreement old merck recorded pretax charge billion represents fixed aggregate amount paid plaintiffs qualifying payment settlement program two us vioxx product liability lawsuit trials scheduled trial company predict timing trials related vioxx litigation company believes meritorious defenses vioxx product liability lawsuits vioxx shareholder lawsuits vioxx foreign lawsuits collectively vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits included settlement program company established reserves potential liability relating vioxx lawsuits included settlement program reserve established connection resolution shareholder derivative lawsuits discussed vioxx investigations unfavorable outcomes vioxx litigation could material adverse effect companys financial position liquidity results operations legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable december old merck aggregate reserve approximately billion vioxx reserve settlement program future legal defense costs related vioxx litigation merck spent approximately million aggregate legal defense costs worldwide including approximately million fourth quarter related vioxx product liability lawsuits ii vioxx shareholder lawsuits iii vioxx foreign lawsuits iv vioxx investigations collectively vioxx litigation addition old merck paid additional billion settlement funds connection settlement program also merck recorded million charges including million fourth quarter solely future legal defense costs vioxx litigation consequently december aggregate amount vioxx reserve approximately million solely future legal defense costs vioxx litigation significant factors considered review vioxx reserve follows actual costs incurred company development companys legal defense strategy structure light scope vioxx litigation including settlement agreement expectation certain lawsuits continue pending number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials table contents vioxx litigation amount vioxx reserve december represents companys best estimate minimum amount defense costs incurred connection remaining aspects vioxx litigation however events additional trials vioxx litigation events could arise course vioxx litigation could affect ultimate amount defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase vioxx reserve time future based upon factors set forth believes would appropriate product liability litigation fosamax previously disclosed old merck defendant product liability lawsuits united states involving fosamax fosamax litigation december approximately cases include approximately plaintiff groups filed pending old merck either federal state court including one case seeks class action certification well damages andor medical monitoring actions plaintiffs allege among things suffered osteonecrosis jaw generally subsequent invasive dental procedures tooth extraction dental implants andor delayed healing association use fosamax addition plaintiffs approximately five percent actions allege sustained stress andor low energy femoral fractures association use fosamax august jpml ordered fosamax product liability cases pending federal courts nationwide transferred consolidated one multidistrict litigation fosamax mdl coordinated pretrial proceedings fosamax mdl transferred judge john keenan us district court southern district new york result jpml order approximately cases judge keenan judge keenan issued case management order various amendments thereto setting forth schedule governing proceedings focused primarily upon resolving class action certification motions completing fact discovery initial group cases october briefing argument plaintiffs motions certification medical monitoring classes completed judge keenan issued order denying motions january january judge keenan issued order dismissing prejudice class claims asserted first four class action lawsuits filed old merck sought personal injury damages andor medical monitoring relief class wide basis daubert motions filed may judge keenan conducted daubert hearing july july judge keenan issued ruling parties respective daubert motions ruling denied plaintiff steering committees motion granted part denied part old mercks motion first mdl trial boles v merck began august ended september september mdl court declared mistrial boles eight person jury could reach unanimous verdict consequently boles case set retried june second mdl case set trial flemings v merck scheduled start january judge keenan granted old mercks motion summary judgment dismissed case november next mdl case set trial maley v merck currently scheduled start april old merck filed motion summary judgment maley mdl court granted part denied part january result company expects trial commence currently scheduled april february judge keenan selected new bellwether case judith graves v merck replace flemings bellwether case mdl court dismissed granted summary judgment favor old merck mdl court set graves trial begin september trial alabama currently scheduled begin may trial florida currently scheduled begin june addition july application made atlantic county superior court new jersey requesting fosamax cases pending new jersey considered mass tort designation centralized management one judge new jersey october new jersey supreme court ordered pending future actions filed new jersey arising use fosamax seeking damages existing dental jawrelated injuries including osteonecrosis jaw solely seeking medical monitoring designated mass tort centralized management purposes judge higbee atlantic county superior court december approximately cases pending old table contents merck new jersey coordinated proceeding july judge higbee entered case management order various amendments thereto setting forth schedule contemplates completing fact discovery initial group cases february followed expert discovery five cases projected trial date july first case tried new jersey coordinated proceeding discovery ongoing fosamax mdl litigation new jersey coordinated proceeding remaining jurisdictions fosamax cases pending company intends defend lawsuits december company remaining reserve approximately million solely future legal defense costs fosamax litigation company spent approximately million added million reserve consequently december company reserve approximately million solely future legal defense costs fosamax litigation significant factors considered establishment reserve fosamax litigation legal defense costs follows actual defense costs incurred thus far development companys legal defense strategy structure light creation fosamax mdl number cases brought company anticipated timing progression related costs pretrial activities fosamax litigation company continue monitor legal defense costs review adequacy associated reserves due uncertain nature litigation company unable reasonably estimate costs beyond third quarter company established reserves potential liability relating fosamax litigation unfavorable outcomes fosamax litigation could material adverse effect companys financial position liquidity results operations nuvaring beginning may number complaints filed various jurisdictions asserting claims companys subsidiaries organon usa inc organon pharmaceuticals usa inc organon international collectively organon scheringplough arising organons marketing sale nuvaring combined hormonal contraceptive vaginal ring plaintiffs contend organon scheringplough failed adequately warn alleged increased risk venous thromboembolism vte posed nuvaring andor downplayed risk vte plaintiffs seek damages injuries allegedly sustained product use including alleged deaths heart attacks strokes majority cases currently pending federal multidistrict litigation venued missouri new jersey state court cases pending states vetsulin december scheringplough animal health named defendant putative class action lawsuit filed us district court northern district ohio lawsuit entitled friedman v scheringplough animal health individual plaintiff seeks represent class people purchased vetsulin household pets suit alleges vetsulin contaminated improperly manufactured vetsulin insulin product administered diabetic dogs cats plaintiff seeks compensatory punitive damages based theories negligence violation consumer sales practices acts breach warranty product liability due allegedly defective manufacturing merck intends defend lawsuit vigorously commercial litigation awp litigation investigations previously disclosed old merck joined ongoing litigation alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used calculations determine public private sector reimbursement levels complaints allege violations federal state law including fraud medicaid fraud consumer protection violations among claims outcome litigations investigations could include substantial damages imposition substantial fines penalties injunctive administrative remedies jpml ordered transfer consolidation pending federal awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions also expanded number manufacturers include like old merck defendants prior pending case may court granted old mercks motion dismiss consolidated class action dismissed old table contents merck class action case old merck many pharmaceutical manufacturers defendants similar complaints pending federal state court including cases brought individually number counties state new york fifty county cases consolidated new york state court old merck dismissed suffolk county case first new york county cases filed addition new york county cases december old merck defendant state cases brought attorneys general eleven states defended february kansas attorney general filed suit old merck several manufacturers awp claims brought attorney general arizona old merck dropped court awp cases pending hawaii listed old merck others set trial mid scheringplough reached settlements claims relating awp august scheringplough five pharmaceutical companies settled claims brought behalf alabama medicaid program combined total million addition july scheringplough reached settlement relator acting behalf united states non intervened awp qui tam action pending us federal district court massachusetts states california florida combined total million settlement resolved claims brought behalf medicaid programs states california florida approved us district court district massachusetts held preclusive claims federal share alleged medicaid overpayment remaining states consistent applicable precedent january us district court district massachusetts held unit scheringplough eight drug makers overcharged new york city new york counties certain generic drugs court reserved issue damages penalties future proceedings company continues respond litigation brought certain states private payors investigations initiated department health human services department justice several states regarding awp company cooperating investigations centocor distribution agreement may centocor wholly owned subsidiary johnson johnson delivered scheringplough notice initiating arbitration proceeding resolve whether result merger centocor permitted terminate companys rights distribute commercialize remicade simponi sales remicade simponi included companys results postmerger period million million respectively sales remicade recognized scheringplough prior merger billion arbitration process involves number steps including selection independent arbitrators information exchanges hearings final decision reached hearing arbitration scheduled commence late september unfavorable outcome arbitration would material adverse effect companys financial position liquidity results operations governmental proceedings previously disclosed february old merck entered corporate integrity agreement cia us department health human services office inspector general hhsoig fiveyear term cia requires among things old merck maintain ethics training program policies procedures governing promotional practices medicaid price reporting required cia old merck retained independent review organization iro conduct systems review promotional policies procedures conduct sample basis transactional reviews old mercks promotional programs certain medicaid pricing calculations old merck also required provide regular reports certifications hhsoig regarding compliance cia similarly previously disclosed scheringplough scheringplough entered cia hhsoig fiveyear term august entered addendum cia also effective five years requirements old merck scheringplough cias similar although identical failure comply cias requirements result financial penalties exclusion participation federal health care programs company believes promotional practices medicaid price reports meet requirements cias table contents vytorinzetia litigation previously disclosed legacy companies received several letters house committee energy commerce subcommittee oversight investigations oi ranking minority member senate finance committee collectively seeking combination witness interviews documents information variety issues related enhance clinical trial sale promotion vytorin well sales stock corporate officers addition previously disclosed since august old merck scheringplough received three additional letters oi including identical letters dated february seeking certain information documents related seas clinical trial previously disclosed legacy companies received subpoenas new york state attorney generals office letter connecticut attorney general seeking similar information documents july legacy companies announced reached civil settlement attorneys general representing states district columbia resolve previously disclosed investigation group whether legacy companies violated state consumer protection laws marketing vytorin zetia part settlement legacy companies agreed reimburse investigative costs states district columbia totaled million make voluntary assurances compliance related promotion vytorin zetia including agreeing continue comply food drug cosmetic act us food drug administration amendments act laws requiring truthful nonmisleading marketing pharmaceutical products settlement include admission misconduct liability legacy companies furthermore previously disclosed september legacy companies received letters civil division doj informing doj investigating whether conduct relating promotion vytorin caused false claims submitted federal health care programs company cooperating investigations responding inquiries previously disclosed legacy companies become aware served approximately civil class action lawsuits alleging common law state consumer fraud claims connection msp partnerships sale promotion vytorin zetia certain lawsuits alleged personal injuries andor sought medical monitoring lawsuits old merck scheringplough consolidated single multidistrict litigation docket judge cavanaugh district new jersey vytorinzetia marketing sales practices products liability litigation august old merck scheringplough jointly announced cholesterol joint venture entered agreements resolve total fixed amount million civil class action lawsuits msp partnership recorded charges second quarter february judge cavanaugh granted final approval settlements also previously disclosed april old merck shareholder filed putative class action lawsuit federal court eastern district pennsylvania alleging old merck chairman president chief executive officer richard clark violated federal securities laws suit since withdrawn refiled district new jersey consolidated another federal securities lawsuit caption merck co inc vytorin securities litigation amended consolidated complaint filed october names defendants old merck merckscheringplough pharmaceuticals llc certain companys current former officers directors specifically complaint alleges old merck delayed releasing unfavorable results enhance clinical trial regarding efficacy vytorin old merck made false misleading statements expected earnings knowing results vytorin study released sales vytorin would decline old mercks earnings would suffer december old merck defendants moved dismiss lawsuit grounds plaintiffs failed state claim relief granted september court issued opinion order denying defendants motion dismiss lawsuit october old merck defendants filed answer amended consolidated complaint similar consolidated putative class action securities lawsuit pending district new jersey filed scheringplough shareholder scheringplough former chairman president chief executive officer fred hassan caption scheringplough corporationenhance securities litigation amended consolidated complaint filed september names defendants schering plough merckscheringplough pharmaceuticals llc certain companys current former officers directors underwriters participated august public offering scheringploughs common preferred stock december scheringplough table contents defendants filed motions dismiss lawsuit grounds plaintiffs failed state claim relief granted september court issued opinion order denying defendants motion dismiss lawsuit september defendants filed motion reconsideration courts september opinion order denying motion dismiss motion reconsideration fully briefed october decision remains pending defendants filed answer consolidated amended complaint november previously disclosed april member old merck erisa plan filed putative class action lawsuit old merck certain companys current former officers directors alleging breached fiduciary duties erisa since time similar erisa lawsuits filed old merck district new jersey lawsuits consolidated caption merck co inc vytorin erisa litigation consolidated amended complaint filed february names defendants old merck various current former members companys board directors plaintiffs allege erisa plans investment old merck stock imprudent old mercks earnings dependent commercial success cholesterol drug vytorin defendants knew known results scientific study would cause medical community turn less expensive drugs cholesterol management april old merck defendants moved dismiss lawsuit grounds plaintiffs failed state claim relief granted september court issued opinion order denying defendants motion dismiss lawsuit november plaintiffs moved strike certain defendants affirmative defenses motion fully briefed december pending court similar consolidated putative class action erisa lawsuit currently pending district new jersey filed member scheringplough erisa plan schering plough certain current former officers directors alleging breached fiduciary duties erisa caption scheringplough corp enhance erisa litigation consolidated amended complaint filed october names defendants scheringplough various current former members scheringploughs board directors current former members committees scheringploughs board directors november company defendants filed motion dismiss lawsuit grounds plaintiffs failed state claim relief granted plaintiffs opposition motion dismiss filed december motion fully briefed january decision remains pending november stockholder company filed shareholder derivative lawsuit local international brotherhood electrical workers pension fund v clark local district new jersey behalf nominal defendant company shareholders company company certain companys officers directors alleged insiders certain predecessor companies former officers directors alleged insiders alleged breaches fiduciary duties waste unjust enrichment gross mismanagement similar shareholder derivative lawsuit cain v hassan filed scheringplough stockholder currently pending district new jersey amended complaint filed may scheringplough stockholder behalf nominal defendant scheringplough scheringplough shareholders lawsuit scheringplough scheringploughs thencurrent board directors certain scheringploughs current former officer directors alleged insiders plaintiffs local cain v hassan allege defendants withheld enhance study results made false misleading statements thereby deceiving causing harm company scheringplough respectively investing public unjustly enriching insiders wasting corporate assets defendants local intend move dismiss plaintiffs complaint defendants cain v hassan moved dismiss amended complaint july motion fully briefed october decision remains pending company intends defend lawsuits referred section unfavorable outcomes resulting government investigations civil litigations could material adverse effect companys financial position liquidity results operations table contents november individual shareholder previously delivered letter old mercks board directors demanding board take legal action responsible individuals recover amounts paid old merck resolve certain governmental investigations delivered another letter board demanding board subcommittee thereof commence investigation matters raised various civil suits governmental investigations relating vytorin securities class action litigation federal securities litigation following scheringploughs announcement february fda conducting inspections manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices delayed approval clarinex several lawsuits filed scheringplough certain named officers lawsuits allege defendants violated federal securities law allegedly failing disclose material information making material misstatements specifically allege scheringplough failed disclose alleged serious risk new drug application clarinex would delayed result manufacturing issues allege company failed disclose alleged depth severity manufacturing issues complaints consolidated one action us district court district new jersey consolidated amended complaint filed october purporting represent class shareholders purchased shares scheringplough stock may february complaint sought compensatory damages behalf class february court signed order preliminarily approving settlement agreement scheringplough would provide settlement fund amount million resolve claims class funds placed escrow time vast majority settlement covered insurance december district court granted final approval settlement settlement due consummated expiration appeal period final approval decision erisa litigation march scheringplough served putative class action complaint filed us district court new jersey alleging scheringplough employee savings plan plan administrator several current former directors certain former corporate officers breached fiduciary obligations certain participants plan complaint seeks damages amount losses allegedly suffered plan complaint dismissed june plaintiffs appealed august us court appeals third circuit reversed dismissal district court matter remanded back district court proceedings september district court entered order granting part denying part named putative class representatives motion class certification scheringplough thereafter petitioned us district court appeals third circuit leave appeal class certification decision scheringploughs petition granted december december third circuit vacated district courts order remanded case proceedings consistent courts ruling kdur antitrust litigation june january scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relating generic versions kdur scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upshersmith filed abbreviated new drug applications following commencement administrative proceeding united states federal trade commission ftc alleging anticompetitive effects settlements resolved scheringploughs favor alleged class action suits filed federal state courts behalf direct indirect purchasers kdur scheringplough upshersmith lederle suits claim violations federal state antitrust laws well state statutory common law causes action suits seek unspecified damages february special master recommended us district court district new jersey dismiss class action lawsuits summary judgment us district court judge yet ruled recommendation table contents thirdparty payor actions discussed july connection settlement investigation doj us attorneys office eastern district pennsylvania schering plough entered fiveyear cia cia amended august connection million settlement investigation state massachusetts involving certain scheringploughs sales marketing clinical trial practices programs massachusetts investigation several purported class action litigations filed following announcement settlement massachusetts investigation plaintiffs actions seek damages behalf thirdparty payors resulting allegations offlabel promotion improper payments physicians issue massachusetts investigation actions consolidated multidistrict litigation federal district court district new jersey july district court dismissed consolidated class action complaint granted plaintiffs leave refile september plaintiffs filed amended complaints companys motion dismiss complaints pending vaccine litigation previously disclosed old merck party individual class action product liability lawsuits claims united states involving pediatric vaccines eg hepatitis b vaccine contained thimerosal preservative used vaccines december approximately thimerosal related lawsuits pending old merck defendant although vast majority lawsuits currently active defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result exposure thimerosal pediatric vaccines cases currently scheduled trial company defend lawsuits however possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations old merck successful cases type either dismissed stayed ground action prohibited national childhood vaccine injury act vaccine act vaccine act prohibits person filing maintaining civil action state federal court seeking damages vaccine manufacturer vaccinerelated injuries unless petition first filed united states court federal claims hereinafter vaccine court vaccine act filing civil action vaccine manufacturer petitioner must either pursue petition conclusion vaccine court timely file election proceed civil action lieu accepting vaccine courts adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribed time periods old merck party vaccine court proceedings petitions brought united states department health human services company aware approximately cases pending vaccine court involving allegations thimerosalcontaining vaccines andor mmr ii vaccine cause autism spectrum disorders thimerosalcontaining vaccines involved vaccine court proceeding company vaccines company sole source mmr ii vaccine domestically special masters presiding vaccine court proceedings held hearings three test cases involving theory combination mmr ii vaccine thimerosal vaccines causes autism spectrum disorders february special masters issued decisions cases finding theory unsupported valid scientific evidence petitioners three cases therefore entitled compensation two three cases currently appeal special masters held similar hearings three different test cases involving theory thimerosal vaccines alone causes autism spectrum disorders decisions issued second set test cases special masters previously indicated would hold similar hearings involving theory mmr ii alone causes autism spectrum disorders stated longer intend vaccine court indicated intends use evidence presented test case hearings guide adjudication remaining autism spectrum disorder cases table contents patent litigation time time generic manufacturers pharmaceutical products file andas fda seeking market generic forms companys products prior expiration relevant patents owned company generic pharmaceutical manufacturers submitted andas fda seeking market united states generic forms fosamax nexium singulair emend cancidas respectively prior expiration old mercks astrazenecas case nexium patents concerning products addition anda submitted fda seeking market united states generic form zetia anda submitted fda seeking market united states generic form vytorin prior expiration scheringploughs patent concerning product generic companies andas generally include allegations noninfringement invalidity unenforceability patents company filed patent infringement suits federal court companies filing andas generic alendronate fosamax montelukast singulair astrazeneca company filed patent infringement suits federal court companies filing andas generic esomeprazole nexium also company scheringplough filed patent infringement suits federal court companies filing andas generic versions ezetimibe zetia ezetimibesimvastatin vytorin also schering corp schering subsidiary company filed patent infringement suits federal court generic companies filing andas generic versions temodar integrilin levitra nasonex similar patent challenges exist certain foreign jurisdictions company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration dates patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products february scheringplough received notice generic company indicating filed anda zetia challenging us patents listed zetia prior merger company marketed zetia joint venture msp singapore company llc march scheringplough msp singapore company llc filed patent infringement suit glenmark pharmaceuticals inc usa parent corporation glenmark lawsuit automatically stays fda approval glenmarks anda october adverse court decision whichever may occur earlier trial matter scheduled commence may previously disclosed february old merck received notice teva pharmaceuticals inc teva generic company indicating filed anda montelukast challenging us patent listed singulair april old merck filed patent infringement action teva trial matter held february august court issued decision upholding validity old mercks singulair patent ordered tevas anda could approved prior expiry old mercks exclusivity rights august teva appealed decision however january teva withdrew appeal trial courts decision upholding validity old mercks singulair patent addition may united states patent trademark office granted petition article one partners llc reexamine old mercks singulair patent december united states patent trademark office issued notice indicating allow claims companys singulair patent product exclusivity accordingly expected maintained august may federal court canada trial division issued decision refusing bar approval generic alendronate grounds old mercks patent weekly alendronate likely invalid decision appealed generic alendronate launched canada june july old merck sued federal court canada apotex corp apotex seeking damages lost sales generic weekly alendronate due patent proceeding october federal court canada issued decision awarding apotex lost profits generic alendronate product period time held market due old mercks lawsuit june trial court decision upheld part companies sought leave appeal supreme court canada january supreme court canada declined hear appeal leaving intact decision apotex entitled damages discrete period time market entry postponed due litigation launched old merck table contents previously disclosed september old merck appealed decision opposition division european patent office epo revoked companys patent europe covers onceweekly administration alendronate march board appeal epo upheld decision opposition division revoking patent march epo issued another patent europe old merck covers onceweekly administration alendronate terms new patent effective july old merck sued multiple parties european countries asserting european patent covering onceweekly dosing fosamax decisions rendered netherlands belgium invalidating patent countries old merck appealed decisions oppositions filed epo patent hearing held march opposition division epo issued appealable decision revoking patent old merck appealed decision addition previously disclosed japan proceeding filed challenging validity old mercks japanese patent onceweekly administration alendronate patent office invalidated patent decision appeal october us patent dorzolamide covering trusopt cosopt expired old merck experienced significant decline us sales products company involved litigation proceedings corresponding patents canada great britain germany november trial court great britain issued decision finding old mercks cosopt patent invalid canada trial held december regarding companys canadian trusopt cosopt patents company awaiting decision old merck astrazeneca received notice october ranbaxy filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium november old merck astrazeneca sued ranbaxy us district court new jersey previously disclosed astrazeneca old merck ranbaxy entered settlement agreement provides ranbaxy bring generic esomeprazole product market united states may company astrazeneca received cid ftc july regarding settlement agreement ranbaxy company cooperating ftc responding cid old merck astrazeneca received notice january ivax pharmaceuticals inc ivax subsequently acquired teva filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium march old merck astrazeneca sued teva us district court new jersey january astrazeneca old merck tevaivax entered settlement agreement provides tevaivax bring generic esomeprazole product market united states may addition january old merck astrazeneca sued dr reddys laboratories dr reddys district court new jersey based dr reddys filing anda esomeprazole magnesium trial scheduled january respect ivaxs dr reddys andas postponed new trial date set also old merck astrazeneca received notice december sandoz inc sandoz filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium january old merck astrazeneca sued sandoz district court new jersey based sandozs filing anda esomeprazole magnesium addition old merck astrazeneca received notice september lupin ltd lupin filed anda esomeprazole magnesium anda contains paragraph iv challenges patents nexium october old merck astrazeneca sued lupin district court new jersey based lupins filing anda esomeprazole magnesium january old merck received notice sandoz filed anda challenging five old merck patents listed fda orange book emend february old merck filed patent infringement suit sandoz lawsuit automatically stays fda approval sandozs anda july adverse court decision whichever may occur earlier case scheduled go trial december europe old merck aware various companies seeking registration generic losartan active ingredient cozaar hyzaar old merck patent rights losartan via license ei du pont de nemours table contents company du pont old merck du pont filed patent infringement proceedings various companies portugal spain norway finland belgium netherlands austria october old merck received notice teva parenteral medicines tpm filed anda caspofungin acetate challenging five patents listed fda orange book cancidas november company filed patent infringement suit tpm lawsuit automatically stays fda approval tpms anda april adverse court decision whichever may occur earlier november schering received notice apotex filed anda mometasone furoate nasal spray challenging two patents listed fda orange book nasonex december schering filed patent infringement suit apotex lawsuit automatically stays fda approval apotexs anda may adverse court decision whichever may occur earlier november scheringplough received notice mylan filed anda ezetimibesimvastatin challenging two patents listed fda orange book vytorin december scheringplough filed patent infringement suit mylan lawsuit automatically stays fda approval mylans anda may adverse court decision whichever may occur earlier july schering licensor cancer research technologies limited crt received notice barr laboratories barr subsidiary teva barr filed anda temodar challenging crts patent temozolomide july schering crt filed patent infringement action barr january court issued decision finding crt patent unenforceable grounds prosecution laches inequitable conduct schering crt process appealing decision january schering licensor millennium received notice teva filed anda eptifibatide challenging three millennium patents listed fda orange book integrilin february schering millennium filed patent infringement actions teva lawsuit automatically stays fda approval tevas anda august adverse court decision whichever may occur earlier may schering bayer schering pharma ag bayer healthcare pharmaceuticals received notice teva filed anda vardenofil challenging bayers patent listed fda orange book levitra june schering bayer filed patent infringement action teva lawsuit automatically stays fda approval tevas anda november adverse court decision whichever may occur earlier legal proceedings related merger connection merger separate class action lawsuits brought old merck scheringplough challenging merger seeking forms relief previously disclosed lawsuits settled pending court approval settlements approved court resolve release claims could brought shareholder old merck scheringplough challenging aspect proposed merger including merger disclosure claims litigation french matter based complaint french competition authority competitor france pursuant court order french competition authority obtained documents french subsidiary company relating subutex one products subsidiary markets sells resolution matter adverse french subsidiary could result imposition civil fines injunctive administrative remedies july juge des liberts et de la dtention ordered annulment search seizure procedural grounds july french authority appealed order french supreme court may french supreme court overturned annulment remanded case paris court appeal table contents basis juge des liberts et de la dtention examined document assess whether seized whether lawfully seized case pending paris court appeal april competitor also requested interim relief portion granted french competition authority december interim relief required companys french subsidiary publish two specialized newspapers information including generic quantitative qualitative composition pharmaceutical form substitutable subutex february paris court appeal confirmed decision french competition authority january french supreme court confirmed decision french competition authority various legal proceedings principally product liability intellectual property suits involving company pending feasible predict outcome proceedings proceedings discussed note opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company proceedings separate assessment provided note environmental matters company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others final costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying providing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties previously disclosed approximately plaintiffs filed amended complaint old merck defendants us district court eastern district california asserting claims clean water act resource conservation recovery act well negligence nuisance suit seeks damages personal injury diminution property value medical monitoring alleged real personal property damage associated groundwater soil contamination found site former old merck subsidiary merced california old merck intends defend claims managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year table contents equity accordance new merck certificate incorporation shares common stock shares preferred stock authorized authorized shares preferred stock series shares designated mandatory convertible preferred stock mandatory convertible preferred stock prior merger august scheringplough issued shares scheringplough preferred stock connection merger holders schering plough preferred stock received preferred stock rights substantially similar rights scheringplough preferred stock accordance new merck restated certificate incorporation result merger preferred stock became subject makewhole acquisition provisions preferred stock effective november makewhole acquisition conversion period ended november preferred stock convertible makewhole conversion rate share preferred stock converted period holder received cash new merck common shares holders also received dividend makewhole payment depending date conversion total shares preferred stock converted shares new merck common stock cash payments approximately million made holders converted addition makewhole dividend payments million made holders converted representing present value remaining future dividend payments conversion date mandatory conversion date august using discount rate stipulated preferred stock designations december shares preferred stock remained issued outstanding outstanding shares automatically convert common shares company cash august pursuant provisions new merck restated certificate incorporation holders may also elect convert time prior august preferred stock million december classified current liability conversions settled combination cash common stock additionally certain conditions company may elect cause conversion less merck preferred stock outstanding preferred stock accrues dividends annual rate shares outstanding dividends cumulative date issuance extent company legally permitted pay dividends board directors declares dividend payable company pay dividends dividend payment date remaining dividend payment dates february may august capital stock summary common stock treasury stock transactions shares millions follows common treasury common treasury common treasury stock stock stock stock stock stock balance january issuances shares connection merger issuances shares connection acquisition novacardia inc issuances purchases treasury stock cancellations treasury stock balance december issuances primarily reflect activity sharebased compensation plans pursuant merger agreement certain old mercks treasury shares cancelled table contents noncontrolling interests connection restructuring ami old merck assumed billion par value preferred stock obligation dividend rate per annum carried kbi included noncontrolling interests small portion preferred stock carried kbi convertible kbi common shares none preferred securities convertible companys common shares therefore included common shares issuable purposes computing earnings per common share assuming dilution available common shareholders see note sharebased compensation plans company sharebased compensation plans employees nonemployee directors employees certain companys equity method investees may granted options purchase shares company common stock fair market value time grant addition stock options company grants performance share units psus restricted stock units rsus certain management level employees plans approved companys shareholders result merger scheringplough stock incentive plan scheringplough sip amended restated sharebased compensation instruments remain available future grant scheringplough sip new merck employees employees scheringplough prior merger outstanding sharebased compensation instruments well sharebased compensation instruments available future grant old merck new merck incentive plans also result merger certain sharebased compensation instruments previously granted scheringplough sip legacy scheringplough incentive plans exchanged new merck replacement awards awards related precombination services became payable cash addition certain stock options scheringplough legacy incentive plans contain lockin feature whereby award holder elect receive cash payment stock options fixed amount based price scheringploughs common stock days prior merger liability associated provision million december upon expiration exercise period associated lockin feature amount reclassified liabilities equity fair value replacement awards attributable precombination service million included calculation consideration transferred see note significant portion legacy scheringplough awards vested opening balance sheet time merger scheringplough sharebased compensation instruments immediately vest upon completion merger exchanged new merck replacement awards generally vest basis original grants made scheringplough legacy incentive plans immediately vest employee terminated company within two years merger certain circumstances fair value new merck replacement awards attributed postcombination services recognized compensation cost subsequent merger requisite service period awards december million shares collectively authorized future grants companys sharebased compensation plans prior merger employee share based compensation awards settled primarily treasury shares subsequent merger awards settled newly issued shares employee stock options granted purchase shares company stock fair market value time grant awards generally vest onethird year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock awards vest well nonforfeitable dividend equivalents fair value stock option rsu awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price fair value stock option rsu psu replacement awards determined fixed time merger psu performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized table contents based ultimate number shares issued rsu psu distributions shares company stock end vesting performance period generally three years subject terms applicable awards total pretax sharebased compensation cost recorded million million million respectively related income tax benefits million million million respectively company uses blackscholes option pricing model determining fair value option grants applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected dividend yield riskfree interest rate volatility term options expected dividend yield based historical patterns dividend payments riskfree rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained market data companys traded options expected life represents expected amount time options granted expected outstanding based historical forecasted exercise behavior weighted average fair value options granted per option respectively determined using following assumptions years ended december expected dividend yield riskfree interest rate expected volatility expected life years summarized information relative stock option plan activity options thousands follows weighted weighted average average remaining aggregate number exercise contractual intrinsic options price term value balance january granted replacement awards exercised forfeited outstanding december exercisable december additional information pertaining stock option plans provided table years ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options fair value stock options vested excludes fair value options vested result merger attributable precombination service table contents summary nonvested rsu psu activity shares thousands follows rsus psus weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested january granted replacement awards vested forfeited nonvested december december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries pension benefits united states based formula considers final average pay years credited service addition company provides medical dental life insurance benefits principally eligible us retirees similar benefits dependents postretirement benefit plans company uses december yearend measurement date pension plans postretirement benefit plans net cost pension postretirement benefit plans consisted following components p ostretir em ent pension benefits benefits years ended december service cost interest cost expected return plan assets net amortization termination benefits curtailments settlements net pension postretirement cost net pension postretirement benefit cost totaled million million million increase compared primarily due million costs associated scheringplough benefit plans date merger december net pension cost attributable us plans included table million million million connection restructuring actions see note termination charges recorded pension postretirement benefit plans related expanded eligibility certain employees exiting merck also connection restructuring activities net curtailment gains recorded curtailment losses recorded pension plans net curtailment gains recorded postretirement benefit plans table contents addition settlement losses recorded certain domestic international pension plans employee benefit plans exception recognition fair value measurement principles business combinations employee benefit plan obligations recognized measured accordance existing authoritative literature accounting benefit plans rather fair value accordingly company remeasured benefit plans sponsored scheringplough recognized asset liability funded status plans merger date summarized information changes plan assets benefit obligation funded status amounts recorded december follows pens io n benef post r et irement b enefits fair value plan assets january actual return plan assets company contributions scheringplough merger effects exchange rate changes benefits paid fair value plan assets december benefit obligation january service cost interest cost scheringplough merger actuarial losses gains benefits paid effects exchange rate changes plan amendments curtailments termination benefits benefit obligation december funded status december recognized assets accrued current liabilities deferred income taxes noncurrent liabilities fair value us pension plan assets included preceding table billion billion pension projected benefit obligation us plans included table billion billion increase fair value pension projected benefit obligation us plans primarily related merger approximately companys pension projected benefit obligation relates international defined benefit plans individual plan significant relative total benefit obligation table contents december accumulated benefit obligation billion billion respectively pension plans december accumulated benefit obligation us pension plans billion billion respectively pension plans benefit obligations excess plan assets december fair value plan assets billion billion respectively benefit obligation billion billion respectively plans accumulated benefit obligations excess plan assets december fair value plan assets billion million respectively accumulated benefit obligation billion million respectively discussed note december company adopted new authoritative guidance issued fasb revised disclosure requirements plan assets defined pension postretirement plans amended guidance requires disclosure investment allocation decisions made major categories plan assets inputs valuation techniques used measure fair value plan assets effect fair value measurements using significant unobservable inputs level changes plan assets period significant concentrations risk within plan assets entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs may used measure fair value level quoted prices active markets identical assets liabilities plans level assets primarily include registered investment companies mutual funds equity securities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities plans level assets primarily include investments commoncollective trusts certain fixed income investments government agency securities corporate obligations level unobservable inputs supported little market activity financial instruments whose values determined using pricing models discounted cash flow methodologies similar techniques well instruments determination fair value requires significant judgment estimation plans level assets primarily include investments insurance contracts real estate funds valued using methodologies management understands plans level investments insurance contracts generally valued using crediting rate approximates market returns invest underlying securities whose market values unobservable determined using pricing models discounted cash flow methodologies similar techniques plans level investments real estate generally valued market appraisals may infrequent nature december million approximately companys pension investments categorized level assets inputs used measure financial assets fall within one level described categorization based lowest level input significant fair value measurement instrument table contents fair values companys pension plan assets december asset category follows f air value suremen ts using quoted prices significant active significant markets observable unobservable identical assets inputs inputs level level level total assets cash cash equivalents securities lending collaterial shortterm investments equity securities us large cap us smallmid cap nonus developed markets emerging markets fixed income securities government agency obligations corporate obligations mortgage asset backed securities fixed income obligations types investments insurance contracts real estate derivatives liabilities liability return collateral securities loaned table provides summary changes fair value including net transfers andor financial assets measured fair value using significant unobservable inputs level companys pension plan assets actual ur n plan ssets relating beginning assets still ending balance held relating purchases schering balance january december assets sold sales plough december settlements net merger insurance contracts real estate total table contents fair values companys postretirement benefit plan assets december asset category follows fair value e asurements u sing quoted prices significant active significant markets observable unobservable identical assets inputs inputs level level level total assets cash cash equivalents securites lending collateral shortterm investments equity securities us large cap us smallmid cap nonus developed markets emerging markets fixed income securities corporate obligations government agency obligations mortgage asset backed securities fixed income obligations total investments liabilities liability return collateral securities loaned total pension postretirement benefit plan assets excluded fair value hierarchy include shortterm payables receivables related purchase sale investments respectively company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines contributions pension plans postretirement benefit plans expected approximately million million respectively table contents expected benefit payments follows pension postretirement benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees following amounts reflected components comprehensive income p ostretire ent pension plans benefit plans years ended december net gain loss arising period prior service cost credit arising period net loss amortization included benefit cost prior service cost credit amortization included benefit cost estimated net loss prior service cost credit amounts amortized aoci net pension postretirement benefit cost million million respectively pension plans million million respectively postretirement benefit plans table contents company reassesses benefit plan assumptions regular basis weighted average assumptions used determining pension plan us pension postretirement benefit plan information follows u pensi ther postretirement pension plans benefit plans december net cost discount rate expected rate return plan assets salary growth rate benefit obligation discount rate salary growth rate net cost rates preceding table include costs associated scheringplough benefit plans date merger december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined country basis developing expected rate return within country longterm historical returns data considered well actual returns plan assets capital markets experience using reference information longterm return expectations asset category weighted average expected return countrys target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate companys expected rate return range compared range us pension postretirement benefit plans health care cost trend rate assumptions postretirement benefit plans follows december health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate one percentage point change health care cost trend rate would following effects e percentag e point increase decrease effect total service interest cost components effect benefit obligation company also maintains defined contribution savings plans united states including plans assumed connection merger company matches percentage employees contributions consistent provisions plan employee eligible total employer contributions plans million million million respectively table contents income expense net years ended december interest income interest expense exchange gains losses net decline interest income compared primarily result lower interest rates change investment portfolio mix toward cash shorterdated securities anticipation merger increase interest expense largely due million commitment fees incremental interest expense related financing merger included net billion gain resulting recognizing mercks previously held equity interest msp partnership fair value result obtaining control msp partnership merger see note also included net billion gain sale old mercks interest merial see note million investment portfolio recognized net gains million charge related settlement vioxx thirdparty payor litigation united states included net aggregate gain distribution azlp billion see note gain million related sale remaining worldwide rights aggrastat million expense contribution merck company foundation million investment portfolio recognized net losses million charge related resolution investigation whether old merck violated state consumer protection laws respect sales marketing vioxx fluctuation exchange losses gains primarily due higher cost foreign currency contracts due lower us interest rates unfavorable impacts periodtoperiod changes foreign currency exchange rates net long net short foreign currency positions considering net monetary assets related foreign currency contracts change net primarily reflects aggregate gain azlp billion impact million charge related resolution certain civil governmental investigations gain million related sale remaining worldwide rights aggrastat partially offset million expense contribution merck company foundation higher investment portfolio recognized net losses million million charge related resolution investigation whether old merck violated consumer protection laws respect sales marketing vioxx interest paid million million million respectively excludes commitment fees table contents taxes income reconciliation effective tax rate us statutory rate follows amount tax rate amount tax rate amount tax rate us statutory rate applied income taxes differential arising gain equity investments foreign earnings tax rate change state tax settlements foreign tax credit utilization amortization purchase accounting adjustments restructuring state taxes inprocess research development includes tax effect contingency reserves research credits export incentives miscellaneous items tax rate reconciliation percentage foreign earnings reflects change mix foreign domestic earnings primarily resulting billion us vioxx settlement agreement charge income loss taxes consisted years ended december domestic foreign taxes income consisted years ended december current provision federal foreign state deferred provision federal foreign state table contents deferred income taxes december consisted assets liabilities assets liabilities intangibles inventory related accelerated depreciation unremitted foreign earnings equity investments pensions postretirement benefits compensation related vioxx litigation reserve unrecognized tax benefits net operating losses tax credit carryforwards subtotal valuation allowance total deferred taxes net deferred income taxes recognized deferred income taxes current assets assets income taxes payable deferred income taxes noncurrent liabilities increases deferred tax assets relating pensions postretirement benefits compensation related net operating losses tax credit carryforwards well increases deferred tax liabilities relating intangibles unremitted foreign earnings primarily reflect impact deferred taxes recorded conjunction merger company net operating loss nol carryforwards several jurisdictions december significant nol carryforwards approximately million united states begin expire million netherlands expire unused company also tax credit carryforwards us research development tax credits us foreign tax credits federal alternative minimum tax amt credit carryforwards december company million research development credit carryforwards begin expire million foreign tax credit carryforwards begin expire million amt credit carryforwards indefinite life valuation allowance primarily relates various foreign entity nol carryforwards resulting primarily losses generated restructuring actions income taxes paid million billion billion respectively stock option exercises reduced income taxes paid million stock option exercises significant impact taxes paid table contents january new authoritative guidance issued fasb accounting reporting uncertain tax positions adopted reconciliation beginning ending amount unrecognized tax benefits follows balance january additions related current year positions additions related prior year positions additons related merger scheringplough reductions tax positions prior years settlements lapse statute limitations balance december reflects settlement internal revenue service discussed company recognize unrecognized tax benefits billion december income tax provision would reflect favorable net impact billion amount unrecognized tax benefits change next months due primarily anticipated closure various tax examinations company estimates change could result reduction unrecognized tax benefits approximately million interest penalties associated uncertain tax positions amounted benefit expense million million million liabilities accrued interest penalties billion billion december respectively previously disclosed internal revenue service irs completed examination old mercks tax returns years result examination old merck made aggregate payment billion february payment offset tax refund million received amounts previously paid matters ii federal tax benefit approximately million related interest included payment resulting net cash cost old merck approximately billion impact years subsequent items reviewed part examination included payment although years remain open respects closing irs examination material impact old mercks results operations amounts previously accrued old merck reported results irs adjustments years various state tax authorities resulted additional tax well interest penalty payments million million respectively million million respectively equivalent reduction balances unrecognized tax benefits accrued interest penalties october irs auditors asserted two interest rate swaps scheringplough entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september scheringplough made payments irs amount million income taxes million interest scheringplough filed refund claims taxes interest irs december following irss denial scheringploughs claims refund schering plough filed suit may us district court district new jersey refund full amount taxes interest scheringploughs tax reserves adequate cover mentioned payments decision favor government announced august scheringplough filed motion retrial motion granted scheringplough intends file appeal rd circuit previously disclosed october canada revenue agency cra issued old merck notice reassessment containing adjustments related certain intercompany pricing matters february old merck cra negotiated settlement agreement regard matters accordance settlement old merck paid additional tax approximately million us dollars interest approximately million us dollars additional amounts penalties due assessment settlement accounted first quarter old merck previously established reserves table contents matters significant portion taxes paid expected creditable us tax purposes resolution matters material effect old mercks financial position liquidity respect associated collateral discussed addition july november cra proposed additional adjustments respectively relating intercompany pricing matters adjustments would increase canadian tax due approximately million us dollars plus million us dollars interest december possible cra propose similar adjustments later years company disagrees positions taken cra believes without merit company intends contest assessments cra appeals process courts necessary management believes resolution matters material effect companys financial position liquidity connection appeals process matters discussed old merck pledged collateral two financial institutions one provided guarantee cra quebec ministry revenue representing portion tax interest assessed result settlement noted guarantees required appeal disputes reduced eliminated approximately million associated collateral released certain cash investments continue collateralized guarantees required appeal canadian tax disputes collateral included deferred income taxes current assets assets consolidated balance sheet totaled approximately million billion december respectively irs examining old mercks federal income tax returns addition various state foreign tax examinations progress significant tax jurisdictions us state foreign companys income tax returns open examination period second quarter irs completed examination scheringploughs federal income tax returns company seeking resolution issue raised examination irs administrative appeals process july scheringplough made payment million irs pertaining examination companys income tax returns remain open irs tax years irs commenced examination federal income tax returns examination expected completed significant tax jurisdictions us state foreign companys income tax returns open examination period december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income taxes would payable upon distribution earnings addition company subsidiaries operating puerto rico singapore tax incentive grants begin expire earnings per share discussed note effective january new guidance issued fasb adopted clarifies unvested sharebased payment awards contain nonforfeitable rights dividends dividend equivalents whether paid unpaid considered participating securities shall included computation earnings per share pursuant twoclass method provisions new guidance retrospective therefore prior periods restated twoclass method earnings allocation formula determines earnings per share common stock participating securities according dividends declared participation rights undistributed earnings method earnings distributed undistributed allocated common shares participating securities based respective rights receive dividends rsus certain psus granted certain management level employees see note participate dividends basis common shares nonforfeitable holder result rsus psus meet definition participating security table contents calculations earnings per share twoclass method follows years ended december basic earnings per common share net income available merck co inc common shareholders less income allocated participating securities net income allocated common shareholders average common shares outstanding earnings per common share assuming dilution net income available merck co inc common shareholders less income allocated participating securities net income allocated common shareholders average common shares outstanding common shares issuable average common shares outstanding assuming dilution issuable primarily sharebased compensation plans million million million respectively common shares issuable sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive table contents comprehensive income components comprehensive income loss follows year ended december pretax tax tax net unrealized loss derivatives net loss realization derivatives net unrealized gain investments net gain realization investments benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment year ended december net unrealized gain derivatives net gain realization derivatives net unrealized loss investments net loss realization investments benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment year ended december net unrealized loss derivatives net loss realization derivatives net unrealized gain investments net gain realization investments benefit plan net gain loss prior service cost credit net amortization cumulative translation adjustment increase cumulative translation adjustment due merger amounts represent cumulative translation adjustments related equity investees components accumulated comprehensive loss follows december net unrealized loss gain derivatives net unrealized gain investments pension plan net loss postretirement benefit plan net loss pension plan prior service cost postretirement benefit plan prior service cost cumulative translation adjustment table contents included cumulative translation adjustment gains million postmerger period eurodenominated debt designated effective economic hedges net investment foreign operation segment reporting companys operations principally managed products basis comprised one reportable segment pharmaceutical segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities large component pediatric adolescent vaccines sold us centers disease control prevention vaccines children program funded us government company also animal health operations discover develop manufacture market animal health products including vaccines additionally company consumer health care operations develop manufacture market otc foot care sun care products united states canada segment composition reflects certain managerial changes implemented segment disclosures prior periods recast comparable basis includes nonreportable segments including animal health consumer health care well revenue companys relationship azlp accounting policies segments described described note revenues profits segments follows pharmaceutical total year ended december segment revenues segment profits included segment profits equity income affiliates depreciation amortization year ended december segment revenues segment profits included segment profits equity income affiliates depreciation amortization year ended december segment revenues segment profits included segment profits equity income affiliates depreciation amortization segment profits comprised segment revenues less certain elements materials production costs operating expenses including components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker merck allocate production costs standard costs research development expenses general administrative expenses well cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits table contents sales companys products follows millions pharmaceutical bone respiratory immunology dermatology singulair fosamax propecia remicade arcoxia nasonex clarinex asmanex cardiovascular vytorin zetia integrilin diabetes obesity januvia janumet infectious disease isentress primaxin cancidas invanz crixivanstocrin pegintron avelox rebetol mature brands cozaarhyzaar zocor vasotecvaseretic proscar claritin rx proventil neurosciences ophthalmology maxalt cosopttrusopt remeron subutexsuboxone oncology emend temodar caelyx intron vaccines proquadmmr iivarivax gardasil rotateq pneumovax zostavax womens health endocrine follistimpuregon nuvaring pharmaceutical segment revenues total segment revenues sales legacy scheringplough products reflect results postmerger period december sales msp partnership products zetia vytorin represent sales postmerger period december prior merger sales zetia vytorin primarily recognized msp partnership results old mercks interest msp partnership recorded equity income affiliates sales zetia vytorin reflect old mercks sales products latin america part msp partnership amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd pharmaceutical primarily includes sales human pharmaceutical products including products within franchises listed separately reflects nonreportable segments including animal health consumer health care revenue companys relationship azlp primarily relating sales nexium well prilosec revenue azlp billion billion billion respectively revenues primarily comprised miscellaneous corporate revenues thirdparty manufacturing sales sales related divested products businesses supply sales included segment results table contents consolidated revenues geographic area derived follows years ended december united states europe middle east africa japan reconciliation total segment profits consolidated income taxes follows years ended december segment profits profits adjustments unallocated interest income interest expense equity income affiliates depreciation amortization research development amortization purchase accounting adjustments gain related msp partnership gain merial divestiture gain distribution astrazeneca lp us vioxx settlement agreement charge expenses net profits primarily comprised miscellaneous corporate profits well operating profits related divested products businesses supply sales adjustments represent elimination effect double counting certain items income expense equity income affiliates includes taxes paid joint venture level portion equity income reported segment profits expenses net include expenses corporate manufacturing cost centers miscellaneous income expense net property plant equipment net geographic area located follows december united states europe middle east africa japan company disaggregate assets products services basis internal management reporting therefore information presented table contents report independent registered public accounting firm board directors shareholders merck co inc opinion accompanying consolidated balance sheets related consolidated statements income equity cash flows present fairly material respects financial position merck co inc subsidiaries december december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion merck maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso mercks management responsible financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included managements report item responsibility express opinions financial statements mercks internal control financial reporting based integrated audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audits obtain reasonable assurance whether financial statements free material misstatement whether effective internal control financial reporting maintained material respects audits financial statements included examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions discussed note consolidated financial statements merck changed manner accounts unrecognized tax benefits discussed note note consolidated financial statements merck changed manner accounts business combinations discussed note consolidated financial statements merck changed manner accounts noncontrolling interests companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp florham park new jersey february table contents b supplementary data selected quarterly financial data contained condensed interim financial data table condensed interim financial data unaudited millions except per share amounts th q rd q nd q st q sales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates income expense net income taxes net income available common shareholders basic earnings per common share available common shareholders earnings per common share assuming dilution available common shareholders sales materials production costs marketing administrative expenses research development expenses restructuring costs equity income affiliates income expense net income taxes net income available common shareholders basic earnings per common share available common shareholders earnings per common share assuming dilution available common shareholders amounts include gain fair value adjustment mercks previously held interest msp partnership see note fourth quarter tax provision reflects favorable impact foreign exchange rate changes benefit relating us research development tax credit amounts third fourth quarter fourth quarter include impact additional vioxx legal defense reserves see note amounts third quarter second quarter first quarter include impact additional fosamax legal defense reserves see note amounts include gain sale old mercks interest merial limited see note amounts reflect favorable impact tax settlements amounts include gain distribution astrazeneca lp see note gain related sale remaining worldwide rights aggrastat realization foreign tax credits expense contribution merck company foundation amounts include impacts merger including amortization intangible assets mergerrelated costs see note amounts include impact restructuring actions see note table contents item changes disagreements accountants accounting financial disclosure prior merger old mercks historical financial statements audited pricewaterhousecoopers llp pwc scheringploughs historical financial statements audited deloitte touche llp deloitte closing date merger board directors company dismissed deloitte companys independent registered public accounting firm audit reports deloitte financial statements scheringplough two fiscal years ended december contain adverse opinion disclaimer opinion qualified modified uncertainty audit scope accounting principles scheringploughs fiscal years ended december scheringploughs subsequent interim period january closing date merger date dismissal deloitte regard financial statements referred disagreements deloitte matter accounting principles practices financial statement disclosure auditing scope procedure disagreements resolved deloittes satisfaction would caused deloitte make reference subject matter disagreement connection report ii reportable events type described item av regulation sk item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective management responsible establishing maintaining adequate internal control financial reporting term defined rule af act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission coso based evaluation management concluded internal control financial reporting effective december effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein november merck co inc scheringplough corporation completed planned merger two entities period leading merger changes either companys internal controls financial reporting reasonably likely material effect postmerger period management maintained operational integrity companys legacy controls financial reporting addition management designed tested new controls financial reporting supported accuracy financial presentation merged companys operations support business integration plans process evaluating addressing necessary changes control environment financial reporting adopted old merck previously disclosed process multiyear implementation enterprise wide resource planning system company intends implement system united states implementation plans revision address combined companys requirements old merck entities implemented worldwide employee data management system implementation system included modifications design operation controls validating components employee master data managements report managements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements table contents prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices company periodically conducts managements stewardship program key management financial personnel program reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included filing managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act companys internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states america management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december inherent limitations internal control financial reporting may prevent detect misstatements projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein richard clark chairman president peter n kellogg chief executive officer executive vice president chief financial officer item b information none table contents part iii item directors executive officers corporate governance required information directors nominees incorporated reference discussion item election directors companys proxy statement annual meeting shareholders held may information executive officers set forth part document pages required information compliance section securities exchange act incorporated reference discussion heading section beneficial ownership reporting compliance companys proxy statement annual meeting shareholders held may company adopted code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer code conduct available companys website wwwmerckcomaboutuspdf company intends post website amendments waivers code conduct printed copy sent without charge stockholder requests writing chief ethics officer merck co inc one merck drive whitehouse station nj required information identification audit committee audit committee financial expert incorporated reference discussion heading board committees companys proxy statement annual meeting shareholders held may item executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table grants planbased awards table outstanding equity awards fiscal yearend table option exercises stock vested table retirement plan benefits related pension benefits table nonqualified deferred compensation related tables potential payments upon termination changeincontrol including discussion subheadings separation separation plan payment benefit estimates table individual agreements change control change control payment benefit estimates table well footnote information various tables companys proxy statement annual meeting shareholders held may required information director compensation incorporated reference discussion heading director compensation related director compensation table schedule director fees table companys proxy statement annual meeting shareholders held may required information headings compensation committee interlocks insider participation compensation benefits committee report incorporated reference companys proxy statement annual meeting shareholders held may item security ownership certain beneficial owners management related stockholder matters information respect securities authorized issuance equity compensation plans incorporated reference discussion heading equity compensation plan information companys proxy statement annual meeting shareholders held may information respect security ownership certain beneficial owners management incorporated reference discussion heading security ownership certain beneficial owners management companys proxy statement annual meeting shareholders held may table contents item certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading related person transactions companys proxy statement annual meeting shareholders held may required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting shareholders held may item principal accountant fees services information required item incorporated reference discussion audit committee beginning caption preapproval policy services independent registered public accounting firm fees companys proxy statement annual meeting shareholders held may part iv item